

A61K 35/74 (2018.01)
 A61P 1/00 (2018.01)
 A61P 11/06 (2018.01)
 A61P 19/02 (2018.01)
 A61P 25/28 (2018.01)
 A61P 29/00 (2018.01)
 A61P 35/00 (2018.01)

FASCICULE DE BREVET D'INVENTION

21 Numéro de dépôt : 1201700486
PCT/GB2016/051768

22 Date de dépôt : 15/06/2016

30 Priorité(s) :

GB n° 1510470.6 du 15/06/2015
 GB n° 1520510.7 du 20/11/2015
 GB n° 1603786.3 du 04/04/2016

24 Délivré le : 29/03/2019

45 Publié le : 17.05.2019

73 Titulaire(s) :

4D Pharma Research Limited,
 Life Sciences Innovation Building,
 Cornhill Road,
 ABERDEEN
 Aberdeenshire AB25 2ZS (GB)

72 Inventeur(s) :

PATTERSON, Angela Margaret (GB)
 GRANT, George (GB)
 MULDER, Imke (GB)
 MCCLUSKEY, Seanin (GB)
 RAFTIS, Emma (GB)


74 Mandataire : SPOOR & FISHER (Inc. NGWAFOR &
 PARTNERS SARL), The Hilton Hotel, Entrance :
 Business Centre, Second Floor, Suite 208A, 20th
 May Boulevard, P.O. Box 8211, YAOUNDE (CM).

54 Titre : Compositions comprising bacterial strains.

57 Abrégé :

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Fig. 1



COMPOSITIONS COMPRISING BACTERIAL STRAINS

TECHNICAL FIELD

This invention is in the field of compositions comprising bacterial strains isolated from the mammalian digestive tract and the use of such compositions in the treatment of disease.

5 BACKGROUND TO THE INVENTION

The human intestine is thought to be sterile *in utero*, but it is exposed to a large variety of maternal and environmental microbes immediately after birth. Thereafter, a dynamic period of microbial colonization and succession occurs, which is influenced by factors such as delivery mode, environment, diet and host genotype, all of which impact upon the composition of the gut microbiota, particularly during early life. Subsequently, the microbiota stabilizes and becomes adult-like [1]. The human gut microbiota contains more than 500-1000 different phylotypes belonging essentially to two major bacterial divisions, the Bacteroidetes and the Firmicutes [2]. The successful symbiotic relationships arising from bacterial colonization of the human gut have yielded a wide variety of metabolic, structural, protective and other beneficial functions. The enhanced metabolic activities of the colonized gut ensure that otherwise indigestible dietary components are degraded with release of by-products providing an important nutrient source for the host. Similarly, the immunological importance of the gut microbiota is well-recognized and is exemplified in germfree animals which have an impaired immune system that is functionally reconstituted following the introduction of commensal bacteria [3-5].

20 Dramatic changes in microbiota composition have been documented in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, the levels of *Clostridium* cluster XIVa bacteria are reduced in IBD patients whilst numbers of *E. coli* are increased, suggesting a shift in the balance of symbionts and pathobionts within the gut [6-9]. Interestingly, this microbial dysbiosis is also associated with imbalances in T effector cell populations.

25 In recognition of the potential positive effect that certain bacterial strains may have on the animal gut, various strains have been proposed for use in the treatment of various diseases (see, for example, [10-13]). Also, certain strains, including mostly *Lactobacillus* and *Bifidobacterium* strains, have been proposed for use in treating various inflammatory and autoimmune diseases that are not directly linked to the intestines (see [14] and [15] for reviews). However, the relationship between different diseases and different bacterial strains, and the precise effects of particular bacterial strains on the gut and at a systemic level and on any particular types of diseases, are poorly characterised.

30 There is a requirement in the art for new methods of treating inflammatory and autoimmune diseases. There is also a requirement for the potential effects of gut bacteria to be characterised so that new therapies using gut bacteria can be developed.

SUMMARY OF THE INVENTION

The inventors have developed new therapies for treating and preventing inflammatory and autoimmune diseases. In particular, the inventors have developed new therapies for treating and preventing diseases and conditions mediated by IL-17 or the Th17 pathway. In particular, the inventors have identified that bacterial strains from the genus *Bacteroides* can be effective for reducing the Th17 inflammatory response. As described in the examples, oral administration of compositions comprising *Bacteroides coprocola* may reduce the severity of the inflammatory response, including the Th17 inflammatory response, in mouse models of asthma, rheumatoid arthritis and multiple sclerosis.

Therefore, in a first embodiment, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway. The inventors have identified that treatment with bacterial strains from this genus can reduce levels of cytokines that are part of the Th17 pathway, including IL-17, can alleviate the Th17 inflammatory response and can provide clinical benefits in mouse models of inflammatory and autoimmune diseases mediated by IL-17 and the Th17 pathway.

In particular embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing a disease or condition selected from the group consisting of: multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); cancer, such as breast cancer, colon cancer, lung cancer or ovarian cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. The effect shown for the bacterial strains from the genus *Bacteroides* on the Th17 inflammatory response may provide therapeutic benefits for diseases and conditions mediated by IL-17 and the Th17 pathway, such as those listed above.

In preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing asthma, such as neutrophilic asthma or allergic asthma. The inventors have identified that treatment with *Bacteroides* strains can reduce recruitment of neutrophils and eosinophils into the lungs, which can help treat or prevent asthma. Furthermore, the inventors have tested and demonstrated the efficacy of *Bacteroides* strains in mouse models of asthma. In certain embodiments, the composition is for use in a method of treating or preventing neutrophilic asthma or eosinophilic asthma. The effect shown for the compositions of the invention on neutrophils and eosinophils mean that they may be particularly effective for treating or

preventing neutrophilic asthma and eosinophilic asthma. Indeed, in certain embodiments, the composition is for use in a method of reducing a neutrophilic inflammatory response in the treatment or prevention of asthma, or the composition is for use in a method of reducing an eosinophilic inflammatory response in the treatment or prevention of asthma. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides coprocola*, for use in the treatment of asthma, and in particular neutrophilic asthma. *Bacteroides coprocola* is shown to have a particularly pronounced effect on neutrophils in asthma models and treatment with *Bacteroides coprocola* may be particularly effective for treating neutrophilic asthma. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides thetaiotaomicron* for use in the treatment of asthma, and in particular eosinophilic or allergic asthma. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides fragilis* for use in the treatment of asthma, and in particular eosinophilic or allergic asthma.

In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing rheumatoid arthritis. The inventors have identified that treatment with *Bacteroides* strains can provide clinical benefits in a mouse model of rheumatoid arthritis and can reduce joint swelling. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides coprocola*, for use in the treatment of rheumatoid arthritis. Compositions using *Bacteroides coprocola* may be particularly effective for treating rheumatoid arthritis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides thetaiotaomicron*, for use in the treatment of rheumatoid arthritis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides fragilis*, for use in the treatment of rheumatoid arthritis.

In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing multiple sclerosis. The inventors have identified that treatment with *Bacteroides* strains can reduce disease incidence and disease severity in a mouse model of multiple sclerosis. In preferred embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides coprocola*, for use in the treatment of multiple sclerosis. Compositions using *Bacteroides coprocola* may be particularly effective for treating multiple sclerosis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides thetaiotaomicron*, for use in the treatment of multiple sclerosis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides fragilis*, for use in the treatment of multiple sclerosis.

In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing cancer, such as breast, lung or liver cancer. Compositions comprising a bacterial strain of the genus *Bacteroides* may reduce tumour growth in mouse models of breast, lung and liver cancer. In certain embodiments, the composition is for use in a method of reducing tumour size or preventing tumour growth in the treatment of cancer. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides coprocola*, for use in the treatment of cancer. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides thetaiotaomicron*, for use in the treatment of cancer. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides fragilis*, for use in the treatment of cancer.

In further preferred embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing uveitis, such as posterior uveitis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides coprocola*, for use in the treatment of uveitis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides thetaiotaomicron*, for use in the treatment of uveitis. In certain embodiments, the invention provides a composition comprising a bacterial strain of the species *Bacteroides fragilis*, for use in the treatment of uveitis.

In certain embodiments, the compositions of the invention are for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway. In particular, the compositions of the invention may be used in reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of asthma, rheumatoid arthritis or multiple sclerosis. Preferably, the invention provides compositions comprising a bacterial strain of the species *Bacteroides coprocola*, for use in reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of asthma, rheumatoid arthritis or multiple sclerosis, or of asthma, rheumatoid arthritis, multiple sclerosis, uveitis or cancer. In certain embodiments, the invention provides compositions comprising a bacterial strain of the species *Bacteroides thetaiotaomicron*, for use in reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of asthma, rheumatoid arthritis, multiple sclerosis, uveitis or cancer. In certain embodiments, the invention provides compositions comprising a bacterial strain of the species *Bacteroides fragilis*, for use in reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of asthma, rheumatoid arthritis, multiple sclerosis, uveitis or cancer.

In certain embodiments, the composition is for use in a patient with elevated IL-17 levels or Th17 cells. The effect on the Th17 inflammatory response shown for *Bacteroides* strains may be particularly beneficial for such patients.

In preferred embodiments of the invention, the bacterial strain in the composition is of *Bacteroides coprocola*. Closely related strains may also be used, such as bacterial strains that have a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Bacteroides coprocola*. Preferably, the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1, 2, 3 or 4. Preferably, the sequence identity is to SEQ ID NO:4. Preferably, the bacterial strain for use in the invention has the 16s rRNA sequence represented by SEQ ID NO:4.

In further preferred embodiments of the invention, the bacterial strain in the composition is of *Bacteroides thetaiotaomicron*. Closely related strains may also be used, such as bacterial strains that have a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Bacteroides thetaiotaomicron*. Preferably, the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Preferably, the bacterial strain for use in the invention has the 16s rRNA sequence represented by SEQ ID NO:5.

In further preferred embodiments of the invention, the bacterial strain in the composition is of *Bacteroides fragilis*. Closely related strains may also be used, such as bacterial strains that have a genome with sequence identity to CR626927.1.

In certain embodiments, the composition of the invention is for oral administration. Oral administration of the strains of the invention can be effective for treating IL-17- or Th17 pathway-mediated diseases and conditions. Also, oral administration is convenient for patients and practitioners and allows delivery to and / or partial or total colonisation of the intestine.

In certain embodiments, the composition of the invention comprises one or more pharmaceutically acceptable excipients or carriers.

In certain embodiments, the composition of the invention comprises a bacterial strain that has been lyophilised. Lyophilisation is an effective and convenient technique for preparing stable compositions that allow delivery of bacteria.

In certain embodiments, the invention provides a food product comprising the composition as described above.

In certain embodiments, the invention provides a vaccine composition comprising the composition as described above.

Additionally, the invention provides a method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway, comprising administering a composition comprising a bacterial strain of the genus *Bacteroides*.

In developing the above invention, the inventors have identified and characterised a bacterial strain that is particularly useful for therapy. The *Bacteroides coprocola* strain of the invention is shown to be effective for treating the diseases described herein, such as arthritis, asthma and multiple sclerosis. Therefore, in another aspect, the invention provides a cell of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408, or a derivative thereof. The invention also provides compositions comprising such cells, or biologically pure cultures of such cells. The invention also provides a cell of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408, or a derivative thereof, for use in therapy, in particular for the diseases described herein.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1: Mouse model of house dust mite-induced asthma - Total BAL fluid cell counts.

Figure 2: Mouse model of house dust mite-induced asthma - Total eosinophil count in BALF.

Figure 3: Mouse model of house dust mite-induced asthma - Proportion of eosinophils in BALF.

Figure 4: Mouse model of house dust mite-induced asthma - Total macrophage count in BALF.

Figure 5: Mouse model of house dust mite-induced asthma - Proportion of macrophages in BALF.

Figure 6: Mouse model of house dust mite-induced asthma - Total neutrophil count in BALF.

Figure 7: Mouse model of house dust mite-induced asthma - Proportion of neutrophils in BALF.

Figure 8: Mouse model of house dust mite-induced asthma - Total lymphocyte count in BALF.

Figure 9: Mouse model of house dust mite-induced asthma - Proportion of lymphocytes in BALF.

Figure 10: Mouse model of severe neutrophilic asthma - Total BAL fluid cell counts.

Figure 11: Mouse model of severe neutrophilic asthma - Total eosinophil count in BALF.

Figure 12: Mouse model of severe neutrophilic asthma - Proportion of eosinophils in BALF.

Figure 13: Mouse model of severe neutrophilic asthma - Total macrophage count in BALF.

Figure 14: Mouse model of severe neutrophilic asthma - Proportion of macrophages in BALF.

Figure 15: Mouse model of severe neutrophilic asthma - Total neutrophil count in BALF.

Figure 16: Mouse model of severe neutrophilic asthma - Proportion of neutrophils in BALF.

Figure 17: Mouse model of severe neutrophilic asthma - Total lymphocyte count in BALF.

Figure 18: Mouse model of severe neutrophilic asthma - Proportion of lymphocytes in BALF.

Figure 19: Mouse model of rheumatoid arthritis - Bodyweights, days -14 to 0. Data are presented as Mean $\pm$ SEM percentages of the initial (Day -14) bodyweights. Statistical significance: $\blacktriangle$ $p < 0.05$ and $\blacktriangle\blacktriangle\blacktriangle\blacktriangle$ $p < 0.0001$ when compared to the vehicle-treated group.

Figure 20: Mouse model of rheumatoid arthritis - Bodyweights, days 0 to 42. Data are presented as Mean $\pm$ SEM percentages of the initial (Day 0) bodyweights. $\blacktriangle$ $p < 0.05$, $\blacklozenge$ $p < 0.05$, $\blacktriangle\blacktriangle\blacktriangle$ $p < 0.001$, $\bullet\bullet\bullet$ $p < 0.0001$ when compared to the vehicle-treated group.

Figure 21: Mouse model of rheumatoid arthritis - Clinical Scores. Data are presented as Mean $\pm$ SEM. $\bullet\bullet\bullet\bullet$ $p < 0.0001$ when compared to Day 21 in the vehicle-treated group. $\blacklozenge$, $\circ$ $p < 0.05$ when compared to the vehicle-treated group on a given day.

Figure 22: Mouse model of rheumatoid arthritis - Splenocyte proliferative response to Collagen II. Media background subtracted [CII-stimulated - media background] counts per minute based on ^3H -TdR incorporation. All data are presented as Mean $\pm$ SEM.

Figure 23: Mouse model of rheumatoid arthritis - Levels of $\text{IFN}\gamma$ in tissue culture supernatants from Vehicle-treated group. Lines represent group median values.

Figure 24: Mouse model of rheumatoid arthritis - Levels of IL-17A in tissue culture supernatants from Vehicle-treated group. Lines represent group median values.

Figure 25: Mouse model of rheumatoid arthritis - Levels of IL-10 in tissue culture supernatants from Vehicle-treated group. Lines represent group median values.

Figure 26: Mouse model of rheumatoid arthritis - Levels of IL-6 in tissue culture supernatants from Vehicle-treated group. Lines represent group median values.

Figure 27: Mouse model of rheumatoid arthritis - Levels of cytokine in tissue culture supernatants from biotherapeutic #675-treated group (Group 4). Lines represent group median values.

Figure 28: Mouse model of house dust mite-induced asthma – Total IgE in Serum

Figure 29: Mouse model of house dust mite-induced asthma – HDM specific IgG1 in Serum

Figure 30: Mouse model of house dust mite-induced asthma – Total IgE in BALF

Figure 31: Mouse model of house dust mite-induced asthma – HDM specific IgG1 in BALF

Figure 32: Mouse model of house dust mite-induced asthma – Histological Analysis – Mean Peribronchiolar Infiltration Score

Figure 33: Mouse model of house dust mite-induced asthma – Histological Analysis – Mean Perivascular Infiltration Score

Figure 34: Mouse model of house dust mite-induced asthma – Histological Analysis – Mean Inflammatory Score (Average of both Peribronchiolar and Perivascular Infiltration Score)

5 **Figure 35:** Mouse model of house dust mite-induced asthma – Histological Analysis – Mucus Score

Figure 36: Mouse model of house dust mite-induced asthma – IL-9 level in lung tissue

Figure 37: Mouse model of house dust mite-induced asthma – IL-1a level in lung tissue

Figure 38: Mouse model of house dust mite-induced asthma – IFN γ level in lung tissue

Figure 39: Mouse model of house dust mite-induced asthma – IL-17A level in lung tissue

10 **Figure 40:** Mouse model of house dust mite-induced asthma – IL-4 level in lung tissue

Figure 41: Mouse model of house dust mite-induced asthma – IL-5 level in lung tissue

Figure 42: Mouse model of house dust mite-induced asthma - IL-1b level in lung tissue

Figure 43: Mouse model of house dust mite-induced asthma - RANTES level in lung tissue

Figure 44: Mouse model of house dust mite-induced asthma - MIP-1a level in lung tissue

15 **Figure 45:** Mouse model of house dust mite-induced asthma - KC level in lung tissue

Figure 46: Mouse model of house dust mite-induced asthma - MIP-2 level in lung tissue

Figure 47: Mouse model of severe neutrophilic asthma – HDM specific IgG1 in Serum

Figure 48: Mouse model of severe neutrophilic asthma – HDM specific IgG2a in Serum

Figure 49: Mouse model of severe neutrophilic asthma – HDM specific IgG1 in BALF

20 **Figure 50:** Mouse model of severe neutrophilic asthma – HDM specific IgG2a in BALF

Figure 51: Mouse model of severe neutrophilic asthma – Histological Analysis – Mean Peribronchiolar Infiltration Score

Figure 52: Mouse model of severe neutrophilic asthma – Histological Analysis – Mean Perivascular Infiltration Score

25 **Figure 53:** Mouse model of severe neutrophilic asthma – Histological Analysis – Mean Inflammatory Score (Average of both Peribronchiolar and Perivascular Infiltration Score)

Figure 54: Mouse model of severe neutrophilic asthma – TNF α level in lung tissue

Figure 55: Mouse model of severe neutrophilic asthma – IL-1a level in lung tissue

Figure 56: Mouse model of severe neutrophilic asthma – IFN γ level in lung tissue

Figure 57: Mouse model of severe neutrophilic asthma – IL-17F level in lung tissue

Figure 58: Mouse model of severe neutrophilic asthma – IL-1b level in lung tissue

5 **Figure 59:** Mouse model of severe neutrophilic asthma - RANTES level in lung tissue

Figure 60: Mouse model of severe neutrophilic asthma - MIP-2 level in lung tissue

Figure 61: Mouse model of severe neutrophilic asthma - KC level in lung tissue

Figure 62: Mouse model of severe neutrophilic asthma – IL-17A level in lung tissue

Figure 63: Mouse model of severe neutrophilic asthma –MIP-1a level in lung tissue

10 **Figure 64:** Mouse model of severe neutrophilic asthma – IL-33 level in lung tissue

Figure 65: Mouse model of rheumatoid arthritis - Visual Template for Histopathology Scoring. Representative images showing composite scores from mouse tarsal joints in a collagen-induced arthritis study.

15 **Figure 66:** Mouse model of rheumatoid arthritis - Histopathology: Inflammation Scores. Data are presented as Mean $\pm$ SEM. ** $p < 0.01$ when compared to the vehicle-treated group.

Figure 67: Mouse model of rheumatoid arthritis - Histopathology: Vehicle-treated group Cartilage Scores. Data are presented as Mean $\pm$ SEM.

Figure 68: Mouse model of rheumatoid arthritis - Histopathology: Bone Scores. Data are presented as Mean $\pm$ SEM.

20 **Figure 69:** Mouse model of rheumatoid arthritis - Histopathology: Total Scores. Data are presented as Mean $\pm$ SEM.

Figure 70: Mouse model of rheumatoid arthritis - Histopathology: Strain #675. Data are presented as Mean $\pm$ SEM.

25 **Figure 71:** Mouse model of rheumatoid arthritis - Histopathology: Representative Pictures. Animal ID (#n.n) and limb (R for right, L for left) are indicated between brackets. Top left image (vehicle): extensive joint and bone destruction with inflammation and fibrosis extending to the peri-articular soft tissues. Lower image (strain #675): synovitis and bursitis extending focally to peri-articular tissues, mild articular cartilage damage and intra-articular debris, bone structure unaffected.

Figure 72: Mouse model of multiple sclerosis - clinical score.

Figure 73: Mouse model of multiple sclerosis - disease incidence.

DISCLOSURE OF THE INVENTION

Bacterial strains

The compositions of the invention comprise a bacterial strain of the genus *Bacteroides*. The examples demonstrate that bacteria of this genus are useful for treating or preventing diseases and conditions mediated by IL-17 or the Th17 pathway. The preferred bacterial strains are of the species *Bacteroides coprocola*. Further preferred bacterial strains are of the species *Bacteroides thetaiotaomicron* or *Bacteroides fragilis*.

Examples of *Bacteroides* species for use in the invention include *Bacteroides massiliensis*, *Bacteroides coprocola*, *Bacteroides thetaiotaomicron* and *Bacteroides caccae*. A further example of a *Bacteroides* species for use in the invention is *Bacteroides fragilis*. *Bacteroides* is a genus of Gram-negative, obligately anaerobic bacteria. *Bacteroides* species are non-endospore-forming bacilli, and may be either motile or non-motile, depending on the species. *Bacteroides* species make up a substantial portion of the mammalian gastrointestinal flora and are essential for processing complex molecules.

Bacteroides coprocola cells cultivated on EG blood agar plates are strictly anaerobic, non-spore-forming, non-motile and Gram-negative. The short rods or rod-shaped cells are about 0.8µm in width and variable in length, generally in the range 1–4µm. Example strains of species *Bacteroides coprocola* are described in [16]. The type strain, M16^T (=JCM 12979^T=DSM 17136^T), was isolated from faeces of a healthy human. Two additional strains [M11 (=JCM 12980) and M156 (=JCM 12981)] are included in this species. GenBank/EMBL/DDBJ accession numbers for the 16S rRNA gene sequence of these *Bacteroides coprocola* strains are AB200223, AB200224 and AB200225 (disclosed herein as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3).

The *Bacteroides coprocola* bacterium deposited under accession number NCIMB 42408 was tested in the Examples and is also referred to herein as strain 675. A 16S rRNA sequence for the 675 strain that was tested is provided in SEQ ID NO:4. Strain 675 was deposited with the international depositary authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Scotland) on 13th May 2015 as “*Bacteroidales* 675” and was assigned accession number NCIMB 42408.

The genome of strain 675 comprises a chromosome and plasmid. A chromosome sequence for strain 675 is provided in SEQ ID NO:6 of WO2016203217. A plasmid sequence for strain 675 is provided in SEQ ID NO:7. These sequences were generated using the PacBio RS II platform.

Bacterial strains closely related to the strain tested in the examples are also expected to be effective for treating or preventing diseases and conditions mediated by IL-17 or the Th17 pathway. In certain

embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Bacteroides coprocola*. Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1, 2, 3 or 4. Preferably, the sequence identity is to SEQ ID NO:4. Preferably, the bacterial strain for use in the invention has the 16s rRNA sequence represented by SEQ ID NO:4.

A further preferred bacterial strain for use in the invention is the *Bacteroides thetaiotaomicron* strain deposited under accession number NCIMB 42341. This strain was deposited with the international depositary authority NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA, Scotland) on 3rd December 2014.

Further preferred *Bacteroides thetaiotaomicron* strains for use in the invention are the type strain ATCC 29148 = CCUG 10774 = CIP 104206 = DSM 2079 = JCM 5827 = NCTC 10582 = VPI 5482 and strain WAL 2926 = ATCC 29741. A further preferred *Bacteroides thetaiotaomicron* strain for use in the invention is the strain described in EP1448995. The accession number for the 16S rRNA gene sequence of *Bacteroides thetaiotaomicron* strain WAL 2926 is M58763 (disclosed herein as SEQ ID NO:5).

In certain embodiments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Bacteroides thetaiotaomicron*. Preferably, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Preferably, the bacterial strain for use in the invention has the 16s rRNA sequence represented by SEQ ID NO:5.

A preferred *Bacteroides fragilis* strain for use in the invention is the type strain ATCC 25285 = CCUG 4856 = CIP 77.16 = DSM 2151 = JCM 11019 = LMG 10263 = NCTC 9343. The accession number for the *Bacteroides fragilis* NCTC 9343 strain complete genome is CR626927.1 (version: CR626927.1 GI:60491031).

In certain embodiments, the bacterial strain for use in the invention has a genome with sequence identity to CR626927.1. In preferred embodiments, the bacterial strain for use in the invention has a genome with at least 90% sequence identity (e.g. at least 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to CR626927.1 across at least 60% (e.g. at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of CR626927.1. For example, the bacterial strain for use in the invention may have a genome with at least 90% sequence identity to CR626927.1 across 70% of CR626927.1, or at least 90% sequence identity to CR626927.1 across 80% of CR626927.1, or at least 90% sequence identity to CR626927.1 across 90% of CR626927.1, or at least 90% sequence identity to CR626927.1 across 100% of CR626927.1, or at least 95% sequence identity to

CR626927.1 across 70% of CR626927.1, or at least 95% sequence identity to CR626927.1 across 80% of CR626927.1, or at least 95% sequence identity to CR626927.1 across 90% of CR626927.1, or at least 95% sequence identity to CR626927.1 across 100% of CR626927.1, or at least 98% sequence identity to CR626927.1 across 70% of CR626927.1, or at least 98% sequence identity to CR626927.1 across 80% of CR626927.1, or at least 98% sequence identity to CR626927.1 across 90% of CR626927.1, or at least 98% sequence identity to CR626927.1 across 100% of CR626927.1.

In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:6 of WO2016203217. In preferred embodiments, the bacterial strain for use in the invention has a chromosome with at least 90% sequence identity (e.g. at least 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to SEQ ID NO:6 across at least 60% (e.g. at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO:6. For example, the bacterial strain for use in the invention may have a chromosome with at least 90% sequence identity to SEQ ID NO:6 across 70% of SEQ ID NO:6, or at least 90% sequence identity to SEQ ID NO:6 across 80% of SEQ ID NO:6, or at least 90% sequence identity to SEQ ID NO:6 across 90% of SEQ ID NO:6, or at least 90% sequence identity to SEQ ID NO:6 across 100% of SEQ ID NO:6, or at least 95% sequence identity to SEQ ID NO:6 across 70% of SEQ ID NO:6, or at least 95% sequence identity to SEQ ID NO:6 across 80% of SEQ ID NO:6, or at least 95% sequence identity to SEQ ID NO:6 across 90% of SEQ ID NO:6, or at least 95% sequence identity to SEQ ID NO:6 across 100% of SEQ ID NO:6, or at least 98% sequence identity to SEQ ID NO:6 across 70% of SEQ ID NO:6, or at least 98% sequence identity to SEQ ID NO:6 across 80% of SEQ ID NO:6, or at least 98% sequence identity to SEQ ID NO:6 across 90% of SEQ ID NO:6, or at least 98% sequence identity to SEQ ID NO:6 across 100% of SEQ ID NO:6.

In certain embodiments, the bacterial strain for use in the invention has a plasmid with sequence identity to SEQ ID NO:7. In preferred embodiments, the bacterial strain for use in the invention has a plasmid with at least 90% sequence identity (e.g. at least 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to SEQ ID NO:7 across at least 60% (e.g. at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO:7. For example, the bacterial strain for use in the invention may have a plasmid with at least 90% sequence identity to SEQ ID NO:7 across 70% of SEQ ID NO:7, or at least 90% sequence identity to SEQ ID NO:7 across 80% of SEQ ID NO:7, or at least 90% sequence identity to SEQ ID NO:7 across 90% of SEQ ID NO:7, or at least 90% sequence identity to SEQ ID NO:7 across 100% of SEQ ID NO:7, or at least 95% sequence identity to SEQ ID NO:7 across 70% of SEQ ID NO:7, or at least 95% sequence identity to SEQ ID NO:7 across 80% of SEQ ID NO:7, or at least 95% sequence identity to SEQ ID NO:7 across 90% of SEQ ID NO:7, or at least 95% sequence identity to SEQ ID NO:7 across 100% of SEQ ID NO:7, or at least 98% sequence identity to SEQ ID NO:7 across 70% of SEQ ID NO:7, or at least 98% sequence identity to SEQ ID NO:7 across 80% of SEQ ID NO:7, or at least 98% sequence identity to

SEQ ID NO:7 across 90% of SEQ ID NO:7, or at least 98% sequence identity to SEQ ID NO:7 across 100% of SEQ ID NO:7.

In certain embodiments, the bacterial strain for use in the invention has a chromosome with sequence identity to SEQ ID NO:6 of WO2016203217 and a plasmid with sequence identity to SEQ ID NO:7.

5 Bacterial strains that are biotypes of the bacterium deposited under accession number 42408 are also expected to be effective for treating or preventing diseases and conditions mediated by IL-17 or the Th17 pathway. Bacterial strains that are biotypes of a bacterium deposited under accession number NCIMB 42341, ATCC 29148 or ATCC 29741 are also expected to be effective for treating or preventing diseases and conditions mediated by IL-17 or the Th17 pathway. A biotype is a closely
10 related strain that has the same or very similar physiological and biochemical characteristics.

Strains that are biotypes of a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 and that are suitable for use in the invention may be identified by sequencing other nucleotide sequences for a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741. For example, substantially the whole genome
15 may be sequenced and a biotype strain for use in the invention may have at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity across at least 80% of its whole genome (e.g. across at least 85%, 90%, 95% or 99%, or across its whole genome). Other suitable sequences for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, (GTG)₅, or REP or [17]. Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, 99%, 99.5%
20 or 99.9% sequence identity to the corresponding sequence of a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741.

Alternatively, strains that are biotypes of a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 and that are suitable for use in the invention may be identified by using the accession number NCIMB 42408 deposit or the accession number
25 NCIMB deposit 42341 or the accession number ATCC 29148 deposit or the accession number ATCC 29741 deposit and restriction fragment analysis and/or PCR analysis, for example by using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprinting, or protein profiling, or partial 16S or 23s rDNA sequencing. In preferred embodiments, such techniques may be used to identify other *Bacteroides coprocola* or *Bacteroides*
30 *thetaiotaomicron* strains.

In certain embodiments, strains that are biotypes of a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 and that are suitable for use in the invention are strains that provide the same pattern as a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 when analysed by amplified
35 ribosomal DNA restriction analysis (ARDRA), for example when using Sau3AI restriction enzyme

(for exemplary methods and guidance see, for example,[18]). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741.

Other *Bacteroides* strains that are useful in the compositions and methods of the invention, such as
5 biotypes of a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741, may be identified using any appropriate method or strategy, including the assays described in the examples. For instance, strains for use in the invention may be identified by culturing in anaerobic YCFA and/or administering the bacteria to the type II collagen-induced
10 arthritis mouse model and then assessing cytokine levels. In particular, bacterial strains that have similar growth patterns, metabolic type and/or surface antigens to a bacterium deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 may be useful in the invention. A useful strain will have comparable immune modulatory activity to the NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 strain. In particular, a biotype strain will elicit
15 comparable effects on the asthma, arthritis and multiple sclerosis disease models and comparable effects on cytokine levels to the effects shown in the Examples, which may be identified by using the culturing and administration protocols described in the Examples.

A particularly preferred strain of the invention is the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408. This is the exemplary 675 strain tested in the examples and shown to be effective for treating disease. Therefore, the invention provides a cell, such as an isolated cell,
20 of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408, or a derivative thereof. The invention also provides a composition comprising a cell of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408, or a derivative thereof. The invention also provides a biologically pure culture of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408. The invention also provides a cell of the *Bacteroides coprocola* strain
25 deposited under accession number NCIMB 42408, or a derivative thereof, for use in therapy, in particular for the diseases described herein.

A derivative of the strain deposited under accession number NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 may be a daughter strain (progeny) or a strain cultured (subcloned) from the original. A derivative of a strain of the invention may be modified, for example at the genetic level,
30 without ablating the biological activity. In particular, a derivative strain of the invention is therapeutically active. A derivative strain will have comparable immune modulatory activity to the original NCIMB 42408, NCIMB 42341, ATCC 29148 or ATCC 29741 strain. In particular, a derivative strain will elicit comparable effects on the asthma, arthritis and multiple sclerosis disease models and comparable effects on cytokine levels to the effects shown in the Examples, which may
35 be identified by using the culturing and administration protocols described in the Examples. A

derivative of the NCIMB 42408 strain will generally be a biotype of the NCIMB 42408 strain. A derivative of the NCIMB 42341, ATCC 29148 or ATCC 29741 strain will generally be a biotype of the NCIMB 42341, ATCC 29148 or ATCC 29741 strain.

References to cells of the *Bacteroides coprocola* strain deposited under accession number NCIMB 42408 encompass any cells that have the same safety and therapeutic efficacy characteristics as the strains deposited under accession number NCIMB 42408, and such cells are encompassed by the invention. References to cells of the *Bacteroides thetaiotaomicron* strain deposited under accession numbers NCIMB 42341, ATCC 29148 or ATCC 29741 encompass any cells that have the same safety and therapeutic efficacy characteristics as the strains deposited under accession number NCIMB 42341, ATCC 29148 or ATCC 29741, and such cells are encompassed by the invention.

In preferred embodiments, the bacterial strains in the compositions of the invention are viable and capable of partially or totally colonising the intestine.

Therapeutic uses

As demonstrated in the examples, the bacterial compositions of the invention are effective for reducing the Th17 inflammatory response. In particular, treatment with compositions of the invention achieves a reduction in IL-17A levels and other Th17 pathway cytokines, and clinical improvements in animal models of conditions mediated by IL-17 and the Th17 pathway. Therefore, the compositions of the invention may be useful for treating or preventing inflammatory and autoimmune diseases, and in particular diseases or conditions mediated by IL-17. In particular, the compositions of the invention may be useful for reducing or preventing elevation of the IL-17 inflammatory response.

Th17 cells are a subset of T helper cells that produce, for example, IL-17A, IL-17F, IL-21 and IL-22. Th17 cell differentiation and IL-17 expression may be driven by IL-23. These cytokines and others form important parts of the Th17 pathway, which is a well-established inflammatory signalling pathway that contributes to and underlies a number of inflammatory and autoimmune diseases (as described in, for example, [19-24]). Diseases wherein the Th17 pathway is activated are Th17 pathway-mediated diseases. Th17 pathway-mediated diseases can be ameliorated or alleviated by repressing the Th17 pathway, which may be through a reduction in the differentiation of Th17 cells or a reduction in their activity or a reduction in the level of Th17 pathway cytokines. Diseases mediated by the Th17 pathway may be characterised by increased levels of cytokines produced by Th17 cells, such as IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-9 (reviewed in [25]). Diseases mediated by the Th17 pathway may be characterised by increased expression of Th-17-related genes, such as Stat3 or IL-23R. Diseases mediated by the Th17 pathway may be associated with increased levels of Th17 cells.

IL-17 is a pro-inflammatory cytokine that contributes to the pathogenesis of several inflammatory and autoimmune diseases and conditions. IL-17 as used herein may refer to any member of the IL-17 family, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. IL-17-mediated diseases and conditions are characterised by high expression of IL-17 and/or the accumulation or presence of IL-17-positive cells in a tissue affected by the disease or condition. Similarly, IL-17-mediated diseases and conditions are diseases and conditions that are exacerbated by high IL-17 levels or an increase in IL-17 levels, and that are alleviated by low IL-17 levels or a reduction in IL-17 levels. The IL-17 inflammatory response may be local or systemic.

Examples of diseases and conditions that may be mediated by IL-17 or the Th17 pathway include multiple sclerosis; arthritis, such as rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, such as Crohn's disease or ulcerative colitis; celiac disease; asthma, such as allergic asthma or neutrophilic asthma; chronic obstructive pulmonary disease (COPD); cancer, such as breast cancer, colon cancer, lung cancer or ovarian cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection. In preferred embodiments, the compositions of the invention are used for treating or preventing one or more of these conditions or diseases. In further preferred embodiments, these conditions or diseases are mediated by IL-17 or the Th17 pathway.

In certain embodiments, the compositions of the invention are for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway. In certain embodiments, the compositions of the invention are for use in treating or preventing an inflammatory or autoimmune disease, wherein said treatment or prevention is achieved by reducing or preventing elevation of the Th17 inflammatory response. In certain embodiments, the compositions of the invention are for use in treating a patient with an inflammatory or autoimmune disease, wherein the patient has elevated IL-17 levels or elevated Th17 cells or is exhibiting a Th17 inflammatory response. In certain embodiments, the patient may have been diagnosed with a chronic inflammatory or autoimmune disease or condition, or the composition of the invention may be for use in preventing an inflammatory or autoimmune disease or condition developing into a chronic inflammatory or autoimmune disease or condition. In certain embodiments, the disease or condition may not be responsive to treatment with TNF- α inhibitors. These uses of the invention may be applied to any of the specific disease or conditions listed in the preceding paragraph.

IL-17 and the Th17 pathway are often associated with chronic inflammatory and autoimmune diseases, so the compositions of the invention may be particularly useful for treating or preventing

chronic diseases or conditions as listed above. In certain embodiments, the compositions are for use in patients with chronic disease. In certain embodiments, the compositions are for use in preventing the development of chronic disease.

5 The compositions of the invention may be useful for treating diseases and conditions mediated by IL-17 or the Th17 pathway and for addressing the Th17 inflammatory response, so the compositions of the invention may be particularly useful for treating or preventing chronic disease, treating or preventing disease in patients that have not responded to other therapies (such as treatment with TNF- α inhibitors), and/or treating or preventing the tissue damage and symptoms associated with IL-17 and Th17 cells. For example, IL-17 is known to activate matrix destruction in cartilage and bone
10 tissue and IL-17 has an inhibitory effect on matrix production in chondrocytes and osteoblasts, so the compositions of the invention may be useful for treating or preventing bone erosion or cartilage damage.

In certain embodiments, treatment with compositions of the invention provides a reduction or prevents an elevation in IL-17 levels, in particular IL-17A levels. In certain embodiments, treatment
15 with compositions of the invention provides a reduction or prevents an elevation in IFN- γ , IL-1 β , RANTES, MIP-1 α , IL-8 or IL-6 levels. Such reduction or prevention of elevated levels of these cytokines may be useful for treating or preventing inflammatory and autoimmune diseases and conditions, in particular those mediated by IL-17 or the Th17 pathway.

Asthma

20 In preferred embodiments, the compositions of the invention are for use in treating or preventing asthma. The examples demonstrate that the compositions of the invention achieve a reduction in the recruitment of neutrophils and/or eosinophils into the airways following sensitisation and challenge with house dust mite extract and so they may be useful in the treatment or prevention of asthma. Asthma is a chronic disease characterised by inflammation and restriction of the airways. The
25 inflammation in asthma may be mediated by IL-17 and/or Th17 cells, and so the compositions of the invention may be particularly effective for preventing or treating asthma. The inflammation in asthma may be mediated by eosinophils and/or neutrophils.

In certain embodiments, the asthma is eosinophilic or allergic asthma. Eosinophilic and allergic asthma are characterised by increased numbers of eosinophils in peripheral blood and in airway
30 secretions and is associated pathologically with thickening of the basement membrane zone and pharmacologically by corticosteroid responsiveness [26]. Compositions that reduce or inhibit eosinophil recruitment or activation may be useful for treating or preventing eosinophilic and allergic asthma.

In additional embodiments, the compositions of the invention are for use in treating or preventing neutrophilic asthma (or non-eosinophilic asthma). High neutrophil numbers are associated with severe asthma that may be insensitive to corticosteroid treatment. Compositions that reduce or inhibit neutrophil recruitment or activation may be useful for treating or preventing neutrophilic asthma.

5 Eosinophilic and neutrophilic asthma are not mutually exclusive conditions and treatments that help address either the eosinophil and neutrophil responses may be useful for treating asthma in general.

Increased IL-17 levels and activation of the Th17 pathway are associated with severe asthma, so the compositions of the invention may be useful for preventing the development of severe asthma or for treating severe asthma.

10 In certain embodiments, the compositions of the invention are for use in methods reducing an eosinophilic inflammatory response in the treatment or prevention of asthma, or for use in methods of reducing a neutrophilic inflammatory response in the treatment or prevention of asthma. As noted above, high levels of eosinophils in asthma is associated pathologically with thickening of the basement membrane zone, so reducing eosinophilic inflammatory response in the treatment or
15 prevention of asthma may be able to specifically address this feature of the disease. Also, elevated neutrophils, either in combination with elevated eosinophils or in their absence, is associated with severe asthma and chronic airway narrowing. Therefore, reducing the neutrophilic inflammatory response may be particularly useful for addressing severe asthma.

In certain embodiments, the compositions reduce peribronchiolar infiltration in allergic asthma, or
20 are for use in reducing peribronchiolar infiltration in the treatment of allergic asthma. In certain embodiments, the compositions reduce peribronchiolar and/or perivascular infiltration in neutrophilic asthma, or are for use in reducing peribronchiolar and/or perivascular infiltration in the treatment of allergic neutrophilic asthma.

In certain embodiments, treatment with compositions of the invention provides a reduction or
25 prevents an elevation in IL-1 β , IFN γ , RANTES, MIP-1 α or IL-8 levels.

In certain embodiments, the compositions of the invention are for use in a method of treating asthma that results in a reduction of the eosinophilic and/or neutrophilic inflammatory response. In certain
embodiments, the patient to be treated has, or has previously been identified as having, elevated neutrophil or eosinophil levels, for example as identified through blood sampling or sputum analysis.

30 The compositions of the invention may be useful for preventing the development of asthma in a new-born when administered to the new-born, or to a pregnant woman. The compositions may be useful for preventing the development of asthma in children. The compositions of the invention may be useful for treating or preventing adult-onset asthma. The compositions of the invention may be useful

for managing or alleviating asthma. The compositions of the invention may be particularly useful for reducing symptoms associated with asthma that is aggravated by allergens, such as house dust mites.

Treatment or prevention of asthma may refer to, for example, an alleviation of the severity of symptoms or a reduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.

Arthritis

In preferred embodiments, the compositions of the invention are for use in treating or preventing rheumatoid arthritis (RA). The examples demonstrate that the compositions of the invention achieve a reduction in the clinical signs of RA in a mouse model, reduce cartilage and bone damage, and reduce the IL-17 inflammatory response, and so they may be useful in the treatment or prevention of RA. RA is a systemic inflammatory disorder that primarily affects joints. RA is associated with an inflammatory response that results in swelling of joints, synovial hyperplasia, and destruction of cartilage and bone. IL-17 and Th17 cells may have a key role in RA, for example because IL-17 inhibits matrix production in chondrocytes and osteoblasts and activates the production and function of matrix metalloproteinases and because RA disease activity is correlated to IL-17 levels and Th-17 cell numbers [27,28], so the compositions of the invention may be particularly effective for preventing or treating RA.

In certain embodiments, the compositions of the invention are for use in lowering IL-17 levels or preventing elevation of IL-17 levels in the treatment or prevention of RA. In certain embodiments, treatment with compositions of the invention provides a reduction or prevents an elevation in IL-17 levels, in particular IL-17A levels. In certain embodiments, treatment with compositions of the invention provides a reduction or prevents an elevation in IFN- γ or IL-6 levels.

In certain embodiments, treatment with the compositions of the invention results in a reduction in the swelling of joints. In certain embodiments, the compositions of the invention are for use in patients with swollen joints or patients identified as at risk of having swollen joints. In certain embodiments, the compositions of the invention are for use in a method of reducing joint swelling in RA.

In certain embodiments, treatment with the compositions of the invention results in a reduction in cartilage damage or bone damage. In certain embodiments, the compositions of the invention are for use in reducing or preventing cartilage or bone damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patient with severe RA that are at risk of cartilage or bone damage.

Increased IL-17 levels and Th17 cell numbers are associated with cartilage and bone destruction in RA [27,28]. IL-17 is known to activate matrix destruction in cartilage and bone tissue and IL-17 has an inhibitory effect on matrix production in chondrocytes and osteoblasts. Therefore, in certain

embodiments, the compositions of the invention are for use in preventing bone erosion or cartilage damage in the treatment of RA. In certain embodiments, the compositions are for use in treating patients that exhibit bone erosion or cartilage damage or patients identified as at risk of bone erosion or cartilage damage.

5 TNF- α is also associated with RA, but TNF- α is not involved in the pathogenesis of the later stages of the disease. In contrast, IL-17 has a role throughout all stages of chronic disease [29]. Therefore, in certain embodiments the compositions of the invention are for use in treating chronic RA or late-stage RA, such as disease that includes joint destruction and loss of cartilage. In certain
10 embodiments, the compositions of the invention are for treating patients that have previously received anti-TNF- α therapy. In certain embodiments, the patients to be treated do not respond or no longer respond to anti-TNF- α therapy.

The compositions of the invention may be useful for modulating a patient's immune system, so in certain embodiments the compositions of the invention are for use in preventing RA in a patient that has been identified as at risk of RA, or that has been diagnosed with early-stage RA. The
15 compositions of the invention may be useful for preventing the development of RA.

The compositions of the invention may be useful for managing or alleviating RA. The compositions of the invention may be particularly useful for reducing symptoms associated with joint swelling or bone destruction. Treatment or prevention of RA may refer to, for example, an alleviation of the severity of symptoms or a reduction in the frequency of exacerbations or the range of triggers that are
20 a problem for the patient.

Multiple sclerosis

In preferred embodiments, the compositions of the invention are for use in treating or preventing multiple sclerosis. The examples demonstrate that the compositions of the invention achieve a reduction in the disease incidence and disease severity in a mouse model of multiple sclerosis (the
25 EAE model), and so they may be useful in the treatment or prevention of multiple sclerosis. Multiple sclerosis is an inflammatory disorder associated with damage to the myelin sheaths of neurons, particularly in the brain and spinal column. Multiple sclerosis is a chronic disease, which is progressively incapacitating and which evolves in episodes. IL-17 and Th17 cells may have a key role in multiple sclerosis, for example because IL-17 levels may correlate with multiple sclerosis
30 lesions, IL-17 can disrupt blood brain barrier endothelial cell tight junctions, and Th17 cells can migrate into the central nervous system and cause neuronal loss [30,31]. Therefore, the compositions of the invention may be particularly effective for preventing or treating multiple sclerosis.

In certain embodiments, treatment with the compositions of the invention results in a reduction in disease incidence or disease severity. In certain embodiments, the compositions of the invention are

for use in reducing disease incidence or disease severity. In certain embodiments, treatment with the compositions of the invention prevents a decline in motor function or results in improved motor function. In certain embodiments, the compositions of the invention are for use in preventing a decline in motor function or for use in improving motor function. In certain embodiments, treatment
5 with the compositions of the invention prevents the development of paralysis. In certain embodiments, the compositions of the invention are for use in preventing paralysis in the treatment of multiple sclerosis.

The compositions of the invention may be useful for modulating a patient's immune system, so in certain embodiments the compositions of the invention are for use in preventing multiple sclerosis in
10 a patient that has been identified as at risk of multiple sclerosis, or that has been diagnosed with early-stage multiple sclerosis or "relapsing-remitting" multiple sclerosis. The compositions of the invention may be useful for preventing the development of sclerosis. Indeed, the examples show that administration of compositions of the invention prevented the development of disease in many mice.

The compositions of the invention may be useful for managing or alleviating multiple sclerosis. The
15 compositions of the invention may be particularly useful for reducing symptoms associated with multiple sclerosis. Treatment or prevention of multiple sclerosis may refer to, for example, an alleviation of the severity of symptoms or a reduction in the frequency of exacerbations or the range of triggers that are a problem for the patient.

Cancer

20 In preferred embodiments, the compositions of the invention are for use in treating or preventing cancer. IL-17 and the Th17 pathway have central roles in cancer development and progression, and so the compositions of the invention may be useful for treating or preventing cancer.

Although the roles of IL-17 and Th17 cells in cancer are not fully understood, numerous pro-tumour effects of IL-17 and Th17 cells are known. For example, Th17 cells and IL-17 can promote
25 angiogenesis, increase proliferation and survival of tumor cells and activate tumour-promoting transcription factors [32-34].

In certain embodiments, treatment with the compositions of the invention results in a reduction in tumour size or a reduction in tumour growth. In certain embodiments, the compositions of the invention are for use in reducing tumour size or reducing tumour growth. The compositions of the
30 invention may be effective for reducing tumour size or growth. In certain embodiments, the compositions of the invention are for use in patients with solid tumours. In certain embodiments, the compositions of the invention are for use in reducing or preventing angiogenesis in the treatment of cancer. IL-17 and Th17 cells have central roles in angiogenesis. In certain embodiments, the compositions of the invention are for use in preventing metastasis.

In certain embodiments, the compositions of the invention are for use in treating or preventing breast cancer. The compositions of the invention may be effective for treating breast cancer, and IL-17 and Th17 cells have important roles in breast cancer [35]. In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of breast cancer. In preferred embodiments the cancer is mammary carcinoma. In preferred embodiments the cancer is stage IV breast cancer.

In certain embodiments, the compositions of the invention are for use in treating or preventing lung cancer. The compositions of the invention may be effective for treating lung cancer, and IL-17 and Th17 cells have important roles in lung cancer [36]. In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of lung cancer. In preferred embodiments the cancer is lung carcinoma.

In certain embodiments, the compositions of the invention are for use in treating or preventing liver cancer. The compositions of the invention may be effective for treating liver cancer, and IL-17 and Th17 cells have important roles in liver cancer [37]. In certain embodiments, the compositions of the invention are for use in reducing tumour size, reducing tumour growth, or reducing angiogenesis in the treatment of liver cancer. In preferred embodiments the cancer is hepatoma (hepatocellular carcinoma).

In certain embodiments, the compositions of the invention are for use in treating or preventing carcinoma. The compositions of the invention may be particularly effective for treating carcinoma. In certain embodiments, the compositions of the invention are for use in treating or preventing non-immunogenic cancer. The compositions of the invention may be effective for treating non-immunogenic cancers.

In further embodiments, the compositions of the invention are for use in treating or preventing acute lymphoblastic leukemia (ALL), acute myeloid leukemia, adrenocortical carcinoma, basal-cell carcinoma, bile duct cancer, bladder cancer, bone tumor, osteosarcoma/malignant fibrous histiocytoma, brainstem glioma, brain tumor, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, breast cancer, bronchial adenomas/carcinoids, Burkitt's lymphoma, carcinoid tumor, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, glioma, childhood visual pathway and hypothalamic, Hodgkin lymphoma, melanoma, islet cell carcinoma, Kaposi sarcoma, renal cell cancer, laryngeal cancer, leukaemias, lymphomas, mesothelioma, neuroblastoma, non-Hodgkin lymphoma, oropharyngeal cancer, osteosarcoma, ovarian cancer,

pancreatic cancer, parathyroid cancer, pharyngeal cancer, pituitary adenoma, plasma cell neoplasia, prostate cancer, renal cell carcinoma, retinoblastoma, sarcoma, testicular cancer, thyroid cancer, or uterine cancer.

The compositions of the invention may be particularly effective when used in combination with further therapeutic agents. The immune-modulatory effects of the compositions of the invention may be effective when combined with more direct anti-cancer agents. Therefore, in certain embodiments, the invention provides a composition comprising a bacterial strain of the genus *Bacteroides* and an anticancer agent. In preferred embodiments the anticancer agent is an immune checkpoint inhibitor, a targeted antibody immunotherapy, a CAR-T cell therapy, an oncolytic virus, or a cytostatic drug. In preferred embodiments, the composition comprises an anti-cancer agent selected from the group consisting of: Yervoy (ipilimumab, BMS); Keytruda (pembrolizumab, Merck); Opdivo (nivolumab, BMS); MEDI4736 (AZ/MedImmune); MPDL3280A (Roche/Genentech); Tremelimumab (AZ/MedImmune); CT-011 (pidilizumab, CureTech); BMS-986015 (lirilumab, BMS); MEDI0680 (AZ/MedImmune); MSB-0010718C (Merck); PF-05082566 (Pfizer); MEDI6469 (AZ/MedImmune); BMS-986016 (BMS); BMS-663513 (urelumab, BMS); IMP321 (Prima Biomed); LAG525 (Novartis); ARGX-110 (arGEN-X); PF-05082466 (Pfizer); CDX-1127 (varlilumab; CellDex Therapeutics); TRX-518 (GITR Inc.); MK-4166 (Merck); JTX-2011 (Jounce Therapeutics); ARGX-115 (arGEN-X); NLG-9189 (indoximod, NewLink Genetics); INCB024360 (Incyte); IPH2201 (Innate Immunotherapeutics/AZ); NLG-919 (NewLink Genetics); anti-VISTA (JnJ); Epacadostat (INCB24360, Incyte); F001287 (Flexus/BMS); CP 870893 (University of Pennsylvania); MGA271 (Macrogenix); Emactuzumab (Roche/Genentech); Galunisertib (Eli Lilly); Ulocuplumab (BMS); BKT140/BL8040 (Biokine Therapeutics); Bavituximab (Peregrine Pharmaceuticals); CC 90002 (Celgene); 852A (Pfizer); VTX-2337 (VentiRx Pharmaceuticals); IMO-2055 (Hybridon, Idera Pharmaceuticals); LY2157299 (Eli Lilly); EW-7197 (Ewha Women's University, Korea); Vemurafenib (Plexxikon); Dabrafenib (Genentech/GSK); BMS-777607 (BMS); BLZ945 (Memorial Sloan-Kettering Cancer Centre); Unituxin (dinutuximab, United Therapeutics Corporation); Blincyto (blinatumomab, Amgen); Cyramza (ramucirumab, Eli Lilly); Gazyva (obinutuzumab, Roche/Biogen); Kadcyla (ado-trastuzumab emtansine, Roche/Genentech); Perjeta (pertuzumab, Roche/Genentech); Adcetris (brentuximab vedotin, Takeda/Millennium); Arzerra (ofatumumab, GSK); Vectibix (panitumumab, Amgen); Avastin (bevacizumab, Roche/Genentech); Erbitux (cetuximab, BMS/Merck); Bexxar (tositumomab-I131, GSK); Zevalin (ibritumomab tiuxetan, Biogen); Campath (alemtuzumab, Bayer); Mylotarg (gemtuzumab ozogamicin, Pfizer); Herceptin (trastuzumab, Roche/Genentech); Rituxan (rituximab, Genentech/Biogen); volociximab (Abbvie); Enavatuzumab (Abbvie); ABT-414 (Abbvie); Elotuzumab (Abbvie/BMS); ALX-0141 (Ablynx); Ozaralizumab (Ablynx); Actimab-C (Actinium); Actimab-P (Actinium); Milatuzumab-dox (Actinium); Emab-SN-38 (Actinium); Naptumonmab estafenatox (Active Biotech); AFM13

(Affimed); AFM11 (Affimed); AGS-16C3F (Agensys); AGS-16M8F (Agensys); AGS-22ME (Agensys); AGS-15ME (Agensys); GS-67E (Agensys); ALXN6000 (samalizumab, Alexion); ALT-836 (Altor Bioscience); ALT-801 (Altor Bioscience); ALT-803 (Altor Bioscience); AMG780 (Amgen); AMG 228 (Amgen); AMG820 (Amgen); AMG172 (Amgen); AMG595 (Amgen);
5 AMG110 (Amgen); AMG232 (adecatumumab, Amgen); AMG211 (Amgen/MedImmune); BAY20-10112 (Amgen/Bayer); Rilotumumab (Amgen); Denosumab (Amgen); AMP-514 (Amgen); MEDI575 (AZ/MedImmune); MEDI3617 (AZ/MedImmune); MEDI6383 (AZ/MedImmune); MEDI551 (AZ/MedImmune); Moxetumomab pasudotox (AZ/MedImmune); MEDI565 (AZ/MedImmune); MEDI0639 (AZ/MedImmune); MEDI0680 (AZ/MedImmune); MEDI562
10 (AZ/MedImmune); AV-380 (AVEO); AV203 (AVEO); AV299 (AVEO); BAY79-4620 (Bayer); Anetumab ravtansine (Bayer); vantictumab (Bayer); BAY94-9343 (Bayer); Sibrotuzumab (Boehringer Ingelheim); BI-836845 (Boehringer Ingelheim); B-701 (BioClin); BIIB015 (Biogen); Obinutuzumab (Biogen/Genentech); BI-505 (Bioinvent); BI-1206 (Bioinvent); TB-403 (Bioinvent); BT-062 (Biotest) BIL-010t (Biosceptre); MDX-1203 (BMS); MDX-1204 (BMS); Necitumumab
15 (BMS); CAN-4 (Cantargia AB); CDX-011 (Celldex); CDX1401 (Celldex); CDX301 (Celldex); U3-1565 (Daiichi Sankyo); patritumab (Daiichi Sankyo); tigatuzumab (Daiichi Sankyo); nimotuzumab (Daiichi Sankyo); DS-8895 (Daiichi Sankyo); DS-8873 (Daiichi Sankyo); DS-5573 (Daiichi Sankyo); MORab-004 (Eisai); MORab-009 (Eisai); MORab-003 (Eisai); MORab-066 (Eisai); LY3012207 (Eli Lilly); LY2875358 (Eli Lilly); LY2812176 (Eli Lilly); LY3012217 (Eli Lilly);
20 LY2495655 (Eli Lilly); LY3012212 (Eli Lilly); LY3012211 (Eli Lilly); LY3009806 (Eli Lilly); cixutumumab (Eli Lilly); Flanvotumab (Eli Lilly); IMC-TR1 (Eli Lilly); Ramucirumab (Eli Lilly); Tabalumab (Eli Lilly); Zanolimumab (Emergent Biosolution); FG-3019 (FibroGen); FPA008 (Five Prime Therapeutics); FP-1039 (Five Prime Therapeutics); FPA144 (Five Prime Therapeutics); catumaxomab (Fresenius Biotech); IMAB362 (Ganymed); IMAB027 (Ganymed); HuMax-CD74
25 (Genmab); HuMax-TFADC (Genmab); GS-5745 (Gilead); GS-6624 (Gilead); OMP-21M18 (demcizumab, GSK); mapatumumab (GSK); IMGN289 (ImmunoGen); IMGN901 (ImmunoGen); IMGN853 (ImmunoGen); IMGN529 (ImmunoGen); IMMU-130 (Immunomedics); milatuzumab-dox (Immunomedics); IMMU-115 (Immunomedics); IMMU-132 (Immunomedics); IMMU-106 (Immunomedics); IMMU-102 (Immunomedics); Epratuzumab (Immunomedics); Clivatuzumab
30 (Immunomedics); IPH41 (Innate Immunotherapeutics); Daratumumab (Janssen/Genmab); CNTO-95 (Intetumumab, Janssen); CNTO-328 (siltuximab, Janssen); KB004 (KaloBios); mogamulizumab (Kyowa Hakko Kirin); KW-2871 (ecromeximab, Life Science); Sonpcizumab (Lpath); Margetuximab (Macrogenics); Enoblituzumab (Macrogenics); MGD006 (Macrogenics); MGF007 (Macrogenics); MK-0646 (dalotuzumab, Merck); MK-3475 (Merck); Sym004 (Symphogen/Merck
35 Serono); DI17E6 (Merck Serono); MOR208 (Morphosys); MOR202 (Morphosys); X Mab5574 (Morphosys); BPC-1C (ensituximab, Precision Biologics); TAS266 (Novartis); LFA102 (Novartis); BHQ880 (Novartis/Morphosys); QGE031 (Novartis); HCD122 (lucatumumab, Novartis); LJM716

(Novartis); AT355 (Novartis); OMP-21M18 (Demcizumab, OncoMed); OMP52M51 (Oncomed/GSK); OMP-59R5 (Oncomed/GSK); vantiactumab (Oncomed/Bayer); CMC-544 (inotuzumab ozogamicin, Pfizer); PF-03446962 (Pfizer); PF-04856884 (Pfizer); PSMA-ADC (Progenics); REGN1400 (Regeneron); REGN910 (nesvacumab, Regeneron/Sanofi); REGN421 (enoticumab, Regeneron/Sanofi); RG7221, RG7356, RG7155, RG7444, RG7116, RG7458, RG7598, RG7599, RG7600, RG7636, RG7450, RG7593, RG7596, DCDS3410A, RG7414 (parsatuzumab), RG7160 (imgatuzumab), RG7159 (obintuzumab), RG7686, RG3638 (onartuzumab), RG7597 (Roche/Genentech); SAR307746 (Sanofi); SAR566658 (Sanofi); SAR650984 (Sanofi); SAR153192 (Sanofi); SAR3419 (Sanofi); SAR256212 (Sanofi), SGN-LIV1A (lintuzumab, Seattle Genetics); SGN-CD33A (Seattle Genetics); SGN-75 (vorsetuzumab mafodotin, Seattle Genetics); SGN-19A (Seattle Genetics) SGN-CD70A (Seattle Genetics); SEA-CD40 (Seattle Genetics); ibritumomab tiuxetan (Spectrum); MLN0264 (Takeda); ganitumab (Takeda/Amgen); CEP-37250 (Teva); TB-403 (Thrombogenic); VB4-845 (Viventia); X Mab2512 (Xencor); X Mab5574 (Xencor); nimotuzumab (YM Biosciences); Carlumab (Janssen); NY-ESO TCR (Adaptimmune); MAGE-A-10 TCR (Adaptimmune); CTL019 (Novartis); JCAR015 (Juno Therapeutics); KTE-C19 CAR (Kite Pharma); UCART19 (Cellestis); BPX-401 (Bellicum Pharmaceuticals); BPX-601 (Bellicum Pharmaceuticals); ATTK20 (Unum Therapeutics); CAR-NKG2D (Celyad); Onyx-015 (Onyx Pharmaceuticals); H101 (Shanghai Sunwaybio); DNX-2401 (DNatrix); VCN-01 (VCN Biosciences); Colo-Ad1 (PsiOxus Therapeutics); ProstAtak (Advantagene); Oncos-102 (Oncos Therapeutics); CG0070 (Cold Genesys); Pexa-vac (JX-594, Jennerex Biotherapeutics); GL-ONC1 (Genelux); T-VEC (Amgen); G207 (Medigene); HF10 (Takara Bio); SEPREHVIR (HSV1716, Virttu Biologics); OrienX010 (OrienGene Biotechnology); Reolysin (Oncolytics Biotech); SVV-001 (Neotropix); Cacatak (CVA21, Viralytics); Alimta (Eli Lilly), cisplatin, oxaliplatin, irinotecan, folinic acid, methotrexate, cyclophosphamide, 5-fluorouracil, Zykadia (Novartis), Tafenlar (GSK), Xalkori (Pfizer), Iressa (AZ), Gilotrif (Boehringer Ingelheim), Tarceva (Astellas Pharma), Halaven (Eisai Pharma), Veliparib (Abbvie), AZD9291 (AZ), Alectinib (Chugai), LDK378 (Novartis), Genetespib (Synta Pharma), Tergenpumatucel-L (NewLink Genetics), GV1001 (Kael-GemVax), Tivantinib (ArQule); Cytosan (BMS); Oncovin (Eli Lilly); Adriamycin (Pfizer); Gemzar (Eli Lilly); Xeloda (Roche); Ixempra (BMS); Abraxane (Celgene); Trelstar (Debiopharm); Taxotere (Sanofi); Nexavar (Bayer); IMM-132 (Immunomedics); E7449 (Eisai); Thermadox (Celsion); Cometriq (Exelixis); Lonsurf (Taiho Pharmaceuticals); Camptosar (Pfizer); UFT (Taiho Pharmaceuticals); and TS-1 (Taiho Pharmaceuticals).

Uveitis

In further preferred embodiments, the compositions of the invention are for use in treating or preventing uveitis. The compositions of the invention may achieve a reduction in disease incidence and disease severity in an animal model of uveitis and so they may be useful in the treatment or

prevention of uveitis. Uveitis is inflammation of the uvea and can result in retinal tissue destruction. It can present in different anatomical forms (anterior, intermediate, posterior or diffuse) and result from different, but related, causes, including systemic autoimmune disorders. IL-17 and the Th17 pathway are centrally involved in uveitis, so the compositions of the invention may be particularly effective for preventing or treating uveitis. References [38-45] describe elevated serum levels of interleukin-17A in uveitis patients, specific association of IL17A genetic variants with panuveitis, the role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis, the imbalance between Th17 Cells and regulatory T Cells during monophasic experimental autoimmune uveitis, the up-regulation of IL-17A in patients with uveitis and active Adamantiades-Behçet and Vogt-Koyanagi-Harada (VKH) diseases, the treatment of non-infectious uveitis with secukinumab (anti-IL-17A antibody), and Th17 in uveitic eyes.

In certain embodiments, the uveitis is posterior uveitis. Posterior uveitis presents primarily with inflammation of the retina and choroid and the compositions of the invention may be effective for reducing retinal inflammation and damage.

In certain embodiments, treatment with the compositions of the invention results in a reduction in retinal damage. In certain embodiments, the compositions of the invention are for use in reducing or preventing retinal damage in the treatment of uveitis. In certain embodiments, the compositions are for use in treating patients with severe uveitis that are at risk of retinal damage. In certain embodiments, treatment with the compositions of the invention results in a reduction in optic disc inflammation. In certain embodiments, the compositions of the invention are for use in reducing or preventing optic disc inflammation. In certain embodiments, treatment with the compositions of the invention results in a reduction in retinal tissue infiltration by inflammatory cells. In certain embodiments, the compositions of the invention are for use in reducing retinal tissue infiltration by inflammatory cells. In certain embodiments, treatment with the compositions of the invention results in vision being maintained or improved. In certain embodiments, the compositions of the invention are for use in maintaining or improving vision.

In certain embodiments, the compositions are for use in treating or preventing uveitis associated with a non-infectious or autoimmune disease, such as Behçet disease, Crohn's disease, Fuchs heterochromic iridocyclitis, granulomatosis with polyangiitis, HLA-B27 related uveitis, juvenile idiopathic arthritis, sarcoidosis, spondyloarthritis, sympathetic ophthalmia, tubulointerstitial nephritis and uveitis syndrome or Vogt-Koyanagi-Harada syndrome. IL-17A has been shown to be involved in, for example, Behçet and Vogt-Koyanagi-Harada diseases.

Treatment or prevention of uveitis may refer to, for example, an alleviation of the severity of symptoms or a prevention of relapse.

Modes of administration

Preferably, the compositions of the invention are to be administered to the gastrointestinal tract in order to enable delivery to and / or partial or total colonisation of the intestine with the bacterial strain of the invention. Generally, the compositions of the invention are administered orally, but they
5 may be administered rectally, intranasally, or via buccal or sublingual routes.

In certain embodiments, the compositions of the invention may be administered as a foam, as a spray or a gel.

In certain embodiments, the compositions of the invention may be administered as a suppository, such as a rectal suppository, for example in the form of a theobroma oil (cocoa butter), synthetic hard
10 fat (e.g. suppicire, witepsol), glycerol-gelatin, polyethylene glycol, or soap glycerin composition.

In certain embodiments, the composition of the invention is administered to the gastrointestinal tract via a tube, such as a nasogastric tube, orogastric tube, gastric tube, jejunostomy tube (J tube), percutaneous endoscopic gastrostomy (PEG), or a port, such as a chest wall port that provides access to the stomach, jejunum and other suitable access ports.

The compositions of the invention may be administered once, or they may be administered sequentially as part of a treatment regimen. In certain embodiments, the compositions of the
15 invention are to be administered daily.

In certain embodiments of the invention, treatment according to the invention is accompanied by assessment of the patient's gut microbiota. Treatment may be repeated if delivery of and / or partial
20 or total colonisation with the strain of the invention is not achieved such that efficacy is not observed, or treatment may be ceased if delivery and / or partial or total colonisation is successful and efficacy is observed.

In certain embodiments, the composition of the invention may be administered to a pregnant animal, for example a mammal such as a human in order to prevent an inflammatory or autoimmune disease
25 developing in her child *in utero* and / or after it is born.

The compositions of the invention may be administered to a patient that has been diagnosed with a disease or condition mediated by IL-17 or the Th17 pathway, or that has been identified as being at risk of a disease or condition mediated by IL-17 or the Th17 pathway. The compositions may also be administered as a prophylactic measure to prevent the development of diseases or conditions
30 mediated by IL-17 or the Th17 pathway in a healthy patient.

The compositions of the invention may be administered to a patient that has been identified as having an abnormal gut microbiota. For example, the patient may have reduced or absent colonisation by *Bacteroides*, and in particular *Bacteroides coprocola*.

The compositions of the invention may be administered as a food product, such as a nutritional supplement.

Generally, the compositions of the invention are for the treatment of humans, although they may be used to treat animals including monogastric mammals such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the invention may be useful for enhancing the growth and performance of animals. If administered to animals, oral gavage may be used.

Compositions

Generally, the composition of the invention comprises bacteria. In preferred embodiments of the invention, the composition is formulated in freeze-dried form. For example, the composition of the invention may comprise granules or gelatin capsules, for example hard gelatin capsules, comprising a bacterial strain of the invention.

Preferably, the composition of the invention comprises lyophilised bacteria. Lyophilisation of bacteria is a well-established procedure and relevant guidance is available in, for example, references [46-48].

Alternatively, the composition of the invention may comprise a live, active bacterial culture.

In preferred embodiments, the composition of the invention is encapsulated to enable delivery of the bacterial strain to the intestine. Encapsulation protects the composition from degradation until delivery at the target location through, for example, rupturing with chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which may be triggered by changes in pH.

Any appropriate encapsulation method may be used. Exemplary encapsulation techniques include entrapment within a porous matrix, attachment or adsorption on solid carrier surfaces, self-aggregation by flocculation or with cross-linking agents, and mechanical containment behind a microporous membrane or a microcapsule. Guidance on encapsulation that may be useful for preparing compositions of the invention is available in, for example, references [49] and [50].

The composition may be administered orally and may be in the form of a tablet, capsule or powder. Encapsulated products are preferred because *Bacteroides* are anaerobes. Other ingredients (such as vitamin C, for example), may be included as oxygen scavengers and prebiotic substrates to improve the delivery and / or partial or total colonisation and survival *in vivo*. Alternatively, the probiotic composition of the invention may be administered orally as a food or nutritional product, such as milk or whey based fermented dairy product, or as a pharmaceutical product.

The composition may be formulated as a probiotic.

A composition of the invention includes a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of a bacterial strain is sufficient to exert a beneficial

effect upon a patient. A therapeutically effective amount of a bacterial strain may be sufficient to result in delivery to and / or partial or total colonisation of the patient's intestine.

A suitable daily dose of the bacteria, for example for an adult human, may be from about 1×10^3 to about 1×10^{11} colony forming units (CFU); for example, from about 1×10^7 to about 1×10^{10} CFU; in another example from about 1×10^6 to about 1×10^{10} CFU.

In certain embodiments, the composition contains the bacterial strain in an amount of from about 1×10^6 to about 1×10^{11} CFU/g, respect to the weight of the composition; for example, from about 1×10^8 to about 1×10^{10} CFU/g. The dose may be, for example, 1 g, 3g, 5g, and 10g.

Typically, a probiotic, such as the composition of the invention, is optionally combined with at least one suitable prebiotic compound. A prebiotic compound is usually a non-digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and transgalacto-oligosaccharides.

In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of from about 1 to about 30% by weight, respect to the total weight composition, (e.g. from 5 to 20% by weight). Carbohydrates may be selected from the group consisting of: fructo- oligosaccharides (or FOS), short-chain fructo-oligosaccharides, inulin, isomalt-oligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans, arable gum modified and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats, and citrus fibers. In one aspect, the prebiotics are the short-chain fructo-oligosaccharides (for simplicity shown herein below as FOSs-c.c); said FOSs-c.c. are not digestible carbohydrates, generally obtained by the conversion of the beet sugar and including a saccharose molecule to which three glucose molecules are bonded.

The compositions of the invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients may be found in the reference [51]. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in reference [52]. Examples of suitable carriers include lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like. Examples of suitable diluents include ethanol, glycerol and water. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s). Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants

include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Preservatives, stabilizers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

The compositions of the invention may be formulated as a food product. For example, a food product may provide nutritional benefit in addition to the therapeutic effect of the invention, such as in a nutritional supplement. Similarly, a food product may be formulated to enhance the taste of the composition of the invention or to make the composition more attractive to consume by being more similar to a common food item, rather than to a pharmaceutical composition. In certain embodiments, the composition of the invention is formulated as a milk-based product. The term "milk-based product" means any liquid or semi-solid milk- or whey- based product having a varying fat content. The milk-based product can be, e.g., cow's milk, goat's milk, sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk and whey without any processing, or a processed product, such as yoghurt, curdled milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk beverages, such as whey beverages, fermented milks, condensed milks, infant or baby milks; flavoured milks, ice cream; milk-containing food such as sweets.

In certain embodiments, the compositions of the invention contain a single bacterial strain or species and do not contain any other bacterial strains or species. Such compositions may comprise only *de minimis* or biologically irrelevant amounts of other bacterial strains or species. Such compositions may be a culture that is substantially free from other species of organism.

The compositions for use in accordance with the invention may or may not require marketing approval.

In some cases, the lyophilised bacterial strain is reconstituted prior to administration. In some cases, the reconstitution is by use of a diluent described herein.

The compositions of the invention can comprise pharmaceutically acceptable excipients, diluents or carriers.

In certain embodiments, the invention provides a pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat a disorder when administered to a subject in need thereof; and wherein the disorder is selected from the group consisting of asthma, allergic asthma, neutrophilic asthma, osteoarthritis, psoriatic arthritis, juvenile idiopathic arthritis, neuromyelitis optica (Devic's disease), ankylosing spondylitis, spondyloarthritis, systemic lupus erythematosus,

celiac disease, chronic obstructive pulmonary disease (COPD), cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, uveitis, scleritis, vasculitis, Behcet's disease, atherosclerosis, atopic dermatitis, emphysema, periodontitis, allergic rhinitis, and allograft rejection.

5 In certain embodiments, the invention provides pharmaceutical composition comprising: a bacterial strain of the invention; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the bacterial strain is in an amount sufficient to treat or prevent a disease or condition mediated by IL-17 or the Th17 pathway. In preferred embodiments, said disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, celiac disease, asthma, allergic asthma, neutrophilic asthma, osteoarthritis, 10 psoriatic arthritis, juvenile idiopathic arthritis, neuromyelitis optica (Devic's disease), ankylosing spondylitis, spondyloarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD), cancer, breast cancer, colon cancer, lung cancer, ovarian cancer, uveitis, scleritis, vasculitis, Behcet's disease, atherosclerosis, atopic dermatitis, emphysema, periodontitis, allergic rhinitis, and allograft rejection.

15 In certain embodiments, the invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is from about 1×10^3 to about 1×10^{11} colony forming units per gram with respect to a weight of the composition.

In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g or 10 g.

20 In certain embodiments, the invention provides the above pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sublingual.

In certain embodiments, the invention provides the above pharmaceutical composition, comprising a carrier selected from the group consisting of lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol and sorbitol. 25

In certain embodiments, the invention provides the above pharmaceutical composition, comprising a diluent selected from the group consisting of ethanol, glycerol and water.

In certain embodiments, the invention provides the above pharmaceutical composition, comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweetener, acacia, tragacanth, sodium alginate, carboxymethyl cellulose, polyethylene glycol, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate and sodium chloride. 30

In certain embodiments, the invention provides the above pharmaceutical composition, further comprising at least one of a preservative, an antioxidant and a stabilizer.

In certain embodiments, the invention provides the above pharmaceutical composition, comprising a preservative selected from the group consisting of sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.

In certain embodiments, the invention provides the above pharmaceutical composition, wherein said bacterial strain is lyophilised.

In certain embodiments, the invention provides the above pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere having 50% relative humidity, at least 80% of the bacterial strain as measured in colony forming units, remains after a period of at least about: 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years.

Culturing methods

The bacterial strains for use in the present invention can be cultured using standard microbiology techniques as detailed in, for example, references [53-55].

Bacterial strains of the genus *Bacteroides* may be cultured using a method such as that outlined below, which may provide good growth and reliability. This method is particularly useful for culturing strains of the species *Bacteroides coprocola*.

Bacterial strains of the genus *Bacteroides*, and in particular of the species *Bacteroides coprocola*, may be cultured by using a liquid stock to inoculate the plate (or a larger liquid culture), rather than a scrape of frozen stock as may generally be used (see, for example, reference [56]). The establishment of mature colonies is reliable and quick if frozen stocks of *Bacteroides* strains are thawed and used as a liquid culture.

A method suitable for culturing a bacterial strain of the genus *Bacteroides*, may comprise:

- (a) providing a frozen stock of the bacterial strain;
- (b) thawing the frozen stock to provide a liquid stock;
- (c) adding the liquid stock to a solid or liquid medium; and
- (d) incubating the solid or liquid media to provide a culture of the bacterial strain.

This method is particularly useful for culturing bacterial strains of *Bacteroides coprocola*.

The frozen stock may be a frozen glycerol stock. The solid or liquid medium may be YCFA agar or YCFA medium. YCFA medium may include (per 100ml, approximate values): Casitone (1.0 g), yeast extract (0.25 g), NaHCO₃ (0.4 g), cysteine (0.1 g), K₂HPO₄ (0.045 g), KH₂PO₄ (0.045 g), NaCl

(0.09 g), $(\text{NH}_4)_2\text{SO}_4$ (0.09 g), $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ (0.009 g), CaCl_2 (0.009 g), resazurin (0.1 mg), hemin (1 mg), biotin (1 μg), cobalamin (1 μg), *p*-aminobenzoic acid (3 μg), folic acid (5 μg), and pyridoxamine (15 μg).

5 The incubating in step (d) may be performed for at least 36 hours, such as 48 or 72 hours. The incubating in step (d) may be performed in an anaerobic environment, such as an anaerobic hood. The culture provided in step (d) may be used to subculture a larger culture of the bacterial strain. Such subculturing allows greater amounts of bacteria to be prepared and may be useful for providing compositions of the invention at a commercial scale.

The thawing in step (b) may be performed at room temperature, or by hand warming.

10 The amount of liquid stock added in step (c) may be between 300 μl and 5ml, such 500 μl . The stock may be 20% glycerol stock.

The above method may be used for preparing a pharmaceutical composition or a food product, in which case the method may comprise additional steps of isolating the bacterial strain, optionally lyophilising the bacterial strain, and combining the bacterial strain with one or more
15 pharmaceutically acceptable excipients or carriers, or one or more food substances. This pharmaceutical composition or food product prepared by the method may be used in a method of treating or preventing a disease or condition mediated by IL-17 or the Th17 pathway.

An exemplary method of culturing bacterial strains of the genus *Bacteroides*, and in particular of the species *Bacteroides coprocola*, may comprise:

- 20 1. 500 μl of 20% glycerol stock is plated onto YCFA agar.
2. Plates are left in the anaerobic hood for 48/72 hours to generate mature colonies.
3. The bacteria are cultured in 10ml volumes, whether this be from a single colony or a 1% liquid subculture.
- 25 4. Plates with colonies are only used for 2/3 days after mature colony morphology is achieved.

Bacterial strains for use in vaccine compositions

The inventors have identified that the bacterial strains of the invention are useful for treating or preventing diseases or conditions mediated by IL-17 or the Th17 pathway. This is likely to be a result of the effect that the bacterial strains of the invention have on the host immune system. Therefore,
30 the compositions of the invention may also be useful for preventing diseases or conditions mediated by IL-17 or the Th17 pathway, when administered as vaccine compositions. In certain such embodiments, the bacterial strains of the invention may be killed, inactivated or attenuated. In certain

such embodiments, the compositions may comprise a vaccine adjuvant. In certain embodiments, the compositions are for administration via injection, such as via subcutaneous injection.

General

5 The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, references [57] and [58-64], *etc.*

The term “comprising” encompasses “including” as well as “consisting” *e.g.* a composition “comprising” X may consist exclusively of X or may include something additional *e.g.* X + Y.

10 The term “about” in relation to a numerical value x is optional and means, for example, $x \pm 10\%$.

The word “substantially” does not exclude “completely” *e.g.* a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the definition of the invention.

15 References to a percentage sequence identity between two nucleotide sequences means that, when aligned, that percentage of nucleotides are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of ref. [65]. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-
20 Waterman homology search algorithm is disclosed in ref. [66].

Unless specifically stated, a process or method comprising numerous steps may comprise additional steps at the beginning or end of the method, or may comprise additional intervening steps. Also, steps may be combined, omitted or performed in an alternative order, if appropriate.

25 Various embodiments of the invention are described herein. It will be appreciated that the features specified in each embodiment may be combined with other specified features, to provide further embodiments. In particular, embodiments highlighted herein as being suitable, typical or preferred may be combined with each other (except when they are mutually exclusive).

MODES FOR CARRYING OUT THE INVENTION

Example 1 – Efficacy of bacterial inocula in a mouse model of house dust mite-induced asthma

Summary

30

Mice were administered with compositions comprising bacterial strains according to the invention and were subsequently challenged with house dust mite (HDM) extract to elicit an allergic

inflammatory response. The inflammatory response to HDM includes eosinophilic and neutrophilic components, is mediated by IL-17 and the Th17 pathway, and is a model for asthma. The magnitude and characteristics of the inflammatory response exhibited by mice treated with compositions of the invention were compared to control groups. The compositions of the invention were found to alleviate the inflammatory response, and to reduce recruitment of eosinophils and neutrophils, indicating that they may be useful for treating IL-17- and Th17-mediated conditions such as eosinophilia, neutrophilia and asthma.

Strain

675: *Bacteroides coprocola*

Study design

Groups:

1. Negative control group. Treatment with vehicle control (per oral).
3. Treatment with therapeutic bacteria inoculum strain 675 (per oral).
7. Positive control group. Treatment with Dexamethasone (i.p.).
8. Untreated Control Group.

Number of mice per group = 5

Day -14 to day 13: Daily administration of vehicle control per oral (Group 1).

Day -14 to day 13: Daily administration of therapeutic bacteria inoculum per oral (Group 2-6).

Day 0, 2, 4, 7, 9, 11 Administration of 15ug HDM (house dust mite extract – Catalogue number: XPB70D3A25, Lot number: 231897, Greer Laboratories, Lenoir, NC, USA) in a volume of 30ul PBS per nasal (Group 1-8).

Day 0, 2, 4, 7, 9, 11 Administration of Dexamethasone (i.p., 3mg/kg, Sigma-Aldrich, Catalogue number D1159) (Group 7).

Day 14 Sacrifice of all animals for analysis.

Total number of mice = 40.

Endpoints and analysis

On day 14 animals were sacrificed by lethal intraperitoneal injection with pentobarbitol (Streuli Pharma AG, Uznach, Cat: 1170139A) immediately followed by a bronchoalveolar lavage (BAL).

Cells were isolated from the BAL (bronchoalveolar lavage) fluid and differential cell counts performed (200 cell counts/ samples).

Material and Methods

Mice. Female 7 week old BALB/c mice were purchased from Charles River Laboratories and randomly allocated to cages totally 5 mice per cage (Ventilated cages sourced from Indulab AG, Gams, Switzerland Cage type: “The Sealsafe™ – IVC cage. Product number 1248L). Cages were labeled with study number, group number and experimental starting date. Mice were monitored weekly and acclimatized to facility for 7 days prior to initiation of study (Study Day -14). Animals

were 8 weeks old on Study Day -14. Potable water and food were available ad libitum. Cage enrichment was present. Daily care of the animals was performed according to local authorization license number 2283.1 (issued and approved by: Service de la consommation et des affaires vétérinaires du Canton de Vaud). Potable water and food were available ad libitum and refreshed once daily. Cage enrichment was present. Animal welfare regulations were observed as given by official authorities of Switzerland under ordinance 455.163 of the FVO (Federal Veterinary Office) on laboratory animal husbandry, production of genetically modified animals, and methods of animal experimentation.

Culturing of bacteria inoculum. Within a sterile workstation, a cryo-vial of bacteria was thawed by warming in gloved hand and ~0.7 ml of contents injected into a Hungate tube (Cat Number, 1020471, Glasgerätebau Ochs, Bovenden-Lenglern, Germany), containing 8 ml of anaerobic YCFA. Two tubes per strain were usually prepared. The Hungate tubes were then incubated (static) at 37°C for up to 24-26 hours (for strain 675).

Since the bacterial ODs of inoculum strain 675 was found to be variable, 3 different culturing approaches were performed each day. 2 vials were cultured as described above and a third sample was cultured utilizing a 400ul aliquot from the prior day's culture for seeding. On 4 treatment days the latter approach was utilized, because of poor growth from the frozen stock. Of note, this approach resulted in robust growth of bacterial strain 675 on all occasions.

Culturing of vehicle control. A Hungate tube containing 8 ml of anaerobic YCFA was incubated (static) at 37°C for 16h.

Administration of bacteria inoculum or vehicle control. 400ul of cultured bacteria inoculum or vehicle control were administered per day per oral gavage.

Intranasal sensitization. Mice were anesthetized by i.p. injection with 9.75 mg xylasol and 48.75 mg ketasol per kg (Dr. E. Graeb AG, Bern, Switzerland) and administered with 15ug of HDM (Catalogue number: XPB70D3A25, Lot number: 231897, Greer Laboratories, Lenoir, NC, USA) in a volume of 30ul PBS per nasal.

Preparation and administration of positive control compound Dexamethasone. Dexamethasone 21-phosphate disodium salt (Sigma-Aldrich, Catalogue number D1159, Lot N° SLBD.1030V) was solved in H₂O and administered to the animals in a dose of 3mg/kg in a volume of 200ul per oral at days indicated in study protocol above.

Terminal procedure. On day 14 animals were sacrificed by lethal i.p. injection with pentobarbitol (Streuli Pharma AG, Uznach, Cat: 1170139A) immediately followed by bronchoalveolar lavage (BAL) in 500 ul of saline.

Measurement of cellular infiltrates into BAL. Cells were isolated from the BAL fluid and differential cell counts were performed based upon standard morphological and cytochemical criteria.

Graphs and statistical analysis. All graphs were generated with Graphpad Prism Version 6 and a one-way ANOVA was applied. Results from the statistical analysis were provided with the individual data tables. Error bars represent Standard Error of the Mean (SEM).

Results and analysis

The results of the experiments are shown in Figures 1-9.

No morbidity or mortality was noted in the mice treated with the bacteria or the vehicle. The two controls, vehicle treatment (negative control) and the dexamethasone treatment (positive control) behaved as expected, with impaired eosinophilia and neutrophilia noted following dexamethasone treatment.

The most important results of this experiment are displayed in Figures 6 and 7, which report on the total number and percentage of neutrophils detected in bronchiolar lavage following challenge with HDM. Strain 675 reduced total neutrophils and the proportion of neutrophils in BAL relative to the vehicle-only control.

Example 2 – Efficacy of bacterial inocula in a mouse model of severe neutrophilic asthma

Summary

Mice were administered with compositions comprising bacterial strains according to the invention and were subsequently sensitised with subcutaneous administrations of house dust mite (HDM) extract and challenged with an intranasal administration of HDM in order to model the inflammatory response of severe neutrophilic asthma. The magnitude and characteristics of the inflammatory response exhibited by mice treated with compositions of the invention were compared to control groups. The compositions of the invention were found to alleviate the inflammatory response, and in particular to reduce recruitment of neutrophils, in a manner comparable to the positive control comprising administrations of anti-IL-17 antibodies. The data therefore indicate that the compositions of the invention may be useful for treating IL-17- and Th17-mediated conditions such as neutrophilia and asthma.

Strain

675: *Bacteroides coprocola*

Study design

Groups:

1. Negative control group. Treatment with vehicle control (per oral).

3. Treatment with therapeutic bacteria inoculum strain 675 (per oral).

7. Positive control group. Treatment anti-IL-17 (i.p.).

8. Untreated Control Group.

9. Healthy mice (baseline).

Number of mice per group (Group 1-8) = 5

Day -14 to day 17: Daily administration of vehicle control per oral (Group 1).

Day -14 to day 17: Daily administration of therapeutic bacteria inoculum per oral (Group 2-6).

Day 0: Sensitization with HDM in CFA (s.c.) (Group 1-8).

Day 7: Sensitization with HDM in CFA (s.c.) (Group 1-8).

Day 13, 15, 17: Administration of anti IL-17 neutralizing antibody per i.p. (Group 7).

Day 14, 15, 16, 17: Challenge with HDM in 30ul PBS per nasal (Group 1-8).

Day 18: Sacrifice of all animals for analysis.

Endpoints and analysis:

On day 14 animals were sacrificed by lethal intraperitoneal injection with pentobarbitol (Streuli Pharma AG, Uznach, Cat: 1170139A) immediately followed by a bronchoalveolar lavage (BAL). Cells were isolated from the BAL fluid and differential cell counts performed (200 cell counts/samples).

Material and Methods.

Mice. Female 7 week old C57BL/6 mice were purchased from Charles River Laboratories and randomly allocated to cages totally 5 mice per cage (Ventilated cages sourced from Indulab AG, Gams, Switzerland Cage type: "The Sealsafe™ – IVC cage. Product number 1248L). Cages were labelled with study number, group number and experimental starting date. Mice were monitored weekly and acclimatized to facility for 7 days prior to initiation of study (Study Day -14). Animals were 8 weeks old on Study Day -14. Potable water and food were available ad libitum. Cage enrichment was present. Daily care of the animals was performed according to local authorization license number 2283.1 (issued and approved by: Service de la consommation et des affaires vétérinaires du Canton de Vaud). Potable water and food were available ad libitum and refreshed once daily. Cage enrichment was present. Animal welfare regulations were observed as given by official authorities of Switzerland under ordinance 455.163 of the FVO (Federal Veterinary Office) on laboratory animal husbandry, production of genetically modified animals, and methods of animal experimentation.

Culturing of bacteria inoculum. Within a sterile workstation, a cryo-vial of bacteria was thawed by warming in gloved hand and ~0.7 ml of contents injected into a Hungate tube (Cat Number, 1020471, Glasgerätebau Ochs, Bovenden-Lenglern, Germany), containing 8 ml of anaerobic YCFA. Two tubes per strain were usually prepared. The Hungate tubes were then incubated (static) at 37°C for up to 24-26 hours (for strain 675).

Since the bacterial ODs of inoculum strain 675 were variable, 3 different culturing approaches were performed each day. 2 vials were cultured as described above and a third sample was cultured utilizing a 400ul aliquot from the prior day's culture for seeding. On 4 treatment days the latter approach was utilized, because of poor growth from the frozen stock. Of note, this approach resulted in robust growth of bacterial strain 675 on all occasions.

Culturing of vehicle control. A Hungate tube containing 8 ml of anaerobic YCFA was incubated (static) at 37°C for 16h.

Administration of bacteria inoculum or vehicle control. 400ul of cultured bacteria inoculum or vehicle control were administered per day per oral gavage.

HDM sensitization. 50 µg of HDM (Catalogue number: XPB70D3A25, Lot number: 231897, Greer Laboratories, Lenoir, NC, USA) in PBS was emulsified in equal volume of complete Freund's adjuvant (CFA Chondrex Inc. Washington, USA) and administered subcutaneously in a volume of 200 µl, twice over two weeks on opposite flanks. A week after the second immunization, mice were anesthetized by i.p. injection with 9.75 mg xylasol and 48.75 mg ketasol per kg (Dr. E. Graeub AG, Bern, Switzerland) and then given intranasal challenges of 15 µg of HDM in a volume of 30ul PBS on 4 consecutive days. Analysis was performed one day after the final challenge.

Preparation and administration of positive control compound anti mouse IL-17 antibody. Anti-IL-17 neutralizing antibody was sourced from Bio X Cell and was stored at 4°C (Clone 17F3, Cat. Number BE0173, Bio X Cell) and administered per i.p. at a dose of 12.5 mg/kg at days indicated in study protocol above.

Terminal procedure. On day 18 animals were sacrificed by lethal i.p. injection with pentobarbitol (Streuli Pharma AG, Uznach, Cat: 1170139A) immediately followed by bronchoalveolar lavage (BAL) in 500 ul of saline.

Measurement of cellular infiltrates into BAL. Cells were isolated from the BAL fluid and differential cell counts were performed based upon standard morphological and cytochemical criteria.

Graphs and statistical analysis. All graphs were generated with Graphpad Prism Version 6 and a one-way ANOVA was applied. Results from the statistical analysis are provided with the individual data tables. Error bars represent Standard Error of the Mean (SEM).

Results and analysis

The results of the experiment are shown in Figures 10-18.

No morbidity or mortality was noted in the mice treated with the bacteria or the vehicle. As shown in Figures 15 and 16, strain 675 exhibited a strong effect and reduced total neutrophil numbers relative to the negative controls. In addition, strain 675 reduced eosinophil numbers relative to the controls, as shown in Figures 11 and 12.

Example 3 – Efficacy of bacterial inocula to treat arthritis in a type II collagen-induced arthritis mouse model

Materials and methods

Strain

675: *Bacteroides coprocola*

Bacterial cultures

Bacterial cultures were grown up for administration in an anaerobic workstation (Don Whitley Scientific) according to the growth scheme below.

- Mon/Weds/Fri: Transfer glycerol stock to ice and streak a YCFA plate from glycerol stock. Use plate as follows for a maximum of 3 days.
- Daily PM: Pick single colony of each strain from plate cultures, transfer to 8 ml hungate tube containing YCFA overnight (ON1)
- AM: Subculture 80 ul (1%) ON1 into fresh 8 ml tube (DC1). Use ON1 culture for AM oral gavage.
- PM: Use DC1 culture for PM oral gavage.

Bacterial strain #675 was grown using glycerol stocks.

Glycerol stocks were stored at -80°C. Three times per week, glycerol stocks were thawed at room temperature and streaked on YCFA plates. A new glycerol aliquot was used on each occasion. Bacteria were allowed to grow on a given plate for up to 72 hours.

Solutions to be administered to the animals were prepared twice daily with an eight hour interval for morning (AM) and afternoon (PM) treatments. A bacterial colony was picked from the streaked plate and transferred into a tube containing YCFA media. Bacterial strain #675 was allowed to grow for 16 hours before AM administrations. Bacteria were sub-cultured at 1% into YCFA media for PM administrations. OD values were recorded for each strain after morning and afternoon treatment preparations.

Type II collagen-induced arthritis mouse model

Adult male DBA/1 mice were randomly allocated to experimental groups and allowed to acclimatise for two weeks. On Day 0, animals were administered by subcutaneous injection with 100 microliters of an emulsion containing 100 micrograms of type II collagen (CII) in incomplete's Freund's adjuvant supplemented with 4 mg/ml *Mycobacterium tuberculosis* H37Ra. On Day 21, animals were administered by subcutaneous injection with a booster emulsion containing 100 µg of type II collagen in incomplete Freund's adjuvant.

Treatments were given according to the administration schedule below. From Day -14 until the end of the experiment on Day 45, animals were weighed three times per week. From Day 21 until the end of the experiment, animals were scored three times per week for clinical signs of arthritis to include swelling of the hind- and front paws, radio-carpal (wrist) joints and tibio-tarsal (ankle) joints.

On Day 45 mice were culled and terminal blood samples were taken for cytokine analysis.

On Day -14, Day 0 and Day 45, faecal samples were collected for microbiological analysis, immediately snap-frozen and stored at -80°C.

The collagen-induced arthritis (CIA) mouse model is a well-established mouse model for rheumatoid arthritis [67]. Immunisation with CII causes a pathogenesis that includes several important pathological features of rheumatoid arthritis, including synovial hyperplasia, mononuclear cell infiltration and cartilage degradation. Significantly, the development of CIA is mediated by Th17 cells through secretion of IL-17A [68]. The immune response underlying the arthritis model is enhanced by the use of Freund's adjuvant supplemented with *Mycobacterium tuberculosis*.

On Day 21, spleens were collected from three satellite animals in each group. Cells were cultured for 72 hours in the presence or absence of type II collagen. Cytokines, including TNF-α, IL-6, IFN-γ, IL-4, IL-10 and IL-17, were quantified in the culture supernatants and in terminal serum by Luminex. Cell proliferation was quantified using a tritiated thymidine incorporation method.

Treatment Groups and Dosages

All Groups were n=15 (n=12 for the main study group and n=3 for satellite groups)

The vehicle used for the biotherapeutics was Yeast extract-Casitone-Fatty Acids (YCFA) medium.

	Group	Dose	Administration		Disease Induction
			Route	Regimen	
1	Vehicle	5 ml/kg	PO	BID: Day -14*-End	Day 0: Collagen/CFA, once, SC Day 21: Collagen/IFA, once, SC
4	Biotherapeutic #675	5 ml/kg			

PO: oral gavage, SC: subcutaneous injection, BID: twice a day, CFA: complete Freund's adjuvant.

* Except Group 4 treated from Day 0.

Bodyweights

- 5 From Day -14 until the end of the experiment, animals were weighed three times per week. Data were graphed (Mean $\pm$ SEM).

Non-specific clinical observations

- 10 From Day -14 until the end of the experiment, animals were checked daily for non-specific clinical signs to include abnormal posture (hunched), abnormal coat condition (piloerection) and abnormal activity levels (reduced or increased activity).

Clinical Observations

- 15 From Day 21 until the end of the experiment on Day 45, animals were scored three times per week for clinical signs of arthritis to include swelling of the hind- and front paws, radio-carpal (wrist) joints and tibio-tarsal (ankle) joints. Each limb was scored using the following scale: (0) normal, (1) slight swelling, (2) mild swelling, (3) moderate swelling and (4) severe swelling. A clinical score was calculated by adding each limb score. The maximum possible clinical score for an animal was (16). Animals with a score equal to (12) on two consecutive occasions and animals with a score greater than (12) on any one occasion were culled. Data were graphed (Mean $\pm$ SEM).

Cell proliferation analysis

- 20 On Day 21, three satellite animals per group were culled and spleens were dissected out. Spleen cells were cultured for 72 hours in presence or absence of type II Collagen. After 72 hours, cells were pulsed overnight in the presence of tritiated thymidine. Cell proliferation was quantified by measuring thymidine incorporation. Data were graphed (Mean $\pm$ SEM). Supernatants were taken and tested for the presence of key cytokines.

25 Cytokine analysis

Terminal supernatants from the spleen cell cultures were tested in order to quantitate TNF- α , IL-6,

IFN- γ , IL-4, IL-10 and IL-17 by Luminex. Data were graphed (Mean $\pm$ SEM).

Microbiological analysis

On Day -14, Day 0 and Day 45, faecal samples were collected from each animal, immediately snap-frozen, and stored at -80°C . Caeca (including content) were immediately snap-frozen and stored at -80°C . A bacterial identification test was performed daily by plating the bacteria.

Histopathology

At the end of the experiment, hind paws were stored in tissue fixative. Samples were transferred into decalcification solution. Tissue samples were processed, sectioned and stained with Haematoxylin & Eosin. Sections were scored by a qualified histopathologist, blind to the experimental design, for signs of arthritis to include inflammation, articular cartilage damage and damage to the underlying metaphyseal bone. A detailed scoring system was used (see below). Data were graphed (Mean $\pm$ SEM). Raw and analysed data were provided as well as representative pictures.

Table 1: Histopathology Scoring System

Grade	Description
Inflammation	
0	Normal joint
1	Mild synovial hyperplasia with inflammation dominated by neutrophils. Low numbers of neutrophils and macrophages in joint space.
2	Synovial hyperplasia with moderate to marked inflammation involving both neutrophils and macrophages. Neutrophils and macrophages in joint space; may be some necrotic tissue debris.
3	Synovial hyperplasia with marked inflammation involving both neutrophils and macrophages. Loss of synoviocyte lining. Inflammation may extend from synovium to surrounding tissue including muscle. Numerous neutrophils and macrophages in joint space, together with significant necrotic tissue debris.
Articular cartilage damage	
0	Normal joint
1	Articular cartilage shows only mild degenerative change. Early pannus formation may be present peripherally.
2	Articular cartilage shows moderate degenerative change and focal loss. Pannus formation is present focally.
3	Significant disruption and loss of articular cartilage with extensive pannus formation.

Damage to the underlying metaphyseal bone

0	Normal joint
1	No change to underlying metaphyseal bone.
2	May be focal necrosis or fibrosis of metaphyseal bone.
3	Disruption or collapse of metaphyseal bone. Extensive inflammation, necrosis or fibrosis extending to medullary space of the metaphysis.

Results and analysis**Survival and Non-specific Clinical Observations**

Some animals were culled prior to the scheduled end of the study due to the severity of the clinical signs of arthritis or due to the severity of the non-specific clinical observations.

- 5 One animal in Group 1 was culled (vehicle-treated, animal arrived from the supplier with broken leg).

Eleven animals were culled due to the severity of the clinical signs of arthritis: five animals in Group 1 (vehicle-treated), and six animals in Group 4 (biotherapeutic #675-treated).

- 10 Five animals were culled due to the severity of the non-specific clinical signs including abnormal posture (hunched), abnormal coat condition (piloerection), abnormal activity levels (reduced activity): three animals in Group 1 (vehicle-treated) and two animals in Group 4 (biotherapeutic #675-treated).

Bodyweights

- 15 Bodyweight data recorded from Day -14 until Day 0 and expressed as a percentage of the initial (Day -14) bodyweights were analysed by two-way ANOVA followed by Dunnett's post-test for multiple comparisons with Day -14 then for multiple comparison with the vehicle-treated group. The data are presented in Figure 19. Data from animals culled prior to the scheduled end of the experiment were excluded from the analyses.

- 20 When compared to Day -14, twice daily administrations by oral gavage induced a significant bodyweight loss in the vehicle-treated group on Day -9 and Day -7.

Group 4 (untreated until Day 0 then biotherapeutic #675-treated) bodyweights were significantly higher than in the vehicle-treated group from Day -11 until Day -1 ($p < 0.0001$ except Day -4 where $p < 0.05$).

- 25 The bodyweights measured between Day -14 and Day -1 in the biotherapeutic-treated groups did not differ from the bodyweights measured in the vehicle-treated group on any given day.

Bodyweight data recorded from Day 0 until Day 28 and expressed as a percentage of the initial (Day

0) bodyweights were analysed by two-way ANOVA followed by Dunnett's post-test for multiple comparisons with Day 0 in the Vehicle group then for multiple comparison with the vehicle-treated group. The data are presented in Figure 20. Data from animals culled prior to the scheduled end of the experiment and from Satellite animals were excluded from the analyses. Day 28, Day 35 and Day 42 data were further analysed by one-way ANOVA followed by Dunnett's post-test for multiple comparisons to the vehicle-treated group.

The onset of clinical signs of arthritis was associated with a significant bodyweight loss on Day 26 and Day 28 ($p < 0.0001$) when compared to Day 0 in the vehicle-treated group.

When compared to the vehicle-treated group, the bodyweights were significantly higher in Group 4 (biotherapeutic #675-treated) on Day 3, Day 5, Day 10 ($p < 0.05$) and on Day 26 ($p < 0.001$).

When analysing the data by one-way ANOVA, the bodyweights were significantly higher in Group 4 (biotherapeutic #675-treated) when compared to the vehicle-treated group on Day 28 ($p < 0.01$). There was no significant difference between experimental groups on Day 35 or Day 42.

Clinical Observations

Clinical score data were analysed by two-way ANOVA followed by Dunnett's post-test for multiple comparisons between days in the vehicle-treated group then for multiple comparisons between experimental groups and the vehicle-treated group each day. The data are presented in Figure 21. Data recorded from animals culled prior to the end of the experiment were excluded from the analysis. When animals were culled due to the severity of the clinical signs of arthritis, the last recorded score was reported for the following days and used in the statistical analyses.

A significant increase of the clinical scores was observed in the vehicle-treated group from Day 28 until Day 45 ($p < 0.0001$) when compared to Day 21.

Biotherapeutic #675 did not reduce the clinical scores when compared to the vehicle-treated group. Animals in this group were immunised at a different time when compared to other experimental groups, which may explain the higher clinical scores observed.

Cell proliferation analysis

To validate the assay, splenocytes were cultured in the presence of soluble anti-CD3 and anti-CD28 (anti-CD3/CD28) as positive control stimuli to confirm the proliferative potential of the cells.

Strong proliferative responses to anti-CD3/CD28 were seen in all experimental groups, showing cells were healthy, viable and able to respond to activation signals.

To test the proliferative response in presence of Collagen II (CII), splenocytes were cultured in the

presence of CII at 50 µg/ml. Splenocyte proliferative response to CII were analysed by two-way ANOVA followed by Sydak's post-test for multiple comparisons between unstimulated and CII-stimulated splenocytes and one-way ANOVA followed by Dunnett's post-test for comparison of CII-stimulated response in different experimental groups with the vehicle-treated group. The data are presented in Figure 22.

CII induced a highly significant increase of ^3H -thymidine incorporation (cpm) when compared to the unstimulated splenocytes in the vehicle-treated group ($p < 0.0001$).

Splenocyte proliferation for group treated with biotherapeutic #675 was set up on a different day, therefore comparison with the vehicle-treated group was not preformed, although a notable reduction was observed.

Cytokine levels in tissue culture supernatants

Levels of each cytokine were measured in tissue culture supernatants derived from anti-CD3/CD28 stimulated cultures by luminex analysis. These showed robust responses for all cytokines measured (mean levels in vehicle group were as follows: IL-4 = 6,406 pg/ml; IL-6 = 306 pg/ml; IL-10 = 10,987 pg/ml; IL-17A = 11,447 pg/ml; IFN- γ = 15,581 pg/ml; TNF- α = 76 pg/ml).

The following sections summarise the data obtained from the Collagen II-stimulated cultures. Where applicable, statistical analyses of the differences between cytokine levels in supernatants of unstimulated and CII-stimulated splenocytes were conducted using two-way ANOVA followed by Sidak's post-test for multiple comparisons, while one-way ANOVA followed by Dunnett's post-test was used for comparison of CII-stimulated response in biotherapeutic-treated groups with the vehicle-treated group. There was no significant difference in cytokine levels between the groups in both cases. This is likely due to the small sample size used ($n=3$).

In order to more accurately present the distribution of the data for the cytokines with substantial spread of the data, these are presented as scatter plots.

The group means of IL-4 in tissue culture supernatants after stimulation with CII were $<5\text{pg/ml}$. These are not considered biologically significant and not included here. The group means of TNF- α in tissue culture supernatants after stimulation with collagen were below limit of quantitation.

Supernatant levels of IFN- γ (Figure 23)

Along with IL-17, IFN- γ is the major cytokine driving disease in the CIA model. The scatter plot in Figure 23 demonstrates IFN- γ levels after CII stimulation, with group median being higher for the Vehicle-treated group compared to the biotherapeutic (see Figure 27).

Supernatant levels of IL-17A (Figure 24)

Levels of IL-17A were 50pg/ml in CII-stimulated cultures for the Vehicle-treated group. The levels of this cytokine appeared to be lower in the biotherapeutic group compared to the Vehicle-treated group (see Figure 27).

5 Supernatant levels of IL-10 (Figure 25)

Levels of IL-10 in Vehicle-treated group were 13 pg/ml and 2.1 pg/ml for CII-stimulated, and media control cultures, respectively. Higher levels of IL-10 (which is an anti-inflammatory cytokine) for the vehicle-treated group may be expected because inflammation and pro-inflammatory cytokine induction could be accompanied by an anti-inflammatory feedback mechanism.

10 Supernatant levels of IL-6 (Figure 26)

Inflammatory cytokines such as IL-6 and TNF- α are not typically produced at high levels in anti-CII cultures. However, their levels may be altered as a result of immune modulation. Levels of IL-6 in CII-stimulated cultures were modest, reaching 10pg/ml. Although higher than in media control cultures, these differences were too small to provide rationale for performing statistical analyses.

15 Tissue culture supernatants in Group 4 - Biotherapeutic #675 (Figure 27)

Splenocyte cultures for this group were set up on a different day and are therefore separate from the Vehicle-treated group. Although direct comparisons may not be appropriate, it appears that treatment with Biotherapeutic #675 was effective at lowering IFN- γ , IL-17A and IL-6 levels.

Microbiological analysis

20 Bacterial growth was confirmed by measuring the optical density at 600 nm using a spectrophotometer. Bacterial identity was confirmed by comparing streaked plate pictures to reference pictures.

Following the improved bacterial preparation method, consistently high doses of bacterial strain were administered from Day -2 and Day -3 (except for strain #675 from Day 0) as indicated by the high

25 OD values measured.

Faecal samples were collected and snap-frozen on Day -14, Day 0 and at termination.

Histopathology

The histopathology results are shown in Figures 66-71. As expected for this model, intra-individual and inter-individual variability was observed in terms of the presence/absence of arthritis or the

30 severity of change present.

The nature of the pathology was as expected for this model, with extensive mixed chronic-active inflammation of the synovium and bursa extending to involve the peri-articular soft tissues (muscle, adipose tissue, dermal collagen). In the most severely affected joints there was articular cartilage degeneration and loss with intra-articular debris and inflammation and disruption of the joint and bone structure by fibrosis and inflammation.

The incidence of histopathological changes was: vehicle – 80% (16/20); Biotherapeutic #675 – 83% (20/24). Biotherapeutic #675 was effective for reducing histopathological damage observed in hind limb joints and reducing joint inflammation scores, cartilage damage scores, bone damage scores and total histopathology scores (see Figure 70), although statistical comparisons with the vehicle group could not be performed.

Summary

Increased clinical scores were observed from Day 28 after the first administration of type II collagen, as expected in this model of arthritis in DBA/1 mice. Biotherapeutic #675 was shown to be effective at treating arthritis in this model. Animals treated with biotherapeutic #675 were immunised at a different time when compared to the vehicle-treated group, which may explain the higher clinical scores observed. However, biotherapeutic #675 was effective for reducing pathological disease in the joints, as demonstrated in the histopathological analysis.

Proliferative recall responses to Collagen II were seen in splenocyte cultures from all experimental groups. Statistics were not performed for cultures of biotherapeutic #675, as these were established at a different time, but a reduction in collagen-specific response relative to the control was observed.

Most of the T cell cytokines tested showed detectable increases between Collagen II-stimulated and media controls in the Vehicle-treated group. These increases were not as obvious in the biotherapeutic-treated group. This broadly supports the proliferative recall responses to Collagen II described above.

There was evidence of suppression of the Th1/Th17 axis, which is the pathogenic response in this model and in human RA. Correlation of reduced levels of cytokines with reduced proliferation is suggestive of immune modulation. There was no evidence that this modulation resulted either from enhanced levels of Th2 associated IL-4 or with increases in the immune modulating cytokine, IL-10.

Example 4 – Further analysis of the effect of bacterial inocula in the mouse model of house dust mite-induced asthma

The mice tested in Example 1 were subjected to further analyses to further characterise the effect of the compositions of the invention on the allergic asthma inflammatory response.

Materials and methods

Blood withdrawal and serum preparation on day 14. Blood samples of animals were collected via cardiac puncture. Serum was isolated from the blood sample by centrifugation for 5 min at 14000g and stored at -20 °C.

- 5 **Organ removal on day 14.** Collection of the left lung lobe in formalin for follow-on histological analysis. Collection of the right lung lobes (all remaining lobes) and removal of serum for snap freezing and follow-on analysis. Remaining BAL fluid was snap frozen for follow-on analysis.

Measurement of antibody levels in serum and BAL fluid

- 10 Total IgE and house-dust-mite (HDM) specific IgG1 antibody production were measured in the BAL and serum by ELISA assay.

Isolation of lung and histological analysis

- 15 Left lung lobes were fixed in formalin followed by embedment in paraffin, sectioning, and staining with hematoxylin and eosin and PAS. Subsequent histological scoring was performed blinded as followed: Five random fields of view per sample were scored for inflammation (peribronchial infiltration and perivascular infiltration) and mucus production. Inflammatory infiltration was scored with the following grading system:

0 - normal

1 - mild inflammatory infiltrates

2 - moderate inflammatory infiltrates

- 20 3 - marked inflammatory infiltrates

4 - severe inflammatory infiltrates

5 - very severe inflammatory infiltrates

In each field of view, airways were measured in size and mucus cell numbers were quantified/ um.

Measurement of inflammatory mediators in lung tissue

- 25 Right lung lobes (all remaining lobes) isolated for quantification of inflammatory mediators were snap frozen for subsequent measurement of CCL11, IFN-gamma, IL-1 alpha, IL-1 beta, IL-4, IL-5, IL-9, IL-17A, CXCL1, CCL3, CXCL2 and CCL5 by commercially available multiplex assay (Merck-Millipore). Analysis was performed according to the manufacturer's instructions.

Results and analysis

The results of the experiments are shown in Figures 28-46.

In support of the findings described in Example 1, analysis of the cellular infiltrates in the lung tissue of mice treated with strain 675 showed a notable and statistically significant reduction in mean inflammation score (see Figures 32 and 34).

Antibody levels in the BAL fluid and serum were analysed (see Figures 28-31). No clear effect of the bacterial treatment on serum antibody levels was observed. This may reflect a failure in the experiment, because the spread of data and the error bars for each treatment are large, and the positive and negative controls do not appear to have behaved as would be expected. Also, the baseline serum antibody levels could have masked any changes.

Similarly, no clear effect of the bacterial treatment on cytokine levels in lung tissue was observed (see Figures 36-46). Again, this may reflect a failure in the experiment, because the spread of data and the error bars for each treatment are large, and the positive and negative controls do not appear to have behaved as would be expected. It is also possible that the mechanism of action involved influences earlier cytokine responses that were no longer detectable on day 4 post the final HDM airway challenge. Some care should be taken when interpreting the cytokine data in the current study, due to the variability in the levels detected. This variability could in part be explained by the fact that the lung tissue was separated for the different analyses, and thus one lung lobe might not have been fully representative or comparable to the same lobe in other mice due to patchy distribution of the inflammation.

Example 5 – Further analysis of the effect of bacterial inocula in the mouse model of severe neutrophilic asthma

The mice tested in Example 2 were subjected to further analyses to further characterise the effect of the compositions of the invention on the neutrophilic response associated with severe asthma.

Materials and methods

Organ removal on day 18. Collection of the left lung lobe in formalin for follow-on histological analysis. Collection of the right lung lobes (all remaining lobes) and removal of serum for snap freezing and follow-on analysis. Remaining BAL fluid was snap frozen for follow-on analysis.

Measurement of inflammatory mediators in lung tissue (follow-on analysis). Right lung lobes (all remaining lobes) isolated for quantification of inflammatory mediators were snap frozen for subsequent measurement of IFN-gamma, IL-1 alpha, IL-1 beta, CXCL1, CCL3, CXCL2, CCL5, IL-17A, TNF-alpha, IL-17F, IL-23 and IL-33 by commercially available multiplex assay (Merck-Millipore). Analysis was performed according to the manufacturer's instructions.

Measurement of antibody levels in serum and BAL fluid (follow-on analysis). House-dust-mite (HDM) specific IgG1 and IgG2a antibody production were measured in the BAL and serum by ELISA assay.

Isolation of lung and histological analysis (follow-on analysis). Left lung lobes were fixed in formalin followed by embedment in paraffin, sectioning, and staining with hematoxylin and eosin and PAS. Subsequent histological scoring was performed blinded as followed: Five random fields of view per sample were scored for inflammation (peribronchial infiltration and perivascular infiltration) and mucus production. Inflammatory infiltration was scored with the following grading system:

0 - normal

1 - mild inflammatory infiltrates

2 - moderate inflammatory infiltrates

3 - marked inflammatory infiltrates

4 - severe inflammatory infiltrates

5 - very severe inflammatory infiltrates

Results and analysis

The results of the experiments are shown in Figures 47-64.

Further analysis of antibody levels revealed that the efficacy of bacterial strain 675 was also reflected in reduced HDM-specific IgG1 levels in the BAL fluid and serum (see Figures 47 and 49). Firm conclusions regarding an effect on IgG2a levels cannot be drawn. Overall, the data from the antibody analysis is suggestive of a reduction related to an overall reduced inflammatory response, as opposed to a selective effect on antibody isotype switching.

Histological analysis supported the differential cell counts from the BAL fluid, showing a reduced cellular infiltrate in mice treated with Strain 675 (see Figures 51-53).

In relation to cytokine levels, as for Example 4, the spread of data and the error bars for each treatment are large, and the positive and negative controls do not appear to have behaved as necessarily would be expected. It is also possible that the mechanism of action involves influencing earlier cytokine responses that were no longer detectable on day 4 post the final HDM airway challenge. Some care should be taken when interpreting the cytokine data in the current study, due to the variability in the levels detected. This variability could in part be explained by the fact that the lung tissue was separated for the different analyses, and thus one lung lobe might not have been fully representative or comparable to the same lobe in other mice due to patchy distribution of the

inflammation. Despite this variability, a clear anti-inflammatory effect on cytokine levels for strain 675 was shown, and the positive control anti-IL-17 Ab generally behaved as expected.

With the above caveats, the data in Figures 56, 58, 59, 61 and 63 suggest that treatment with the bacterial strains of the invention may achieve a reduction in the levels of IL-1b, IFN γ , RANTES, MIP-1a and KC (the mouse orthologue of human IL-8), which may be indicative of a mechanism of action related to influences on chemokine release (and thus recruitment of cells) by stromal or innate immune cells. These cytokines are part of the Th17 pathway. Taking this dataset together, a clear conclusion can be drawn that Strain 675 was highly effective at protecting mice against inflammation in this mouse model of severe neutrophilic asthma.

Example 6 – Efficacy of bacterial inocula in a mouse model of multiple sclerosis

Summary

Mice were administered with compositions comprising bacterial strains according to the invention and the mice were subsequently immunised with myelin oligodendrocyte glycoprotein to induce experimental autoimmune encephalomyelitis (EAE). EAE is the most commonly used experimental model for human multiple sclerosis. The compositions of the invention were found to have a striking effect on disease incidence and disease severity.

Strain

675: bacteria deposited under accession number NCIMB 42408

Study design

Groups:

1. Negative control group. Treatment with vehicle control (per oral).
3. Treatment with therapeutic bacteria inoculum strain 675 (per oral).
9. Positive control group. Treatment with Dexamethasone (i.p.).
10. Untreated Control Group.

Number of mice per group = 10

Days -14 to day 27: Daily administration of vehicle control per oral (Group 1).

Days -14 to day 27: Daily administration of therapeutic bacteria inoculum per oral (Group 4).

Days 0-28: administration of Dexamethasone (i.p.) three times a week (Group 9)

Day 0: MOG35-55 (myelin oligodendrocyte glycoprotein - 2mg/ml) and CFA (2mg/ml MTB) were mixed 1:1 resulting in 1mg/ml solutions. 100 μ l of the peptide-CFA mixture was injected subcutaneously into each hind leg. Administration of pertussis toxin intraperitoneally (300ng).

Day 1: Administration of pertussis toxin intraperitoneally (300ng).

Days 7-onwards: Measurement of disease incidence and weight three times a week.

Endpoints and analysis

Mice were analysed for disease incidence and disease severity three times a week. Scoring was performed blind. Disease severity was assessed using a clinical score ranging from 0 to 5, with 5 indicating a dead mouse (see clinical scoring system below).

5 Monitoring

On the indicated days mice were weighed and observed for disease activity score and disease incidence.

Disease activity score observations:

- 0 - No obvious changes in motor function compared to non-immunized mice.
- 10 0.5 - Tip of tail is limp.
- 1.0 - Limp tail.
- 1.5 - Limp tail and hind leg inhibition.
- 2.0 - Limp tail and weakness of hind legs.
- OR - There are obvious signs of head tilting when the walk is observed. The balance is poor.
- 15 2.5 - Limp tail and dragging of hind legs.
- OR - There is a strong head tilt that causes the mouse to occasionally fall over.
- 3.0 - Limp tail and complete paralysis of hind legs.
- 3.5 - Limp tail and complete paralysis of hind legs.
- 20 In addition to: Mouse is moving around the cage, but when placed on its side, is unable to right itself.
- Hind legs are together on one side of body.
- 4.0 - Limp tail, complete hind leg and partial front leg paralysis.
- Mouse is minimally moving around the cage but appears alert and feeding
- 4.5 - Complete hind and partial front leg paralysis, no movement around the cage.
- 25 Mouse is immediately euthanized and removed from cage.
- 5.0 Mouse is euthanized due to severe paralysis.

When an animal has equal or greater disease activity score of 1, it is considered to have a positive disease incidence score.

Results

- 30 The results of the study are shown in Figures 72 and 73.

Disease induction in the negative control groups was successful with high scores shown by the

vehicle control and the untreated control. The effect of treatment with strain 675 was striking and the mice treated with strain 675 exhibited notably reduced disease incidence and disease severity. Indeed, the reduction in disease incidence and disease severity was comparable to the positive control group. These data indicate the strain 675 may be useful for treating or preventing multiple sclerosis.

Example 7 – Stability testing

A composition described herein containing at least one bacterial strain described herein is stored in a sealed container at 25°C or 4°C and the container is placed in an atmosphere having 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90% or 95% relative humidity. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, at least 50%, 60%, 70%, 80% or 90% of the bacterial strain shall remain as measured in colony forming units determined by standard protocols.

Sequences

SEQ ID NO:1 (*Bacteroides coprocola* gene for 16S rRNA, partial sequence, strain: M11 - AB200223)

```
15      1 agagtttgat cctgggtcag gatgaacgct agctacaggc ttaacacatg caagtgcagg
      61 ggcagcatga acttagcttg ctaagtttga tggcgacgg cgcacgggtg agtaacacgt
     121 atccaacctt ccgtttactc agggatagcc ttctgaaaga aagattaata cctgatagta
     181 tggtgagatt gcatgatggc accattaaag atttattggt aaacgatggg gatgcgttcc
     241 attaggtagt aggcggggta acggcccaac tagcctgcga tggatagggg ttctgagagg
20     301 aaggtccccc acattggaac tgagacacgg tccaaactcc taoggagggc agcagtgagg
     361 aatattggtc aatggggcag agcctgaacc agccaagtag cgtgaaggat gaaggtccca
     421 cggattgtaa acttctttta tacgggaata aagtttccta cgtgtaggat tttgtatgta
     481 ccgtatgaat aagcctcggc taactccgtg ccagcagccg cggtaataac gaggatgcga
     541 gggttatccg gatttatggg gtttaaagg agcgacagac ggagattaag tcagttgtga
25     601 aagtttgagg ctcaaacgta aaattgcagt tgatactggg ttcccttgagt gcagttgagg
     661 caggcgggaat tgggtgtgta ggggtgaact gottagatat cacgaagaac ccgattgcg
     721 aaggcagctt gctaaactgt aactgaact catgctcgaa agtgtgggta tcaaacagga
     781 ttagataccc tggtagtcca cacggtaaac gatggatact cgtgttggc gatatactgt
     841 cagcggccaa gcgaaagcat taagtatccc acctggggag tacgccggca acggtgaaac
30     901 tcaaaggaat tgacgggggc ccgcacaagc ggaggaacat gtggtttaat tcgatgatac
     961 gcgaggaacc ttaccgggac ttaaattgca gacgaattac gaggaaactt gtaagccgca
    1021 aggcgtctgt gaaggtgctg catggttgtc gtcagctcgt gccgtgaggt gtccggttaa
    1081 gtgccataac gagcgcaacc ctctgtgtca gttactaaca ggttaagctg agggctctgg
    1141 ccagactgcc atcgtaagat gtgaggaagg tggggatgac gtcaaatcag cacggccctt
35    1201 acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggcgctac ccggcaacgg
    1261 gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaacccg actccacgaa
    1321 gctggattcg ctagtaatcg cgcctcagcc acggcgcggt gaatacgttc ccgggccttg
    1381 tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag
```

1441 cgccttaggg taaaaccggg aattgggggt aagtctaaca aggtaaccaa g

SEQ ID NO:2 (*Bacteroides coprocola* gene for 16S rRNA, partial sequence, strain: M16 - AB200224)

```

      1 agagtttgat cctggctcag gatgaacgct agctacaggc ttaacacatg caagtcgagg
5    61 ggcagcatga acttagcttg ctaagtttga tggcgaccgg cgcacgggtg agtaacacgt
    121 atccaaacctt ccgtttactc agggatagcc ttctgaaaga aagattaata cctgatagta
    181 tggtagagatt gcatgatggc accattaaag atttattggt aaacgatggg gatgcgttcc
    241 attaggtagt aggcggggta acggcccacc tagcctgcga tggatagggg ttctgagagg
    301 aagggtcccc acattggaac tgagacacgg tccaaactcc tacgggaggg agcagtgagg
10   361 aatattggtc aatgggcgag agcctgaacc agccaagtag cgtgaaggat gaaggtccta
    421 cggattgtaa acttctttta tacgggaata aagtttcta cgtgtaggat tttgtatgta
    481 ccgtatgaat aagcatcggc taactccgtg ccagcagccg cggtaatacg gaggatgcga
    541 gcgttatccg gatttattgg gtttaaaggg agcgcagacg ggagattaag tcagttgtga
    601 aagtttgagg ctcaaccgta aaattgcagt tgatactggt ttcttgagt gcagttgagg
15   661 caggcggaat tcgtggtgta gcggtgaaat gcttagatat cacgaagaac cccgattgcg
    721 aaggcagctt gctaaactgt aactgacgtt catgctcgaa agtgtgggta tcaaacagga
    781 ttagataccc tggtagtcca cacggtaaac gatggatact cgtgttggc gatatactgt
    841 cagcggccaa gcgaaagcat taagtatccc acctggggag tacgccggca acggtgaaac
    901 tcaaaggaat tgacgggggc ccgcacaagc ggaggaacat gtggtttaat tcgatgatac
20   961 gcgaggaacc ttaccggggc ttaaattgca gacgaattac gaggaaactt gtaagccgca
    1021 aggcgtctgt gaagggtgctg catggttgtc gtcagctcgt gccgtgaggt gtcggcttaa
    1081 gtgccataac gagcgcaacc ctctgtggtc gttactaaca ggttaagctg aggcctctgg
    1141 ccagactgcc atcgtaagat gtgaggaagg tggggatgac gtcaaatcag cacggccctt
    1201 acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggcgctac ccggcaacgg
25   1261 gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaacctg actccacgaa
    1321 gctggattcg ctagtaatcg cgcatacagc acggcgcggt gaatacgttc ccgggccttg
    1381 tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag
    1441 cgccttaggg taaaaccggg aattgggggt aagtctaaca aggtaaccaa

```

SEQ ID NO:3 (*Bacteroides coprocola* gene for 16S rRNA, partial sequence, strain: M158 - AB200225)

```

      1 agagtttgat cctggctcag gatgaacgct agctacaggc ttaacacatg caagtcgagg
      61 ggcagcatga acttagcttg ctaagtttga tggcgaccgg cgcacgggtg agtaacacgt
    121 atccaaacctt ccgtttactc agggatagcc ttctgaaaga aagattaata cctgatagta
    181 tggtagagatt gcatgatagc accattaaag atttattggt aaacgatggg gatgcgttcc
35   241 attaggtagt aggcggggta acggcccacc tagcctnoga tggatagggg ttctgagagg
    301 aagggtcccc acattggaac tgagacacgg tccaaactcc tacgggaggg agcagtgagg
    361 aatattggtc aatgggcgag agcctgaacc agccaagtag cgtgaaggat gaaggtccta
    421 cggattgtaa acttctttta tacgggaata aagtatccta cgtgtaggat tttgtatgta
    481 ccgtatgaat aagcatcggc taactccgtg ccagcagccg cggtaatacg gaggatgcga
40   541 gcgttatccg gatttattgg gtttaaaggg agcgcagacg ggagattaag tcagttgtga

```

601 aagtttggcg ctcaaccgta aaattgcagt tgatactggt ttcccttgagt gcagttgagg
 661 caggcggaat tcgtggtgta gcggtgaaat gcttagatat cacgaagaac cccgattgog
 721 aaggcagett gctaaactgt aactgacgtt catgctcgaa agtgtgggta tcaaacagga
 781 ttagataccc tggtagtcca caccgtaaac gatggatact cgctgttggc gatatactgt
 5 841 cagcgggocaa gcgaaagcat taagtatccc acctggggag tacgcccggca accgtgaaac
 901 tcaaaggaat tgacgggggc cgcacaagc ggaggaacat gtggtttaat tcgatgatac
 961 gcgaggaacc ttaccggggc ttaaattgca gacgaattac gaggaaactt gtaagccgca
 1021 aggcgtctgt gaagggtgctg catggttgtc gtcagctcgt gccgtgaggt gtcggcttaa
 1081 gtgccataac gacgcgaacc ctctgtgtca gttactaaca ggttaagctg aggactctgg
 10 1141 ccagactgcc atcgtaagat gtgaggaagg tggggatgac gtcaaactag caccggccctt
 1201 acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggcagctac cggcgacgg
 1261 gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaaccgg actccacgaa
 1321 gctggattcg ctagtaatcg cgcacagcc accggcgggt gaatacgttc cggggccttg
 1381 tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag
 15 1441 cgccctaggg taaaaccggg aattggggct aagtcgtaac aaggtaacca a

SEQ ID NO:4 (consensus 16S rRNA sequence for *Bacteroides coprocola* strain 675)

GTCTGGCTCAKGATGAACGCTAGCTACAGGCTTAACACATGCAAGTCGAGGGGCAGCATGAACCTAGCTTGCTAAGT
 TTGATGGCGACCGGCGCACGGGTGAGTAACACGTATCCAACCTCCCGCTTACTCAGGAATAGCCTTTTCAAAGAAAAG
 ATTAATGCCTGATGGTATCTTAAGCACACATGTAATTAAGATTAAAGATTTATCGGTAAGCGATGGGGATGCGTTCC
 20 ATTAGGTAGTAGGCGGGTAACGGCCCACCTAGCCGACGATGGATAGGGGTTCTGAGAGGAAGGTCCCCACATTGG
 AACTGAGACACGGTCCAACTCCTACGGGAGGCAGCAGTGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCAGCC
 AAGTAGCGTGAAGGATGAAGGTCTATGGATTGTAACTTCTTTTATACGGGAATAAAGTGGTCCACGTGTGGGCCT
 TTGCATGTACCGTATGAATAAGCATCGGCTAACTCGTGCCAGCAGCCGCGGTAATACGGAGGATGCGAGCGTTATC
 CGGATTTATTGGGTTTAAAGGGAGCGCAGACGGGGGATTAAAGTCAGTTGTGAAAGTTTGGCGCTCAACCGTAAATTT
 25 GCAGTTGATACTGGTTCCCTTGAGTGCAGTTGAGGCAGGCGGAATTCGTGGTGTAGCGGTGAAATGCATAGATATCA
 CGAAGAACCCCGATTGCGAAGGCAGCCTGCTAAGCTGTAAGTACGTTGAGGCTCGAAAGTGTGGGTATCAAACAGG
 ATTAGATACCCTGGTAGTCCACACGGTAAACGATGGATACTCGCTGTTGGCGATATACTGTCAGCGGCCAAGCGAAA
 GCATTAAGTATCCACCTGGGGAGTACGCCGGCAACGGTGAAGTCAAAGGAATTGACGGGGGCCCGCACAAGCGGA
 GGAACATGTGGTTTAAATTCGATGATACGCGAGGAACCTTACCCGGGCTTAAATTCGAGACGAATTACTTGGAAACAG
 30 GTAAGCCGCAAGGCGTCTGTGAAGGTGCTGCATGGTTGTGCTCAGCTCGTGCCGTGAGGTGTCCGGCTTAAGTGCCAT
 AACGAGCGCAACCCCTCGTGGCCAGTTACTAGCAGGTAACGCTGAGGACTCTGGCCAGACTGCCATCGTAAGATGCGA
 GGAAGGTGGGGATGACGTCAAATCAGCACGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGGAGGTACAGAA
 GGCAGCTACCCGGCGACGGGATGCCAATCTCCAAAGCCTCTCTCAGTTCGGACTGGAGTCTGCAACCCGACTCCACG
 AAGCTGGATTGCTAGTAATCGCGCATCAGCCACGGCGCGGTGAATACGTTCGGGGCCTTGACACACCGCCCGTC
 35 AAGCCATGAAAGCCGGGAGTACCTGAAGTGCGTAACCGCAAGGAGCGCCCTAGGGTAAACCGGTAATTGGGGCTAA
 GTCNTACGGGG

SEQ ID NO:5 (*Bacteroides thetaiotaomicron* gene for 16S rRNA, partial sequence - M58763)

1 cttntacaat gaagagtttg atccctggctc aggatnaacg ctagctacag gcttaacaca
 40 61 tgcaagtcna ggggcagcat ttcagtttgc ttgcaaaactg gagatggcga cggcgccacg
 121 ggtgagtaac acgtatccaa cctgocgata actcggggat agccttttga aagaaagatt
 181 aatacccnat ggtataatca gaccgcatng tcttrttatt aaagaatttc gggtatcgat
 241 ggggatgcgt tccattagga agttggtgag gtaacggctc acnnaacctt cgatggatag
 301 gggttctgag aggaaggtcc cccacattgg aactgagaca cgggtccaaac tectacggga
 45 361 ggcagcagtg aggaatatgg gtcgaatggc gcaggcctga accagccaag tagcgtgaag
 421 gatgactgcc ctatgggttg taaacttctt ttatatggga ataaagtttt ccacgtgtgg

481 aattttgtat gtaccatatg aataaggatc ggctaactcc gtgccagcag cncgntnat
 541 acggagnatc cgagcggttat ccggatttat tgggtttaaa gggagcgtag gtggacagtt
 601 aagtcagttg tgaaagtgtt cggtcaacc gtaaaattgc agttgatact ggctgtcttg
 661 agtacagtag aggtgggcgg aattcgtggt gtagcgggtga aatgcttaga taccacgaag
 5 721 aactccgatt gcgaaggcag ctactggac tgcaactgac actgatgctc gaaagtgtgg
 781 gtatcaaaca ggattagata ccctggtagt ccacacagta aacgatgaat actcgtgttt
 841 tgcgatatac agtaagcggc caagcgaaag cattaagtat tccacctggg gagtacgccg
 901 gcaacgggtga aactcaaagg aattgacggg ggccngcaca agcggaggaa catgtggttt
 961 aattcgatga tacgcgagga acctaccgg ggcttaaatt gcatttgaat atattggaaa
 10 1021 cagtatagcc gyaaggcaaa tgtgaagggt ctgcatgggt gtgcgcagct cgtgccgtga
 1081 ggtgtcggtt taagtgccat aacgagcgca accttatct ttagttacta acaggtcatg
 1141 ctgaggactc tagagagact gccgtcgtaa gatgtgagga aggtggggat gacgtcaaatt
 1201 cagcaacgcc cntacgtccg gggtacaca cgtgttaca tgggggggtac agaaggcagc
 1261 tacctgggtga caggatgcta atcccaaaag cctctctcag ttccgatcga agtctgcaac
 15 1321 ccgaactcgt gaagctggat tcgctagtaa tcgcgcacga gccatggcgc ggtgaatacg
 1381 ttcccgggcn ttgtacacac cgcgcgtcaa gccatgaaag ccgggggtac ctgaagtacg
 1441 taaccgcaag gagcgtccta gggtaaaact ggtaattggg gc

SEQ ID NO:6 (strain 675 chromosome sequence) – see WO2016203217.

20 SEQ ID NO:7 (strain 675 plasmid sequence) – see electronic sequence listing.

REFERENCES

- [1] Spor *et al.* (2011) *Nat Rev Microbiol.* 9(4):279-90.
- [2] Eckburg *et al.* (2005) *Science.* 10;308(5728):1635-8.
- [3] Macpherson *et al.* (2001) *Microbes Infect.* 3(12):1021-35
- [4] Macpherson *et al.* (2002) *Cell Mol Life Sci.* 59(12):2088-96.
- [5] Mazmanian *et al.* (2005) *Cell* 15;122(1):107-18.
- [6] Frank *et al.* (2007) *PNAS* 104(34):13780-5.
- [7] Scanlan *et al.* (2006) *J Clin Microbiol.* 44(11):3980-8.
- [8] Kang *et al.* (2010) *Inflamm Bowel Dis.* 16(12):2034-42.
- [9] Machiels *et al.* (2013) *Gut.* 63(8):1275-83.
- [10] WO 2013/050792
- [11] WO 03/046580
- [12] WO 2013/008039
- [13] WO 2014/167338
- [14] Goldin and Gorbach (2008) *Clin Infect Dis.* 46 Suppl 2:S96-100.
- [15] Azad *et al.* (2013) *BMJ.* 347:f6471.
- [16] Kitahara *et al.* (2005) *Int J Syst Evol Microbiol.* 55(Pt 5):2143-7.
- [17] Masco *et al.* (2003) *Systematic and Applied Microbiology.* 26:557-563.
- [18] Srůtková *et al.* (2011) *J. Microbiol. Methods.* 87(1):10-6.
- [19] Ye *et al.* (2015) *PLoS One.* 10(1):e0117704.
- [20] Fabro *et al.* (2015) *Immunobiology.* 220(1):124-35.
- [21] Yin *et al.* (2014) *Immunogenetics.* 66(3):215-8.
- [22] Cheluvappa *et al.* (2014) *Clin Exp Immunol.* 175(2):316-22.
- [23] Schieck *et al.* (2014) *J Allergy Clin Immunol.* 133(3):888-91.

- [24] Balato *et al.* (2014) *J Eur Acad Dermatol Venereol.* 28(8):1016-24.
- [25] Monteleone *et al.* (2011) *BMC Medicine.* 2011, 9:122.
- [26] Fahy (2009) *Proc Am Thorac Soc* 6:256–259
- [27] Miossec and Kolls (2012) *Nat Rev Drug Discov.* 11(10):763-76.
- [28] Yang *et al.* (2014) *Trends Pharmacol Sci.* 35(10):493-500.
- [29] Koenders *et al.* (2006) *J. Immunol.* 176:6262-6269.
- [30] Amedei *et al.* (2012) *Int J Mol Sci.* 13(10):13438-60.
- [31] Shabgah *et al.* (2014) *Postepy. Dermatol. Alergol.* 31(4):256-61.
- [32] Numasaki *et al.* (2003) *Blood.* 101:2620–2627.
- [33] Zhang *et al.* (2008) *Biochem. Biophys. Res. Commun.* 374: 533-537.
- [34] Karin (2006) *Nature.* 441: 431-436.
- [35] Faghih *et al.* (2013). *Iranian Journal of Immunology.* 10(4):193–204.
- [36] Numasaki *et al.* (2005) *J. Immunol.* 175: 6177-6189
- [37] Hammerich and Tacke (2014) *Clin Exp Gastroenterol.* 7:297-306.
- [38] Zhang (2015) *Inflammation.* Aug 23.
- [39] Sun *et al.* (2015) *Cytokine.* 74(1):76-80.
- [40] Mucientes *et al.* (2015) *Br J Ophthalmol.* 99(4):566-70.
- [41] Jawad *et al.* (2013) *Ocul Immunol Inflamm.* 21(6):434-9.
- [42] Maya *et al.* (2014) *J. Ophthalmology.* 310329
- [43] Chi *et al.* (2007) *J. Allergy and Clinical Immunology.* 119(5):1218–1224.
- [44] Chi *et al.* (2008) *Investigative Ophthalmology & Visual Science.* 49(7): 3058–3064.
- [45] Luger and Caspi (2008) *Semin. Immunopathol.* 30(2): 134-143.
- [46] Miyamoto-Shinohara *et al.* (2008) *J. Gen. Appl. Microbiol.*, 54, 9–24.
- [47] Cryopreservation and Freeze-Drying Protocols, ed. by Day and McLellan, Humana Press.
- [48] Leslie *et al.* (1995) *Appl. Environ. Microbiol.* 61, 3592–3597.
- [49] Mitropoulou *et al.* (2013) *J Nutr Metab.* (2013) 716861.
- [50] Kailasapathy *et al.* (2002) *Curr Issues Intest Microbiol.* 3(2):39-48.
- [51] Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by A Wade and PJ Weller
- [52] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985)
- [53] *Handbook of Microbiological Media, Fourth Edition* (2010) Ronald Atlas, CRC Press.
- [54] *Maintaining Cultures for Biotechnology and Industry* (1996) Jennie C. Hunter-Cevera, Academic Press
- [55] Strobel (2009) *Methods Mol Biol.* 581:247-61.
- [56] "Creating Bacterial Glycerol Stocks for Long-term Storage of Plasmids" Addgene - <https://www.addgene.org/plasmid-protocols/create-glycerol-stock/>
- [57] Gennaro (2000) *Remington: The Science and Practice of Pharmacy.* 20th edition, ISBN: 0683306472.
- [58] *Molecular Biology Techniques: An Intensive Laboratory Course*, (Ream *et al.*, eds., 1998, Academic Press).
- [59] *Methods In Enzymology* (S. Colowick and N. Kaplan, eds., Academic Press, Inc.)
- [60] *Handbook of Experimental Immunology*, Vols. I-IV (D.M. Weir and C.C. Blackwell, eds, 1986, Blackwell Scientific Publications)
- [61] Sambrook *et al.* (2001) *Molecular Cloning: A Laboratory Manual*, 3rd edition (Cold Spring Harbor Laboratory Press).
- [62] *Handbook of Surface and Colloidal Chemistry* (Birdi, K.S. ed., CRC Press, 1997)
- [63] Ausubel *et al.* (eds) (2002) *Short protocols in molecular biology*, 5th edition (Current Protocols).
- [64] *PCR (Introduction to Biotechniques Series)*, 2nd ed. (Newton & Graham eds., 1997, Springer Verlag)
- [65] *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987) Supplement 30
- [66] Smith & Waterman (1981) *Adv. Appl. Math.* 2: 482-489.
- [67] Brand *et al.* (2007) *Nature Protocols.* 2(5):1269-1275
- [68] Jiao *et al.* (2014) *Immunopathology and Infectious Diseases.* 184(4):1085-93.

CLAIMS

1. A composition comprising a bacterial strain of the genus *Bacteroides*, for use in a method of treating or preventing an inflammatory or autoimmune disease, or cancer, wherein the bacterial strain has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:4.

2. The composition of claim 1, wherein the composition is for use in a method of treating or preventing a disease or condition selected from the group consisting of asthma, including allergic asthma or neutrophilic asthma; arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, or juvenile idiopathic arthritis; multiple sclerosis; neuromyelitis optica (Devic's disease); ankylosing spondylitis; spondyloarthritis; psoriasis; systemic lupus erythematosus; inflammatory bowel disease, including Crohn's disease or ulcerative colitis; celiac disease; chronic obstructive pulmonary disease (COPD); cancer, including breast cancer, colon cancer, lung cancer or ovarian cancer; uveitis; scleritis; vasculitis; Behcet's disease; atherosclerosis; atopic dermatitis; emphysema; periodontitis; allergic rhinitis; and allograft rejection.

3. The composition of claim 2, wherein the composition is for use in a method of treating or preventing asthma, including neutrophilic asthma or allergic asthma.

4. The composition of claim 3, wherein the composition is for use in a method of reducing neutrophilia or eosinophilia in the treatment of asthma.

5. The composition of claim 2, wherein the composition is for use in a method of treating or preventing rheumatoid arthritis.

6. The composition of claim 5, wherein the composition is for use in a method of reducing joint swelling in rheumatoid arthritis.

7. The composition of claim 2, wherein the composition is for use in a method of treating or preventing multiple sclerosis.

8. The composition of claim 7, wherein the composition is for use in a method of reducing disease incidence or disease severity.

9. The composition of claim 2, wherein the composition is for use in a method of treating or preventing cancer, including lung cancer, breast cancer or liver cancer.

10. The composition of claim 9, wherein the composition is for use in a method of reducing tumour size, reducing tumour growth, preventing metastasis or preventing angiogenesis.

11. The composition of claim 2, wherein the composition is for use in a method of treating or preventing uveitis.

12. The composition of claim 11, wherein the composition is for use in a method of reducing or preventing retinal damage in uveitis.

13. The composition of any preceding claim, wherein the composition is for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of the inflammatory or autoimmune disease, or cancer.

14. The composition of any preceding claim, wherein the composition is for use in a patient with elevated IL-17 levels or Th17 cells.

15. The composition of any preceding claim, wherein the bacterial strain is of *Bacteroides coprocola*.

16. The composition of any preceding claim, wherein the bacterial strain has a 16s rRNA sequence that is at least 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:4, or wherein the bacterial strain has the 16s rRNA sequence represented by SEQ ID NO:4.

17. The composition of any preceding claim, wherein the bacterial strain is lyophilised.

18. A food product or vaccine composition comprising the composition of any preceding claim, for the use of any preceding claim.

19. A cell of the strain deposited under accession number NCIMB 42408, or a derivative thereof.

20. A biologically pure culture of the strain deposited under accession number NCIMB 42408, or a derivative thereof.

21. A cell of the strain deposited under accession number NCIMB 42408, or a derivative thereof, for use in therapy.

22. The cell of claim 21, wherein the cell is for use in a method defined in any of claims 1-14.

ABSTRACT

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

FIG. 1
Total cell counts.




FIG. 1
Total cell counts.




FIG. 2
Total eosinophils.




FIG. 3
Eosinophils %.




FIG. 4
Total macrophages.




FIG. 5
Macrophages %.




FIG. 6
Total neutrophils.




FIG. 7
Neutrophils %.




FIG. 8
Total lymphocytes.




FIG. 9
Lymphocytes %.




FIG. 10
Total cell counts.




FIG. 11
Total eosinophils.




FIG. 12
Eosinophils %.




FIG. 13
Total macrophages.




FIG. 14
Macrophages %.




FIG. 15
Total neutrophils.




FIG. 16
Neutrophils %.




FIG. 17
Total lymphocytes.





FIG. 18
Lymphocytes %.



19/71

FIG. 19
Bodyweights




FIG. 20
Bodyweights




FIG. 21
Clinical Scores




FIG. 22

Splenocyte proliferation to Collagen II






FIG. 23




22/71

23/71



24/71

FIG. 27



25/71





FIG. 27(contd.)

26/71

FIG. 28
Total IgE in Serum



27/71

FIG. 29 HDM specific IgG1 in Serum




FIG. 30
Total IgE in BALF




FIG. 31
HDM specific IgG1 in BALF





FIG. 32 Histological Analysis – Mean Peribronchiolar Infiltration Score



FIG. 33 Histological Analysis – Mean Perivascular Infiltration Score

FIG. 34 Histological Analysis – Mean Inflammatory Score (Average of both Peribronchiolar and Perivascular Infiltration Score)



33/71

FIG. 35
Histological Analysis – Mucus Score




FIG. 36
IL-9 level in lung tissue






FIG. 37
IL-1a level in lung tissue



36/71

FIG. 38
IFN γ level in lung tissue



37/71

FIG. 39
IL-17A level in lung tissue





FIG. 40
IL-4 level in lung tissue



39/71

FIG. 41
IL-5 level in lung tissue




FIG. 42
IL-1b level in lung tissue




FIG. 43
RANTES level in lung tissue




FIG. 44
MIP-1a level in lung tissue




FIG. 45
KC level in lung tissue





FIG. 46
MIP-2 level in lung tissue



45/71






FIG. 48 HDM specific IgG2a in Serum




47/71




48/71


FIG. 50
HDM specific IgG2a in BALF



49/71



50/71

FIG. 52 Histological Analysis – Mean Perivascular Infiltration Score

51/71

FIG. 53 Histological Analysis - Mean Inflammatory Score (Average of both Peribronchiolar and Perivascular Infiltration Score






FIG. 54
TNF α level in lung tissue




53/71

FIG. 55
IL-1a level in lung tissue



54/71

FIG. 56
IFNg level in lung tissue



55/71

FIG. 57
IL-17F level in lung tissue






FIG. 58
IL-1b level in lung tissue



57/71

FIG. 59
RANTES level in lung tissue



58/71

FIG. 60
MIP-2 level in lung tissue




FIG. 61
KC level in lung tissue





FIG. 62
IL-17A level in lung tissue



61/71

FIG. 63
MIP-1a level in lung tissue





FIG. 64
IL-33 level in lung tissue




63/71

FIG. 65
Visual Template for Histopathology Scoring




Grade 0




Grade 1

64/71

FIG. 65(contd.)



Grade 7



Grade 4

65/71



Grade 9

FIG. 65(contd.)

FIG. 66
Histopathology: Inflammation Scores





FIG. 67
Histopathology: Cartilage Scores



67/71

FIG. 68
Histopathology: Bone Scores




FIG. 69

Histopathology: Total Scores






FIG. 70
Histopathology: Strain #675



69/71


FIG. 71

Vehicle (#1.11R, Grade 9)




Strain #675 (#4.9L, Grade 5)

FIG. 72



71/71

FIG. 73



P065778_P067963GB sequence listing_updated MRX002p1_ch.txt
SEQUENCE LISTING

<110> 4D PHARMA RESEARCH LIMITED

<120> COMPOSITIONS COMPRISING BACTERIAL STRAINS

<130> P065778WO

<160> 6

<170> Seqwin2010, version 1.0

<210> 1

<211> 1491

<212> DNA

<213> Bacteroides coprocola

<400> 1

```

agagtttgat cctggctcag gatgaacgct agctacagggc ttaacacatg caagtcgagg 60
ggcagcatga acttagcttg ctaagtttga tggcgaccgg cgcacgggtg agtaacacgt 120
atccaacctt ccgtttactc agggatagcc tticgaaaga aagattaata cctgatagta 180
tggtgagatt gcatgatggc accattaaag atttattggg aaacgatggg gatgcgttcc 240
attaggtagt aggcggggta acggcccacc tagcctgcga tggatagggg ttctgagagg 300
aagggtcccc acattggaac tgagacacgg tccaaactcc tacgggaggc agcagtgagg 360
aatattgggtc aatgggagcag agcctgaacc agccaagtag cgtgaaggat gaaggtccta 420
cggattgtaa acttctttta tacgggaata aagtttccta cgtgtaggat tttgtatgta 480
ccgtatgaat aagcatcggc taactccgtg ccagcagccg cggtaatacg gaggatgcga 540
gcgttatccg gatttattgg gtttaaaggg agcgcagacg ggagattaag tcagttgtga 600
aagtttgagg ctcaaccgta aaattgcagt tgatactggt ttccttgagt gcagttgagg 660
caggcggaat tcgtggtgta gcggtgaaat gcttagatat cacgaagaac cccgattgag 720
aaggcagctt gctaaactgt aactgacgtt catgctcgaa agtggtgggt tcaaacagga 780
ttagataccc tggtagtcca cacggtaaac gatggatact cgctgttggc gatatactgt 840
cagcggccaa gcgaaagcat taagtatccc acctggggag tacgccggca acggtgaaac 900
tcaaaggaat tgacgggggc ccgcacaagc ggaggaacat gtgggtttaat tcgatgatac 960
gagaggaacc ttacccgggc ttaaattgca gacgaattac gaggaactt gtaagccgca 1020
aggcgtctgt gaaggtgctg catggttgtc gtcagctcgt gccgtgaggt gtcggcttaa 1080
gtgccataac gagcgcaacc ctcgtggtca gttactaaca ggttaagctg agggctcttg 1140
ccagactgcc atcgttaagt gtgaggaagg tggggatgac gtcaaatacag cacggccctt 1200
acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggccgctac ccggcaacgg 1260
gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaaccgg actccacgaa 1320
gctggattcg ctagttaatc cgcacagcc acggcgcggt gaatacgttc ccgggccttg 1380
tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag 1440
cgccctaggg taaaaccggt aattggggct aagtctaaca aggtaaccaa g 1491

```

<210> 2

<211> 1490

<212> DNA

<213> Bacteroides coprocola

<400> 2

```

agagtttgat cctggctcag gatgaacgct agctacagggc ttaacacatg caagtcgagg 60
ggcagcatga acttagcttg ctaagtttga tggcgaccgg cgcacgggtg agtaacacgt 120
atccaacctt ccgtttactc agggatagcc tticgaaaga aagattaata cctgatagta 180
tggtgagatt gcatgatggc accattaaag atttattggg aaacgatggg gatgcgttcc 240
attaggtagt aggcggggta acggcccacc tagcctgcga tggatagggg ttctgagagg 300
aagggtcccc acattggaac tgagacacgg tccaaactcc tacgggaggc agcagtgagg 360
aatattgggtc aatgggagcag agcctgaacc agccaagtag cgtgaaggat gaaggtccta 420
cggattgtaa acttctttta tacgggaata aagtttccta cgtgtaggat tttgtatgta 480
ccgtatgaat aagcatcggc taactccgtg ccagcagccg cggtaatacg gaggatgcga 540
gcgttatccg gatttattgg gtttaaaggg agcgcagacg ggagattaag tcagttgtga 600
aagtttgagg ctcaaccgta aaattgcagt tgatactggt ttccttgagt gcagttgagg 660
caggcggaat tcgtggtgta gcggtgaaat gcttagatat cacgaagaac cccgattgag 720
aaggcagctt gctaaactgt aactgacgtt catgctcgaa agtggtgggt tcaaacagga 780
ttagataccc tggtagtcca cacggtaaac gatggatact cgctgttggc gatatactgt 840
cagcggccaa gcgaaagcat taagtatccc acctggggag tacgccggca acggtgaaac 900
tcaaaggaat tgacgggggc ccgcacaagc ggaggaacat gtgggtttaat tcgatgatac 960
gagaggaacc ttacccgggc ttaaattgca gacgaattac gaggaactt gtaagccgca 1020
aggcgtctgt gaaggtgctg catggttgtc gtcagctcgt gccgtgaggt gtcggcttaa 1080
gtgccataac gagcgcaacc ctcgtggtca gttactaaca ggttaagctg agggctcttg 1140

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

ccagactgcc atcgtaagat gtgaggaagg tgggggatgac gtcaaatcag cagggccctt 1200
acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggccgctac ccggcaacgg 1260
gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaacccg actccacgaa 1320
gctggattcg ctagtaatcg cgcacagcc acggcgcggt gaatacgttc ccgggccttg 1380
tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag 1440
cgccctaggg taaaaccggt aattggggct aagtctaaca aggtaacca 1490

```

```

<210> 3
<211> 1491
<212> DNA
<213> Bacteroides coprocola

```

```

<400> 3
agagtttgat cctggctcag gatgaacgct agctacaggc ttaacacatg caagtcgagg 60
ggcagcatga acttagcttg ctaagtttga tggcgaccgg cgacacgggt agtaacacgt 120
atccaacctt ccgtttactc agggatagcc tticgaaaga aagattaata cctgatagta 180
tggtagagatt gcatgatagc accattaaag atttattggt aaacgatggg gatgcgttcc 240
attaggtagt aggcggggta acggccacc tagcctncga tggatagggg ttctgagagg 300
aagggtcccc acattggaac tgagacacgg tccaaactcc tacgggaggc agcagtgagg 360
aatattgggtc aatgggagag agcctgaacc agccaagtag cgtgaaggat gaaggctcta 420
cggattgtaa acttctttta tacgggaata aagtatccta cgtgtaggat ttgtatgta 480
ccgtatgaat aagcatcggc taactccgtg ccagcagccg cggtaatacg gaggatgcga 540
gcgttatccg gatttattgg gtttaaaggg agcgacagcg ggagattaaag tcagttgtga 600
aagtttgagg ctcaaccgta aaattgcagt tgatactggg ttcttgagt gcagttgagg 660
caggcggaat tcgtgggtgta gcggtgaaat gcttagatat cacgaagaac cccgattgag 720
aaggcagctt gctaaactgt aactgacgtt catgctcgaa agtggtggta tcaaacagga 780
ttagatacc tggtagtcca cacggtaaac gatggatact cgctgttggc gatatactgt 840
cagcgcccaa gcgaaagcat taagtatccc acctggggag tacgcccggc acggtgaaac 900
tcaaaggaat tgacgggggg ccgcacaagc ggaggaacat gtggtttaat tcgatgatac 960
gcgaggaacc ttaccggggc ttaaattgca gacgaattac gaggaactt gtaagccgca 1020
aggcgtctgt gaaggtgctg catggttgtc gtcagctcgt gccgtgaggt gtcggcttaa 1080
gtgccataac gagcgcaacc ctctgtggtc gttactaaca ggttaagctg aggactctgg 1140
ccagactgcc atcgtaagat gtgaggaagg tggggatgac gtcaaatcag caggccctt 1200
acgtccgggg ctacacacgt gttacaatgg gaggtacaga aggcagctac ccggcgacgg 1260
gatgccaatc cccaaaacct ctctcagttc ggactggagt ctgcaacccg actccacgaa 1320
gctggattcg ctagtaatcg cgcacagcc acggcgcggt gaatacgttc ccgggccttg 1380
tacacaccgc ccgtcaagcc atgaaagccg ggggtacctg aagtgcgtaa ccgcaaggag 1440
cgccctaggg taaaaccggt aattggggct aagtgcgtaac aaggtaacca a 1491

```

```

<210> 4
<211> 1474
<212> DNA
<213> Bacteroides coprocola

```

```

<400> 4
gtctggctca kgatgaacgc tagctacagg cttaacacat gcaagtcgag gggcagcatg 60
aacttagctt gctaagtttg atggcgaccg gcgcacgggt gagtaacacg tatccaacct 120
cccgttact caggaataga ctittcgaag aaagattaat gcctgatggg atcttaagca 180
cacatgtaat taagattaaa gatttatcgg taagcagtg ggatgcgttc cattagtag 240
taggcggggg aacggccacc ctacccgacg atggataggg gttctgagag gaagggtccc 300
cacattggaa ctgagacacg gtccaaactc ctacgggagg cagcagttag gaatattgg 360
caatgggagc gagcctgaac cagccaagta gcgtgaagga tgaagggtcct atggattgta 420
aacttctttt atacgggaat aaagtgtgcc acgtgtgggc ctttgcagt accgtatgaa 480
taagcatcgg ctaactccgt gccagcagcc gcggtaatat ggaggatgag agcgttatcc 540
ggattttatt ggtttaaagg gagcgcagac gggggattaa gtcagttgtg aaagtttgag 600
gctcaaccgt aaaattgcag ttgatactgg ttcccttgag tgcagttgag gcaggcggaa 660
ttcgtgggtg agcgggtgaa tgcatagata tcacgaagaa ccccgattgc gaaggcagcc 720
tgctaagctg taactgacgt tgaggctcga aagtgtgggt atcaaacagg attagatacc 780
ctggtagtcc acacggtaaa cgatggatac tcgctgttgg cgatatactg tcagcggcca 840
agcgaaagca ttaagtatcc cacctgggga gtacgcccgc aacggtgaaa ctcaaaggaa 900
ttgacggggg ccgcacaagc cggaggaaca tgtggtttta ttgatgata cgcgaggaa 960
cttaccgggg cttaaattgc agacgaatta cttggaacaa ggttaagccg aaggcgtctg 1020
tgaaggtgct gcatggttgt cgtcagctcg tgccgtgagg tgtcggctta agtgccataa 1080
cgagcgcaac cctcgtggcc agttactagc aggttaacgt gaggactctg gccagactgc 1140
catcgtaaga tgcgaggaag gtggggatga cgtcaaatca gcacggccct tacgtccggg 1200
gctacacacg tgttacaatg ggaggtacag aaggcagcta cccggcgacg ggatgccaat 1260
ctccaaagcc tctctcagtt cggactggag tctgcaaccc gactccacga agctggattc 1320
gctagtaatc gcgcacagc cacggcgcgg tgaatacgtt cccgggcctt gtacacaccg 1380
cccgtcaagc catgaaagcc gggagtacct gaagtgcgta accgcaaggga gcgcccctag 1440

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt
 gtaaaaccgg taattggggc taagtcttac gggg 1474

<210> 5
 <211> 1482
 <212> DNA
 <213> Bacteroides thetaiotaomicron

<400> 5
 ctntacaat gaagagtttg atcctggctc aggatnaacg ctagctacag gcttaacaca 60
 tgcaagtcna ggggcagcat ttcagtttgc ttgcaaaactg gagatggcga ccggcgacag 120
 ggtgagtaac acgtatccaa cctgccgata actcggggat agcctttcga aagaaagatt 180
 aatacccnat ggtataatca gaccgcatng tcttrttatt aaagaatttc ggttatcgat 240
 ggggatgcgt tccattaggc agttgggtgag gtaacggctc acnnaacctt cgatggatag 300
 ggggtctgag aggaaggtcc cccacattgg aactgagaca cgggtccaaac tcctacggga 360
 ggagcagtg aggaatattg gtcaatgggc gcaggcctga accagccaag tagcgtgaag 420
 gatgactgcc ctatgggttg taaacttctt ttatatggga ataaagtttt ccacgtgtgg 480
 aactttgtat gtaccatag aataaggatc ggctaactcc gtgccagcag ccncgntnat 540
 ccggagnatc cgagcgttat ccggttttat tgggtttaaa gggagcgtag gtggacagtt 600
 aagtcagttg tgaagtttg cggctcaacc gtaaaattgc agttgatact ggctgtcttg 660
 agtacagtag aggtgggcgg aattcgtggt gtagcggta aatgcttaga tatcacgaag 720
 aactccgatt gcgaaggcag ctactggac tgcaactgac actgatgctc gaaagtgtgg 780
 gtatcaaaca ggattagata ccctggtagt ccacacagta aacgatgaat actcgtgtt 840
 tgcgatatac agtaagcggc caagcgaag cattaaagtat tccacctggg gagtacgccg 900
 gcaacgggtga aactcaaagg aattgacggg ggccngcaca agcggaggaa catgtgtgtt 960
 aattcgatga tacgcgagga accttaccgg ggcttaaatt gcatttgaat atattggaaa 1020
 cagtatagcc gyaaggcaaa tgtgaagggt ctgcatgggt gtcgtcagct cgtgccgtga 1080
 ggtgtcggct taagtgccat aacgagcgca acccttatct ttagttacta acaggtcatg 1140
 ctgaggactc tagagagact gccgtcgtaa gatgtgagga aggtggggat gacgtcaa 1200
 cagcacngcc cntacgtccg gggtacaca cgtgttaca tgggggttac agaaggcagc 1260
 tacctggtga caggatgcta atcccaaaag cctctctcag ttcggatcga agtctgcaac 1320
 ccgacttcgt gaagctggat tcgctagtaa tcgcgcacat gccatggcgc ggtgaatacg 1380
 ttcccgggcn ttgtacacac cgcccgtaa gccatgaaag ccgggggtac ctgaagtacg 1440
 taaccgcaag gagcgtccta gggtaaaact ggtaattggg gc 1482

<210> 6
 <211> 67022
 <212> DNA
 <213> Bacteroides coprocola

<400> 6
 gaaaaacacg cttctttacat tgtccggact gatacccgaa ggaacagcca cccatgccga 60
 ggatgacgaa tccgtaccgg cagccttcga cttgtaaccg ccattgtcctc tgatttcata 120
 cccctgact tcaattccct ttccgtcagt atatgggaat ccgatattgt agccttcaaa 180
 ttttccggtt ttctgtctcc ttataaggga aataaagggt gaaagagccg ttacagtcgc 240
 ttttgacagt ccgcgccgga agaacagtcc ggggtattttt tccgtatcaa ccggcttcac 300
 ctcatatctg gaagcgtcaa acacaccgca tgattttcct accgatttaa catactccct 360
 gtccctccctg tattcaggtt caggcatgtt ggcaaaacgt gccatgacct tggctatctt 420
 ctgccactca tcttttccgg ataccgtaaa ggaagaaaga ttctcacgga tgagtgtcac 480
 cacatctccc ttggaaccgt cagcgggaa gaaggctgtt gccgccttgt cgttgggatg 540
 gctgacaatc agcgtatccc ttctgttgcc gccttcaccg agcaccagtt cgatgtaacg 600
 tccgataccg gctttcctgt ccagacggta tcccagggca tatgcaatgt catcaatccc 660
 cacacgggat ttcatttccc tgaaattaac cttgtagtca ctcatgtctt ccgatttaag 720
 atgttatata gaatttcata taccaagtc tgtaccggca ttccggttcc ggcccatcat 780
 ggtaatctcc ggttcgtatg tcttccgtgc cgtcatgttc aggaagcct ccttgtcctt 840
 ccagtcgta agctggaaga atgtccctggc cgtttccctg gaaaccttct tcagccccag 900
 ttccacacca tcgtatgacg cacggatggc atagtctccg gaacgggtct tgacaatggc 960
 cgcattcctg aaaggcatct cctcgtccgc actgacagga gccagcgggt cattctttgc 1020
 cagataaggc tgttcgccga gagccagacg ctgtttgtcc acatgggtcaa gaatcaggtc 1080
 ggaagcccta ttacgtcag ccattgaccga taccgataaac ttcggttcct gtttcagtac 1140
 accaatccac gagtccagat aggcagcaga gttgtccgtt atcctggaat caaatcccat 1200
 ggaatggctg atcatggcag ccgtaagttc cgccaccagc tctccttggt catatttcgg 1260
 gtcaccgaac ctccgcccc tctccctgtt cagacgtcc cgttccgcca cgttaggttt cttccggaga 1380
 catttcatgc agcatagtag aataatactc ccttcattgg cagcaccaca atatccttc agggagaata 1440
 ataggcaccg ttctcacgct tgtcggcacg tatcgggcat agccactgct gcgtctccac 1500
 catacggctg agtgcggcat ggggtgtacat accttccgta tccctaagtt ccggaacctt 1560
 gaacctgtcc ataagcttct gcattccttc cggctgcact tcggccaagt tgggtctgtgc 1620
 cacattgtac accgggaaag acttgatgaa aggaataaca tccatattct tcttctcttc 1680

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

cttactcatt	gtacgggtatt	cctccgtgct	tatcctcttg	ccgtgactgt	cctttatcat	1740
catatcccag	tacaccaccg	ggaaagcctt	ttcacccttc	aggacatgag	ccttcaggtt	1800
atgcgcctgc	ttgaagggtca	gatataccgg	aagctggtag	ttcatggctg	cagtatgcat	1860
ctgaaggaag	aaggaattgg	aaccggaata	gttgccgcca	cccacattct	gcggaagtcc	1920
ggcataaccc	gatgcaccgc	caatccatcc	ctgtttccat	ccggtatcct	tcatctgctg	1980
catacgctca	atcatcattg	cagcgaagcg	gtctatggcc	gcctgtccgc	tgtttccctg	2040
agagtacgtt	ccagatgcca	tagctgtcgt	catccattac	ctgacgggtc	atctgtcga	2100
tgtccgtctg	ttccacatag	aactcagccg	attcatccga	agggtcagta	ccgtgtgaac	2160
ggcaccactc	cagataatca	tctgcattcc	cactgtccat	aacaaagcgg	aggaaaccta	2220
tcttgccctc	ctgcagaagc	tccacaagct	cctcatgatt	catttttagct	gacatataac	2280
ttgtatttta	gttttctgat	tatgttacat	ttttatagaa	gccgatttct	ccacctttgc	2340
ggtgttgccg	gcaagcatat	cggttatttc	cgtattcagg	tacttgcccg	caatctgttc	2400
ccttggtggc	gtccttggtc	tgaaaagcga	atagccgtca	tcgaaggaga	tttcatgccg	2460
ggaagtctgt	cccttttctc	cgaggtcaac	cgacaccttc	catttggtgt	cgttcctgtc	2520
cttggtccaca	cgcacaccct	tggggtcac	accttcagga	agctgatact	tctcgtatgc	2580
ggatttcaga	tgcagacgtt	ccccgaagtt	cttctcaata	agctgggttg	gagtggccac	2640
cctgtcgaag	taggcattca	ggtcctggcg	tgaagccacg	gcagacatgt	tcgtatcccc	2700
aacctgaaca	tagaaccttg	atttcccaaa	gtcaggacgc	tgctcgtcct	tctccttata	2760
gacattgaac	ttgttaacgg	ttatggaacc	gtccggctct	gcaatctcca	ttggcatacg	2820
gaaggcttcc	tcagaaacct	tcggcatcag	ctttgtcgga	tagtagcggt	ccatcagctg	2880
cgttaccgtc	atttccctgt	tctgataggc	tgcgaaggtc	gctgcattca	tcttctgcgg	2940
cttgagctgc	tgctcgtcaa	tccttgccgt	aaagtaccat	tcggcaggat	tggtgttact	3000
ctggtaggca	tggccgtgag	taaccttctc	accattggca	gtcaccatct	gaggctcacg	3060
tggcttgctg	tcctgtgctg	tttccgcttt	ctgctcttcc	ttattttcgg	cctttacctg	3120
agtatcagcc	tttacttcat	ctttagtacc	ggcatcacc	ctggagtcct	tttcccttgc	3180
aggttttacg	tcaacagtgt	tctccactgt	cctgtcagga	gcttctctga	cacctgtttt	3240
ctgttccctt	ttcttcttcc	ccatatctgt	actgttttga	atggttctgt	cattgttctc	3300
agccttgtcc	tgctcggcct	tcttcttcaa	ggtactgtcc	agaaaatcgc	atattgtcat	3360
cctcacgcct	gaacgtataa	gcctggcgag	ataagtgtcc	aaagccgatt	gggggaatga	3420
tgtgaccttt	accggccggt	tgtagtccag	cagaatcctg	tctgcaatat	tgattccaag	3480
cagtactgca	gcctttacgg	catcctgcct	gtacagttca	tagaaactgt	tccgtctgaa	3540
cagcagcagt	gcacccggat	gcttcttctt	cagttcgttg	aactgccgga	ttataccggt	3600
accattttct	gaatctttct	ttctggccat	atgaatcagt	tttagagttt	aaggctgttt	3660
gcttttggtt	ccttccggga	tggagagagt	tggaatggac	gctcaacgga	ttgctgtgcc	3720
accaccttct	ggtattccca	tcggttcctg	tcagtcattga	caaggccgag	atattcagga	3780
tgaagttcgt	catagcggat	tttctgctgc	ctttcccaat	ccttcatgtc	gcccttgata	3840
agcttgaatc	cctgttgctc	cttcaggtca	atgccgaccg	aaaccttctc	accgcccaca	3900
ttcagctcaa	caggttttcc	ctcacgtatc	tgctgtctct	gctgcatacc	cagttcgata	3960
tcgttccact	tctccatata	cttcagacgc	ttatgtctgt	ttatgtctgt	tacacgtctg	4020
tggatgacgg	atttcgtctc	cggatcaagc	tggagatact	gctgagtcct	ttcaccgttt	4080
acgttgaccg	ccttctgtat	tacctcacct	ttggccaaac	gttcagcctc	ctggtgagtc	4140
agattgagaa	tcttggtgcg	ttccctgtcc	agctccgcac	gtaccggata	ggcaatcaat	4200
cctggagcac	cgtttctgtc	tgtagtcaac	tggagtttca	tcggcatggg	gatgacactg	4260
gcgttccctg	ctgtgtatga	tacctgcatt	atgggagttc	cttcacctgc	catcagcttc	4320
tccttccact	ccatgggtaa	gttggtccgc	ttttcacggt	ctatacccag	tattgccagt	4380
ttctcatatg	gcaacaaatc	ggactgattt	ctgttgtgca	tttccatatt	actgtaatta	4440
agctgttata	tttgcggtta	taaccacctg	aataccacaa	atgtattcat	ggtaattccc	4500
tgaaaaagaa	atgcgcaaca	ctattctgat	ttctctgcta	ctgatgattc	tgccggtaag	4560
cgtatcggga	cagttctata	cgataaccag	ggaatcggaa	cttctgccag	cagtaagaca	4620
aaaagaggcc	tataactatg	ctggaaagga	tgttacagaa	gggaaaaaga	ataagataat	4680
ggcaaaggat	accctgactg	tcagatcaaa	caatcataat	gaatcagaag	aaaacagccg	4740
gaatagtac	aggaaaagcat	ccctgaaaac	agaacagcaa	aagaaaacag	atgacactat	4800
aaaagcagaa	aatcatcttc	ctgaacttac	catcccaaac	ctttataaag	aaatcataag	4860
aaacggaatc	ctgtacccca	aaattgtatt	ggctcaggcc	attctagaga	caggatgggt	4920
tcgttccatca	gtatgcttaa	acaaacacaa	tcttttcgga	ctaaccaatc	cacgtacagg	4980
gaaatactat	gaattcaatc	attggacgga	aagtgtcaga	gcctattaca	ctaaagtgca	5040
atataagtac	aaagggtgaa	actatttgct	ttggcttgat	aagattgggt	atgcagaaga	5100
tccgaattat	ataatggcga	ttataagtat	attggatatg	tcattataat	aattgtccct	5160
tataatattt	attatcataa	aaaatcagta	tattatactt	attgttcaac	ttaaatttca	5220
atagtcaaac	atttctttga	gttcatactt	taaaactcgt	atatttgcgt	tcaaaacaga	5280
taaatatagt	tttatggaag	atttaaatag	attaaaacta	gttttggttg	agaagaaaaa	5340
aacgaacaag	tggcttctct	aagaattagg	tgtaataaca	acaactgttt	ctaagtgggtg	5400
tacaaataca	tctcagccgg	atttgtatac	acttaaaaag	atttctttga	aatttaggtgt	5460
aaatattaag	gatttattat	gcgatacttt	ataaaaaat	tattaaagca	ctaaaaagca	5520
tatggcaaat	tttataacat	gttatgataa	agatttacaa	gatttggcag	attttttaaa	5580
aatacttgta	tcagcaaatg	actcaattaa	taatcttgat	tttagtttag	tccaatttaa	5640
gaatcaagat	attgtatcta	aagaatatgt	tctatactta	ggagaaaaaa	gtgttcatag	5700
gaaatcacaa	atgttttaag	atatttacaa	taaatatggt	attcatatag	gatattatgg	5760
gaaaaatgca	tggctgtatt	gtgaggactt	tgattggacg	gaaaaatcat	atttaaattt	5820

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

taaaaatagac	cttataacta	ttttaagaga	tttaaattta	gattatagaa	aaatagatgc	5880
taatatagaa	aagggcgtag	aattttttatc	tgctgatttg	aatgatccag	gttgtaaggt	5940
tctttgggaa	accgctgtta	atgattgtag	aaaatttgaa	gaagaggatg	ataaatcacg	6000
tgttattatc	ccatttctga	aatttgatga	agttgaatgt	tttcaaaatt	gtatatctga	6060
attcatcgat	caatacttctg	gtaaaattttt	accgataaat	taaaattaaa	catagaatcg	6120
gcataatccg	gttcaaaaatt	atattcaaga	gatcattgaa	atactgtcaa	gaataaatcg	6180
tcaaggagta	agaaaaggga	tgaaaaagat	atgctaaca	gctgaaaatc	aacagaaaaa	6240
gtatttcata	attcactgat	tttagtaaa	ttagaagtac	ttcaccactt	ttaattatga	6300
ctaaagaatc	actccttatg	caataccaat	ccgagtgcag	aaacgctctc	gaatcagctg	6360
taaatataag	caaattctttt	cagaaagtat	tcatggatgc	aatgaaatta	ttcatggcta	6420
tacctgaccg	catcaatttc	ctacaaatgg	gacggatgg	atgttttctg	gaacagacat	6480
accgcaacaa	ttttgagaac	gacggctttg	actggttttc	cttcaatgaa	gccatcatca	6540
gggaacacct	taaaggtggg	cgcaaggcga	tagccgttga	tccgtctttc	attccaaaaa	6600
caggcagcaa	aacgcccgtg	attggctatt	tctggtccgg	ttgtgcccgt	gaatacaaac	6660
gtggactgga	aataaccggg	attggagtta	tagacgttga	caaccatgaa	tgtatgactt	6720
tgggctctgt	acagacacct	gacaacgcaa	cgctggaaag	ctgtgagaag	aatcttgttg	6780
actggtagac	ctcttacctt	atcagcatat	aggaacagct	gaaacgtatt	tctggcacag	6840
tcgtgtgtga	tgctgtcttt	tcaaaggcaa	ctttcatcaa	accattgtac	gataacgggt	6900
tccacgtaat	aagccgtttc	aggaatgatg	ccgtattgtt	ttatccacc	ttagaaaaata	6960
ggacaggaaa	acgaggacgt	ccaaaattac	atgacgagaa	aattgacttt	gaaaatctgg	7020
acatcacaag	atgtaccgag	tacaaagtga	acaagggtaa	actttacgga	ctgaaagcat	7080
actccaaagc	actcaaacgc	tttgtgagcc	tggtgtatg	gtaccccatg	gatggaagaa	7140
cggacaaaatg	gcagctgtat	ttctctacaa	acgaaatata	gaacgcacag	gatgtcctgg	7200
acttttacag	aacacgtttc	caactcgaat	tctgctttcg	ggatgccaa	caacatgccg	7260
gaatagcaaa	ctgtcagctt	acagacttca	ggaaactggc	attccacttt	aatgcatcac	7320
ttgcagcgat	aaacctcgcc	aaggctgcct	gtaagaagat	gggaataaaa	tattccatat	7380
catcatgcaa	gtcagtcata	cacaatgctt	acatgcttga	acgattttat	tgctgtctgt	7440
ggattgaacc	aaacacgcaa	ttaattgaca	aacttttcaa	agaactcatt	ttattttactg	7500
ccagagccgc	ttaggctggg	ctaattttta	acgaactatt	gtatgatacc	aaaaaaactt	7560
atctaattgt	atttttttcc	ctttgtttg	ggagggtgtt	tagtaattta	tatatattg	7620
ttttagtagaa	ttaatagcaa	gatgtgtttt	tggtgtccaca	aaaaccaa	cttgccctgat	7680
aaatcaggag	tttagccccc	tcgcaacttg	ggggcatata	ttatttagta	tcatagtatg	7740
aaagcaataa	aaagagatag	aatagtga	gttcgcttaa	cgaatttaga	atatgaagaa	7800
ctaactaaag	cttctaatac	tagcaaatgt	atgtcagatt	atttttagaca	gagagtcttt	7860
aggaaaggag	ttggtcttat	tgaccctaaa	gaattttatt	gttcgatgga	tgaaatttgt	7920
ttggaaatga	aacgtatagg	aaataatata	aatcagttgg	ctaggtatgt	aaatatccat	7980
aaggaagaag	ttaatcaaga	ggttctta	gaggtagaaa	agaaaatggc	agactatgta	8040
attatgcaag	ataaattgaa	tgttacttgg	cgtaagtgtg	tgtcaatcaa	ataatatatg	8100
tatatataat	attgatatat	ataattttag	tgataaagac	agcgttacta	tttcttttcc	8160
ctaaagtict	ttgtgtcgtt	tctctctata	cttgaatata	ggaaaacggc	tgcatcataa	8220
aagaaaagac	accgacacca	ttcaagaact	accgcccac	ggcaaaaagg	ttgcatctaa	8280
ttgatacctt	ttctgcctgc	actggagaga	aaccgggaag	gtattttgata	ccgtactttt	8340
ccgggttctg	cccggcatgg	acgataagag	aacattatta	tgataccaaa	aaacttttag	8400
gaaaaatatt	ataatataat	ataatataat	ataatataat	attttgtatat	ttatttatag	8460
aataaattat	attgaaatat	tctttttattg	aatattttgtt	tgtatatttg	cggtgtgaag	8520
ttataaatat	ggtagtagta	gttttaaaag	cggcaacttc	tttcgctggg	attgattata	8580
atgagcgaaa	gaatgaggaa	ggcaagagtg	aacttcttgt	tgcagaaaat	tttgctatga	8640
atccagataa	tttgaagaag	tcggattata	tagcttatat	ggaatctgtc	tgtaggacta	8700
atccagcggt	caaggcaaaa	caatttcattg	cagtgtatttc	atgtaagggg	cgtgaattat	8760
cggcagagga	tttgaaaaat	gtagctttgc	aatatataaa	taaaatgggt	tatggaataa	8820
atccttatat	gatatatattt	cattctgata	cagaaaataa	tcatgtacat	attgtttcta	8880
cacgagtaca	gaagaacgga	cagaaggtaa	aagataatat	ggaagctgtg	cgctcacaga	8940
aagtcataaa	tcaaataatg	aatgttgatt	tagctttgaa	ggctaaagat	gacatttcaa	9000
aatacatgga	gttttctttt	tctacagtgc	agcaatataa	gttggttactt	gaacaatcag	9060
gatggaaatt	aagagaaaag	gatggattat	taattttgta	taagggtggg	gaaaagcacg	9120
cttcaattca	attagagcag	ataaaaagata	aagctaaaca	atatacacct	gatgaagaaa	9180
gaagaaaaca	gataacagct	cttttattta	aatataagca	aggactttcc	tatacagaac	9240
ttcaaaacttt	gatgaaagat	aagtttggtta	taaatttagt	ctttcatata	ggaaaaggac	9300
atactaaacc	ttatggatat	acattaatgt	attatagaaa	taagagagtt	ttgaaagggtg	9360
gggaagttat	gaattttgaag	gaacttttag	tagagcctaa	taaacaagca	aaagttgaac	9420
actgtaatag	tataattaat	cttcttttga	aagatggaac	aaaatataca	atggatagtt	9480
tcaagaaatt	aatgttagat	tacggttata	ggttttcaat	gaatggcata	atattttataa	9540
atggtgatga	taaggcttta	ttggttcttg	ataaaaaact	gttgaaagaa	cttagatata	9600
atagcagagt	gtatgaagca	aataaaattta	atgttgctac	acttaaaagaa	gccgagttgt	9660
taagtagaat	ttatcatgtg	aaaaaaagatg	atattttgat	tcaagagcat	atggataaaa	9720
aaaatactgt	ctattctgat	atgataaata	gttatttggc	tcatagttca	gattttacatt	9780
ctacattaag	agaaaaagga	attctttttg	ttgaagatga	taatttagtt	tattctaatag	9840
ataaaaaagaa	taaagtaatc	gtaagtactg	atgatttagg	aatcaatatt	ataaaaagatg	9900
gctatagtaa	agataggatt	actctagtta	ctcttgataa	gatggaaaga	ataaatgttg	9960

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

aacaagattc	agaactggca	aggggattta	atctgattga	tgctatttgt	gatattctta	10020
gccagcatat	aaatgtacag	caagataaat	ctcctaatag	gaaaaagaaa	agaggcagcg	10080
aacaaaatta	ataaatataa	taagatatga	taatatattt	tggaatcag	aaaggcggtt	10140
gtggtaaaac	gactaattgc	atacaatttg	ccaactatct	agtagaaaaa	ggaaaagaag	10200
ttctagtatt	ggatttagat	tttcagcggt	cattatcggg	tagaagaaaa	gaagatattg	10260
cgacctatga	taatgaacct	aaatatgagg	ttatacaaac	cgatatatct	aatgtttgcta	10320
aaattattag	tgattttact	aagggttgagc	cattagcaat	attaatagat	ttgcctggta	10380
agattgatga	tgatgctctg	ggaactattc	ttaaagctgc	ggatataata	atatgcccat	10440
ttaaatacga	taaattttaca	atggatagta	caggtttttt	tatccaagtg	ttacagtatt	10500
taaattgtaa	agccaaaata	ttctttttac	ctaacaatat	gagaactgcg	gtaagatatg	10560
aaacaaaaga	acaggtagtt	gatattctta	agcaagttgg	ttttgttaca	gatgaaatac	10620
cagcttctgt	tgctatggaa	cgataaataa	ctttagcaat	tagtaatgag	tgtattgata	10680
aggtgaagaa	tgcttatgat	tatatcattc	aagaaggagc	aataaaaata	aatatttctt	10740
taatagatat	ttgttataaa	gttattcatt	tattgtatat	atttgcacat	ggctgataaa	10800
ttaaggaaaa	agcaaaatga	aggtatttct	agtgttctgg	aatagctaa	aatgataaga	10860
ggtgaagaat	tgcatgggag	tagtataaat	gaagctccta	ttcaagaagc	taaatatgaa	10920
gittgaagagg	agaaaagaac	acttcagtga	gaaattgaaa	caacttcttc	ggaagttttt	10980
aatttttaag	gctctagtga	aatggatttg	acggacttat	tagagtacat	taaaaggaaa	11040
aattataatt	gcaagggaagt	tctatatgtt	gatacagatg	taaaagaggt	gtttgggttg	11100
ctcaaagcta	aagccaaaat	acctatttca	tcttttagttt	cgtttatttt	ggaagattgg	11160
ttactaaac	accgtagcga	cataagttct	ttgattaagc	aaaaaaagaa	ccgttttctt	11220
tagtacagaa	aaagggtcgt	tttgtgaaac	aaaagatttt	ggttaggcta	gtttagaaaa	11280
cacttttctt	ttttgttttt	atgggtatcaa	ttctttgcgt	ccggcttccg	gcagcttttt	11340
gtattttggt	tcaaaaaggtt	gttctgcagg	gtgtgccagg	aatgataaatt	cggtatcatt	11400
tcatcatgcc	atgtttgccc	atcagtgccg	gaactccgaa	aagtacggta	tcacaaattc	11460
tttaaagtaa	tattgaaaat	aaaagagagt	attttgtact	ctcttttatt	ttattaaggc	11520
tgtaataaat	tgatggcttt	ttgaagatta	gcttctagct	cttttttagc	gtttgacata	11580
gcattcctcat	agtttttttc	tgattgtcct	ataatttcta	ttataacaga	attataattg	11640
gctttttgtg	cttcatcttc	ttctgtatta	gaaatcagat	aaaacttttc	actaaatatt	11700
aaatctataa	aaacatagtt	agaataaaaa	ttcagcactt	gaaataaaaag	ttttaggctg	11760
cccccttttc	ctagttcaag	atttgaaatc	gcattttgtt	tacagtttag	ctgttctgct	11820
aattgagctt	gggaatatcc	tatatgctct	cggatttgct	ttaaccttgt	gcctaaaatt	11880
ggtaatgtaa	tggtatacat	attgttctat	tactgtttct	acttcgtcgt	atatttctct	11940
aaagtttttt	tcagtaattt	tctctctatt	atctgctgtc	ccaaagttat	atacttttgg	12000
cagttctttg	taggcttctt	cttctttctt	aatttttttt	aaatctaaat	tggttttgca	12060
atggtacatc	gctgttgga	aattatcttc	ttgtccaaaa	tctaattgca	cttgccctac	12120
taatgtacca	gcttgtaatt	aagatatttt	ggatgccggg	ataacaaaat	ccattttgtt	12180
attcatatta	attgttggtt	cgtttcttct	gatagtaacg	ccttctttta	cttgcttaac	12240
ttttccaaat	agtttttgta	gccaatctaa	agtttcagga	gcttttagctt	gcccggataa	12300
agtgttacct	ataatagaag	ttatagtttt	tgccgtagct	ttgccgtatt	gttcttctaa	12360
ttgccgtagt	tcctgtaatc	ccaaacaaat	tgaacacctt	ttgctacgtg	cagtagaaag	12420
tagtgttgca	agttgataaa	aatataatgt	gggacattca	tctactatga	ttgaagtagg	12480
gtagttacct	tttgtattga	caagtctagt	taatcggtta	atgataagtg	catttaaagc	12540
actattcctg	ctttgtgttt	tagggttatt	tgcaatgata	agataactag	ggtctttttt	12600
atctgatact	tttaaatgta	aatcattgcc	actaaatacc	caaaaagatt	cttttagttgc	12660
tagtcttgat	aactgtactt	ttagacttgc	catctgtcct	tctaattggg	ccactgctcc	12720
tgatttatat	gcagcttcaa	atggggaaac	tagtgatttt	aattcagggt	cggaaaagag	12780
gactttaaaa	agtagtcat	attcttgatt	aaggaaagcc	agtacatgcg	gtaaatctga	12840
atatttgcca	tctctgtatc	tagaccaaaa	ataaatagaa	ctgtctaaca	agtttactgc	12900
tgatgtttta	aaaaaatcgc	tattacctcc	acttcttttg	tgcgcttttt	gtaaactctc	12960
atataatgct	tctgccgitt	ctgttgcatc	tgctaggatt	tctatatatt	ctcgtttcaa	13020
tggggtttatt	cttctactat	attcaatatc	agaaaaatta	atgacattga	acttgaaatt	13080
acttgggtatt	tttcctaatt	gtttgttctt	ttgataatta	taatatgcaa	ttttggcaag	13140
ttcaggaaat	ttgaagtcgt	aaacaacttc	tgcaaatcct	ttagctgaat	gttgtcttat	13200
aaaagaattt	ataacagaaa	aagatttacc	acttcaggc	gttcttatta	cgaaagttcc	13260
acgaaaacag	ttgcatatat	tcagccaccc	attatgccac	tttctattgt	agaaaaactt	13320
catcggaata	ttgacagaga	attctgtttc	taccttgtct	ttagattgtt	caaagctttc	13380
attctctata	ttaaatctat	ctttcataaa	gtttgatatt	atacgttttg	aaatgttatc	13440
tagagctgaa	tttattaatg	tcgctccaat	tattgatagt	ataatgtaag	ctatatata	13500
ccattctaaa	ctagtttctc	cttttctttt	aaagaaaaga	aagcatatac	ttccaaagaa	13560
cattatgaat	ccgaagatta	aaggaaaaat	gatttgttta	gtcgggtcta	attctaaatc	13620
cttttttgaa	cgtgttccaa	tgcaagtaac	cattataata	aagaatgtaa	atagttttact	13680
ataaagaata	ttagaataga	taggaatttt	tgccattttt	gataataagg	gcataatttg	13740
ttcactaaa	ggaaaatgaa	caaatagtag	aatctctatg	caaacagtta	tataaatgaa	13800
tgcttgcatg	aatccatata	gtttttgtaa	ttctttgctt	tcttccatga	tttaatcggg	13860
tatttttaact	ttttcaggtt	cctcacattg	aaaagccttg	aaatcttcta	tagctaattt	13920
caagtcttct	aaaaaattgc	tattgcaacc	tttttctact	gctatctggg	aatatgcttc	13980
cattgtttgg	acggaacaaa	tatctgttcc	gcattattaca	aaagctggaa	tgtcttctaa	14040
taggcacttg	tgtaataatc	ttttttggtc	tttcatctta	ttaattcaaa	tgaaaatacc	14100

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

actctttttat	gcagtgagag	tgggtattggt	ttttattttt	tgggtatcata	ataatgttct	14160
cttatcgtcc	atgccgggca	gaacccggaa	aagtacggta	tcaaatacct	tctcgggttc	14220
tctccagtg	aggcagaaaa	gggtatcaatt	ctactggtaa	ttttcttgtc	cgaatatatg	14280
ttgaaccatt	gcataatttt	caccactgtt	agacttatgc	agcttatcat	caataaaaaat	14340
ttttacttcg	actgtccttag	gtagctgtaa	attttcaagg	ttttcttcat	ctttagggtat	14400
agggtaggca	gatagccata	aatatgttcc	ttgtttggct	tcttgctcaa	atgtgaatgg	14460
actttctaca	ataatttctt	tggcagcttc	ttcgggagct	tcggaagaaa	tatctactcc	14520
tactgtataa	tgtattagaa	gtttgaaatt	ttctgggtcg	cttacggtag	cttcataacg	14580
tacttttct	gtatctcctg	taggtggagt	attagggtcg	ttgttatcgt	ctttattgca	14640
tccagacaac	ataaggctta	aaccaatcat	tactaatgat	aaatactttt	tcatattgtt	14700
tcttttaaat	agttgataat	tcaatgtgta	tgcgttccatt	tgcagcatta	tatgtacttt	14760
cttcaatatt	ggtgaaccgt	cttattgatt	ctttccattc	tctgtttgt	ggattgtggt	14820
aatattcttc	ttctaataga	cttatcaaat	tattttattg	tttgtcagat	agataaatct	14880
tttctccaac	ccttggaaact	acaggtaatt	ggattgggtat	agaaatattg	ttcacaccat	14940
ctataggaat	atggatgttt	atttctatca	tagccatttc	atgttttagta	tatttttggg	15000
cggcttaaat	ttaacaactt	ccttttctgg	aacttctaca	ggttctccag	ttgccggatt	15060
tctagctatc	cgagctggct	gaataatctt	tttgaaagta	ccaaaatctt	ttatagaatc	15120
atctttttct	cttagatttt	gagataattc	tttgaaaaaa	ctatcaatta	tttctgctac	15180
ttcttttgtt	ggtttatttg	ccttttcagc	aaccattttg	attaaatcag	tcttattcat	15240
ttgcataatca	ataatattta	attacttaaa	tcacttaaac	aaatttcagg	aataatttgg	15300
gtatagtctt	ctgtatctgg	tctataatgt	attgattcaa	ctatattgac	ctcacagata	15360
acatcatata	cccatgcttt	aaaatttctt	tctaaatcat	cctcaccatc	attgaattta	15420
ttaaaatcac	ttttagcttc	attctgttaga	tattctaata	aattttgata	ggtaaaattca	15480
ttctgaaaca	ttataatgtg	aggtgaaatt	tcttcgccta	tccttgggaag	atgcggaaaa	15540
ttccaatcac	cctttacctt	cattcctctc	tctttaaaaa	aatggctata	aattataaat	15600
tctattttca	tatttagtttt	atttttaaat	catcgttcag	tacaagcttt	ctttccatcg	15660
gttgcccgtt	tttatcatga	aatccagtta	acacaggtgt	ttcttttttc	tcgcaaagtt	15720
ctattgcttc	ttcgggagtt	atagaacgtc	ctgacatttc	acgccaaatg	acaaaatcac	15780
attttaatct	gacatttcta	tagttggaac	aatatataggc	ttttttgttt	atatataagt	15840
ttcctccaca	cttaggacac	ttacacaatg	tattgtcaaa	agaaatatct	aagttctctg	15900
ttagaaccag	ccgtgaagaa	aaatcatttc	cttctcttga	tttaaatcca	gtcataaacg	15960
gtgttttttt	tcctctggca	agtatttctg	ctgtctccaa	tgggtatttct	ctttgtgcaa	16020
tagttttggg	tatatagagg	ttacaaaact	ttgtgtgtgc	cttgcctttt	tgtgaataacc	16080
ctttacaagc	atatccattt	agtaaaattt	caatttctct	accacacaca	ggacacggag	16140
tttctaatac	ttcattttacg	aaagaaggaa	taacgatttc	attttcgata	gtcagatatg	16200
cagaaaaagg	aactcctttt	ttattatgga	agtcatgaaa	tatatctgtt	ttccctgttg	16260
ttattaattg	cctggctatt	tcttctgtaa	tctcttttcc	ccaatatgaa	tgataaatat	16320
taaatgtaca	tttgtcattc	atgttttttg	agtaattaca	ggaatatcct	aaactgcctt	16380
tcattatgtg	tcctttctgg	caaatagggc	ataagcctaa	atctttgatt	gtatcattat	16440
ccatttaata	tcctccttta	ctaattccatt	taataccggt	taaaatatta	tctacttttt	16500
gtttccact	attttacatat	ttaaattgtc	cgggtacaag	tgtttttagt	actccagccc	16560
ttttagcggg	tttcattttgt	cggcatacag	cgtatgcaag	tcctcgcat	cgtctaagtt	16620
cattgaccac	atgaatacat	aaatctatcc	tttgcttatt	atccataaga	tttttttcac	16680
cgccttgcaa	tgctatatgt	tttatgtata	tcattaaatc	tacacttcga	ctgataagct	16740
catactctgt	ttttgcaatt	atgggttaata	atttaggggtc	tccaactgca	tatttagctg	16800
cttcggattg	gtatttagct	atgtctctag	ctaagggtga	agcataaata	atatcttttc	16860
cattttttcac	aactgcatta	actgtagaaa	gatagttgta	tgtcttctcc	tgtaaggatt	16920
gaatttgatt	cattttttgt	tggattaaaa	tttgaaagtt	gcggattttt	gtttccctac	16980
tttgtatgtc	tttcaataca	ccttggtgct	cctgtgggga	ataaaccat	gtttccaatca	17040
ttaccgggtc	aatgacaata	gattgtgcta	gtccttttat	gttgccctaac	agtaacatta	17100
gggaaaaaaa	taaaagcact	cctttcatat	cattatctgt	ttgtaaattc	atatattcct	17160
tttttctttt	tttgttcttc	tactctattt	ctgatgggtt	gaattatata	actattagct	17220
ttaagaccat	tcatcagtag	ttctgggtgt	gatttatcgc	cagaataaat	gtagatatgt	17280
gtgtgtttta	ttaaagactg	gataaaaact	tgcttttctt	cataatcata	taccgatat	17340
aattctatgt	agttaatcct	ttttgaaagc	actccttgat	atatttttat	ttgctctcta	17400
gttataatcc	attttgtaca	aagtaacatt	gaaatatatc	tgtagaaaat	tataaatatc	17460
aacaatacta	atatcggttc	actgataaat	tttaataatt	catgttctct	tatatattta	17520
ctaaaaatga	atacgaaaat	cgctaattgt	attaaaagga	aattcttcat	taaccaatat	17580
cggaaatttag	gctttaatat	aatatcatca	gaagctatgt	ttgttccatc	attcataact	17640
taatactttt	ttttgtttca	tggtgtttca	ttagaatttc	attgaaatct	tttgcttttt	17700
ctgctttatg	agaaatcata	ggagctatta	ttttgctttt	ttccctaaaa	ctttctagtg	17760
aaacgtcatt	tttgtttaata	gtgaattctc	tacccttagt	tttaaacagc	acatcatctt	17820
tattttcttt	tattgtcatt	tctgtattac	taatgatctc	agacacttta	atgtcatata	17880
aattaccggt	taaatcatta	tcaaaacagg	tatgtacttt	agcttggtgg	tatcgcaata	17940
aagtgttttt	tatttgatta	actgaaatgt	accctcttac	actacaaaaa	acactttctt	18000
ctaatttgat	tttgtttagca	ttgagctgat	agaagctcat	agcatctaaa	gcggattctg	18060
caaagtatat	atgttttgcc	atttgggggg	gtgggcaaaa	atcagcaatc	caaagcgagt	18120
tacttttatc	acctccggca	gccattcctt	tgaatccata	gtttcttaat	tcgtaatttg	18180
ttactttggt	gtctttatct	tttggtattaa	tatagggaaa	acctatatta	taataattgc	18240

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

cgtttccttg	taagtcctta	acccttggtg	taaagtgtg	aaacttttct	acgacttgat	18300
gatttatatt	tcttttcatt	gtgagaaatc	ttaaatcagc	gagtgtagta	ggaaattctt	18360
tatatctatc	tctgtcaaaa	gatttggttt	ctgcttttac	aactttgaat	gcttcatatt	18420
taggactata	aggctcattt	gcgtaatgtc	ctaaaatcat	attgattcgc	acaaatgtat	18480
tttgatgttg	gaattgtggg	aagtcgttaa	tatgattttt	gatgaactga	attaaatctc	18540
cacctttata	attcctatca	tagtagtggt	cttgtagact	atgaggatic	ttgatgatga	18600
tttcatccaa	cttggtacct	gtccggtctg	tcagtttaaa	aacaggcgaa	acctttcctt	18660
tgctaattgc	ttgtttatat	cctaaatctt	caagtatttg	aatgatggat	attttagcct	18720
tataatcgtc	aaatgttagc	ataatattat	agtttcattg	ttggagtatc	attatttttt	18780
ccgtaggttc	taccatatcc	gagaatagat	gcttcttgct	tcgctgttgc	tttaatagaa	18840
ctatctattt	tatccatttg	ggtagatatt	tgttctccga	cagtttggtt	agtagcttcc	18900
ctagagctgg	aatatgtttt	ttctactttc	ttgtaagaag	cataatcttt	agaaagttta	18960
tgttttctta	aaaaggcagc	catttcggtg	ggtttatctt	taaaaatttc	atcaatccct	19020
ttagctcctt	tttgggtcac	aaactctaatt	ctttctttat	cagatatata	tctttctttc	19080
cctattgttt	gttctttctt	ttcagtcgct	tttaatttcta	tagtatttgc	atctttgatt	19140
gataatccat	ttctggcatt	caaactctagt	tttacttttg	cagctttggt	tagttcctcg	19200
tttacaatgg	taatttcttt	tccatttttg	agattttctt	gctgcatagg	agtaagctct	19260
attcctccaa	gtttttgggg	aatatgaatg	tcttttgctt	ttattgatac	tatctcatta	19320
gtatctttgt	cacgttggtg	caatgttctt	tctctttttg	aattagtctt	tactacgaca	19380
ttatcagctt	ttagggtctt	tatttcatcc	ttagtaaagg	ataaatcatt	ttttatttct	19440
tgctggttag	gaatgagcaa	gatagcaatc	ccagcgattg	ggtaaactac	tgtaatatgt	19500
gcgattgtcta	gtttcttagc	attgatacca	tcaattttga	tgcgtttacc	ttcttctttg	19560
aaatcaattt	cggttggttt	taatttagat	tttttttcag	gtgtattctc	ggctgttata	19620
tatttaagag	ttgttgcttt	cccccaaaa	tgtagttttc	cattttctgt	tttataagac	19680
actttttcat	tgtctagaag	tgttctatta	ccgggagtat	cttcaatgga	aaaatttagc	19740
atacctgttt	ttttcccatt	tttgatgttt	gcaatatctt	cggggcttaa	attttccggt	19800
ttaaactccta	cttcattaaa	cttggtccag	tctatatcaa	catatgaacc	tttaccatct	19860
agggtttggg	tttggtcata	agcatatcga	taaaggctct	ctcctttata	tgcaatttta	19920
ttttcaaggt	caatgactgt	aaatccgtct	ttatatcctt	cattcttggt	agtaccttgt	19980
tttatatcat	cccattttat	aattgcaaca	ttgtgggttt	ctcgtaaata	ttggctatat	20040
tcttggaat	tattgctagc	ttgttcttta	tcaaagaaac	tgattattct	ttcttttagat	20100
tgctctaata	aagattctct	atttatctct	aaattgccaa	gtttaagtgt	attcagtgga	20160
taagtatatg	tttcattacc	tttgaaaag	gtaatatcac	cattccgata	ttcttctgaa	20220
tatccaagaa	ttgctgctat	tgctcggcat	tgctcggcat	tttcataact	atattgcaaa	20280
gcttcaaatt	ttttcttttc	ttccatttta	taatttgaat	ttatgttcta	cttttagattg	20340
cgattcattt	ccaagtgttg	ttttttgtcc	tttcatgtat	tctatatatt	catttctggt	20400
tttatcagta	tgaatagttc	ctataatttg	tggtttatgc	cgggcataag	ctattttctg	20460
ttctgtctcg	aagtcctagga	attttatttc	tcttggtatta	tttaaatcta	atcttatggc	20520
aattttttct	ttgtcaacat	tcaaaattaa	ttctttacct	gatttttagag	tttctttttg	20580
ttgcttatcc	agctcaacac	cttttatgtt	tgaagggtatt	gaaatacttt	tgatttttgt	20640
tttaagcaat	tcgtttgttt	caggggtctaa	ttgtacgaga	tatttttcat	tgtaatatgt	20700
ttttgttatt	atctcgttat	cttgaagtcg	ttctaactcc	tttggtttaa	ggttttatatc	20760
attcattatt	tctggtctga	ctggatgaac	tttaacgcc	gcattgttgc	tatctttcca	20820
gtacaaactt	atttttctct	tcatacttat	ttcttttcca	ttattatcgt	gaaaagaaag	20880
gtctagtaaa	ctggttctct	ttccagataa	tagagctgtg	atatttgcct	tatccaaaga	20940
ccatatctgt	ttttttgata	ttcctattag	ttctaattct	ttatatggaa	tatcattttc	21000
attaaaaata	gcttgctttt	tatccatgta	atgtatat	ttgccccaaa	gtaataaaaa	21060
tatcaatatg	aagaataaat	ttatcatggt	ttttacttat	tcattgtttt	tttcagtga	21120
tggtactgtg	cagtttataa	cggatttaca	gaaaaaggat	attcctaagg	cggaaactgt	21180
attagcaacg	acagaaaata	aattgataga	agaaaaagaa	aaggctgttg	tcgtcaatga	21240
tgctttgact	acagaacgac	ttgcatactg	gaagcaaaga	aggtattttat	ctttgcccac	21300
tgattcaatg	gtgataaact	cccattatgg	taaaagaaaa	gaccatttta	ctggaaaaat	21360
agcaaatcat	agagggatag	accttaaagg	caacaacgac	tatgtttatt	cgataatgcc	21420
gggaatgggt	gtaaaaacag	gaaaaaataa	agggttgggc	aattatgtag	aagtgcgcta	21480
tggtgatgtt	acttctatct	atgggcattt	atacagtggt	cttgtaaatg	cgaaacaagc	21540
tggtgaagct	gggcaaccac	taggcattag	tggaagtacc	gggagcagca	caggagaaca	21600
cttacatttt	caaatggaat	acaaagataa	aactatagac	cctaagccaa	ttcttgatta	21660
tattaatgag	gtaatcagaa	ccgttaaagg	acaaatttca	cagcaaatag	ataatgagtt	21720
aagacgcaaa	taaatagaaa	aagaggattg	gaaaagccag	tcctctcttt	ttggaagaat	21780
cagaagaaac	ctttttttta	tcctttttct	tgcttttgaa	ctttttctag	tgaagattga	21840
agttgtaaca	gagcttcttt	cattcctttt	tttacttcag	gattcgttac	ggattcaata	21900
agctcttttc	ctctttgaa	gttagtggtt	agtatttctt	tattcttcat	ctgttttgaa	21960
cgactttcat	ctataaaaa	agatggcata	cttttgcaac	tccattcacc	attttactaga	22020
ttgaaatctt	taattctttc	tttcgctaag	taggttggtg	tagaaatctt	atctacagcc	22080
ttatcactgt	ataattgatt	tgcaagtttc	attagtccat	ttacggcttt	ggtatgtgaa	22140
tcaatatcgg	ctaactgtcc	ttgtccttta	cttagtactt	cttcttgata	cctgttgtaa	22200
agtcctagtt	gggtaaactc	cttgggggct	gcaataatat	atgcttcaac	tctaaatcct	22260
gcattcttaa	atttttgtgc	tgtctttaaa	ggcacatctg	gatttctcat	agttccttct	22320
ataataatat	tgcatttccg	tttaatggct	tcttctatta	gtttttctgt	aaaaacgcta	22380

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

gaaaaaatct ggggttcaat ggggtattta atagggtctt ttattagttc cttattgggg 22440
tgaaactgtc tgttaaaggctc accattaaca gtgagaaaaa ctaagttagg atgggtctttc 22500
tttgcaacat ttataagagt gctttttccg caagctgggt gtccacctaa gattatagca 22560
ataggctttt gtgatgatat attgatgtcc tcaaataagc catctttttt ttgttcaaag 22620
atggcttcta cttcatagcg ttgcataata tgctttcaat ttagggtgctt aatagttttg 22680
tatcttatcc atgactgata agcgcacatt ttcagaaact tcaaactgca acaatccatt 22740
tgctattttt tcttctgtgt tgagaacaga aagttctttt tgcagtattt tttttctgtt 22800
ttcatccttc tcttctgata tttcatctat cttcatcatg cggagtgtcc cgataatgtc 22860
gagcgcaaca tccaagctca tttcttttatt catggttcat tatagtitta tgatttatac 22920
ttcaatagat tctgtgaatt ttaataatgg aataactttc actgtatgaa atgaaagttg 22980
gttaaaaagc ttatgggtct ttagcatttc aatcgtctga tcagccgtaa caacaccttg 23040
ttcataaagc cggattgttg catataactg gtcattggca acgggtccca ttattaaatc 23100
atagctgttt tttccttttc ctctgcggtt attaactaca aactccagcc actcttttgt 23160
agcccatca aatcgaagga ctgaaaactc tctatcaaga atattatcgg ggacttcata 23220
aactgaaacg accgcttttt taccatgttc ccgatttctt ttgagtattg cccacttctt 23280
agcctgttca aaattagttg tcgtatagaa tctttttcca aagtcagtag ctttacgccc 23340
tttctgtata ttaggggatt tgacggtaac tgtttgagcg tgatatagtt tcatgacctt 23400
ttattgatat aagttattat agtatctaatt atatactctg tatcttgtgt gtgcagcatt 23460
tcaaaatttt catatagaaa ttcaaaaacg ccatgattgg aaaacagcaa aagagtttct 23520
ttagcactta ttttttagt ttccctgtaa ttttcagcac aaaacatttg aaaaagcaat 23580
atctttggat tgtccttttg tactttcttc tgttctgttt tctctttttc taatgcttca 23640
taaagtgata atgtacttga ataccatagt tttgtattct cgtccaataa tgccittgtac 23700
aaattggaag aatatatata gtataacgca tttcttaaaag gttagcgtttt tcttttcatg 23760
actgtatcaa ccaattctct catacaaat gggagcatag ctgaaccaag ttcattttga 23820
tatgtttgat tagtttccat aactatttat tttctaattt tatatagcta tcttgctgat 23880
gtctttagca aagatagaga aaaaacaatc atcatagacc tattgtattg attagtttgt 23940
aaataggttc ttgtatttc tttagatttt taatttgtat aacatactta ttgattccta 24000
actcattaaa gatttctgct tacattttta ttatggattt tctgtagtag atgggttaatc 24060
ctactattgc aatgcaaata aaaatcaaat agactagttc actatacgca tagattgcta 24120
atacaaaaat tccaccata gcccataaaa agctacttaa aagaaatctt aagatattca 24180
taattttgtt tgctgttctt tatactggca gccaaaccag ctttaaagggt ttgtttatct 24240
ctttattttc aatactcaaa gatagtgggt ttctataaat gtcgcaaata ataggacaat 24300
tatttttgtt aaaaatagtt ttaggtttat agactgccga agttttattt ttccctaaag 24360
tttttggat cataataatg ttctcttctc gtccatgccg ggcagaaccg ggaaaagtac 24420
ggatatcaaat accttcccggt tttctctcca gtgcaggcag aaaagggtatc aattagatgc 24480
aatccttttg ctgatggcg atagttcctg aatgggtgctg gtatcgtttc ttttatgatg 24540
cagccgtttt tctgtattca gatatagaga gaaacgacac aaagaacttt agggaaaaga 24600
agattcttcg tgttgctctt tctggaagtg gagtatatatt atcatatatt atagttttat 24660
aggttcataa attatattat cattatattt ttatatatag tgttttctct ttgttctttt 24720
tccctaattg tttatgggat caattttttg tgtccggctt ccggcagctt ttgtattttg 24780
gtatcaaaaa ggcgttcttc agaatatatc gagcatgata attcgggtatc atttcatcat 24840
gccatgtttg cccatcagtg ccggaactcc gaaagtagc gtatcaattt ctttccagac 24900
tataaaaaca agaccgagag ttttacctcc cggcttttgt taatagaaat ctctcttttt 24960
aatattcatc atttgtgata aatatttcta ctctcttatt tttagcacgt ccagcttcac 25020
ttgtattgtc tgcaatgggt tcgctatata cttttccatc ttctgttatg ttgtttgttt 25080
ctataccagc ggttctaagg taatttctta ctgctgtctg tctattttta gaaagtatga 25140
tattgtattg tttttctcct atattgtcag tatgcccaat tattttaatc ttagtattgg 25200
gtatttcagt aatgatatta cataagtcag aaagcatttt ttgagcttct tcattttaatt 25260
catatgaatc aagatttcaat aggatttcac tttgagctgt tgctttaaac tgttcttttc 25320
cattttttatc ttatagctg gagattgata agccatcaat agcttttagt ttatttcttc 25380
tagcttctat cttttcttgg atagctttat ctctttcttc ttttaactaat ttgtcacttc 25440
caccaactat tgaagcgggt gaatagttac tattattttc tatcatgtct ttttctttgt 25500
cgcttagttc agcgttactg aaagtatatc tatgcgttga agtacatgcg gtaaaaaatg 25560
taacaacgaa ggctgctagt ataattattt tctttttcat gattatctta ttgctataat 25620
aggctctgatt ttaaatgaat ttcttttgct tgtactgggt gctcttctct ttgttaatga 25680
agaaattagt gcaaacactt taggagtatc ttttctgtct ccacttctct tagaactcca 25740
gtaccaacca tcaaagtgcg ttcctccaat gattgagaaa gaagaatata ctttttcaag 25800
attattagag attgctttgt tttgtgcgat agagccaata aaccaacctg taacaccttt 25860
tgggtgcgat tctatagctt tttgagctgc tggataagct aaactatctt ttatagcaaa 25920
gttcattatt gcggcagtat tagctgtctc atcaaagctg ttttcatctt ccgaagcatt 25980
agctatatcc tcgtctgtat ctattaaagg attttcttct aaatcttcta atgaaacggc 26040
ataagcgggt tcttttatat caggattatt cccatcatta caccaaaata caactccaat 26100
ggcttctttt tcattgggtg aaaaaagtga gggatgcact atacttccat cactacataa 26160
gatactaccc ggctgtaagt atgtgtctat aatatcttct tgttttgtac atgatgatat 26220
tacctctata atggataata ttttttttct atacttaatt atttatttga 26280
aatrtgacac ctactaataa tccatttctg aaatggctac ggttccaaaa gacaaaatca 26340
tttttttgca ttacaaagac ttgcattcca tttctaaatg aatagctata ttctaaacct 26400
atatcaatgg aagcctgaaa cccttttctg ttagctccta aatctgctcc aaaccgccat 26460
cttaaattac tgttttgcc tcgtgagatt gtaggtttat atgctgcacc tatgccgaat 26520

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

gttttatagc	tccagaaact	atcagagcat	accttattac	ataccgggca	tttatcatat	26580
gctgtagcta	aatcaatata	tagttcataa	gcattgtgat	atttaccctc	aaactccagc	26640
cctacaactg	cattgacggg	atttttccat	tgccaacctc	ctgaaatatt	aaaaaactta	26700
tcaccatcac	cagccattga	ctttagggaa	aaaaataagg	tgataacaag	aaatgctatt	26760
cttttcataa	tcgtaaaatt	ttattcagta	aaagcatctg	catgaagaat	gtctgcataa	26820
tcaattctta	atgttatagt	acgtccctgaa	atctgttttt	cagatatttc	tatggtaaga	26880
actttttcgt	ctgggaaagt	aaatttttca	aagacaaaaa	tatttcgata	gttcttcttg	26940
aaaacaagat	tcttattaac	ttgcatcaat	ggaagtattt	ctatagattg	aaaattagta	27000
gcctttgttt	gttttttatc	ttctattttg	aagcgtattt	ggtctatatc	atatcgtatt	27060
tttgttttat	taatcataga	aatatcaata	aagaaatact	tatctaattg	gtagatattg	27120
tttagtacaa	ttttcattag	gttactttta	ctggaaacat	catagaattt	attttttgaa	27180
ataaacattc	tatgtgcgta	atcacacatt	tgtgcttttg	ttaagttcac	ttctggattc	27240
ataatagctac	gtaaatcagc	ataagggata	ttaaagcgag	tgtatgcttt	tgctaaatcg	27300
ctactatata	ctagcatata	ttgtacgaaa	aatctttctg	taacaatggg	gataactcca	27360
ctagctccct	cttttggtgg	ctttattcta	agagagttac	cagtaggaat	atcgccaaca	27420
ataicattga	ctgatataat	aacatatttt	atatctttca	tagctataaa	atgctgtgaa	27480
acatctttgt	tgacgtatat	aacctttagt	tcttctgggt	tttcacctgc	aagctcgatg	27540
ttttctccaa	taggggtgtt	ctgtgcattt	cctgtaataa	cagaaaccat	tgtgcataat	27600
gcaataaaaa	tctttctcat	attattgttc	tttatctttg	ttgtttacta	aaaaaacttg	27660
tgtgttatat	tttaatttgg	ctttgttttt	tttgatgttt	ttggaaagag	cttgggttgt	27720
actacggtag	gcattcttga	aagcacctaa	agcgaaattg	tctactcctt	ctgattggct	27780
gttcatttgt	atagtttggc	ttcctatttg	cgctccaaca	tctttactca	aatctctaaa	27840
agctgatgaa	ggaacaaaga	aaccttcttg	tccgtcatta	tcatatacag	ataaatctac	27900
tttcatttgt	ctgccatcaa	ccattataga	ggaaatatta	atgtgtactc	tttgagcttt	27960
aaagccagat	acattcccat	ataggtaagt	gccttttagt	aaaagagcgt	cattaatcat	28020
tatatcatct	agaagccgta	tgcgtaactg	gctaccatct	gttactttta	aagtttcatc	28080
taatatagct	gtgatttagt	aagttttttg	tcttttccct	acagtattaa	aatatacttc	28140
tgcgggattt	ttcgctttta	caacttctat	agccttttct	tttggctttt	catcttggtt	28200
tttttgaggt	gttctaggac	gtggattttg	taatgaatct	atataagcca	tttgcatttt	28260
aaaaagctcc	atttcttctt	gcattcttga	tttttcagga	gcttttctag	tttctgtttg	28320
acttgattca	tctatagtag	gaaatccttt	tatttgttgt	tccaattcct	tttctcggat	28380
tctagaagct	tgattttaa	tgtcaatttg	ccttatttca	tcattggagt	aaagagaacc	28440
agaactttca	tttcgcttaa	cttcttcttc	tttatctatg	gtttgtattg	atgaataatc	28500
agaagattta	ttgaaagctc	ctttgagtga	ttcaaattta	ctttttatct	ctcttttttc	28560
taaattagca	tcaggaatat	caagatttaa	ttcttccgtt	tctactaatg	tagtttcttc	28620
tgctggggca	gagtttatca	tatccttaac	tagccatcct	atccctagaa	taaaaggtag	28680
gatgagtatc	ggaatgatgt	acttaggctt	tttaatatca	atctgtttca	tacgtatttt	28740
atttaattta	ttgtataaat	tttttattcg	tatagtgtct	tctggagtta	atttcccat	28800
ttttcttagc	tcatttgcat	cttttgcatt	tttaactact	tctaacaagt	cgtgaactcc	28860
tacttggttt	ttttgtaggg	tactatcaat	gttaatttgt	actttgcttt	tttcttcggt	28920
gaaaacttgc	attggctttc	tttctggacg	cattactaat	gatagaattg	tgacgaaaga	28980
aaggaatgaa	atcgtaattc	caaacatagc	tttacgggtg	atatcagccc	acgccaataa	29040
cggttcacaa	gcgttattaa	ctccgaactt	ttgaaatatt	ttagtaagaa	gaacagctgt	29100
agcttgctcg	gccttagtct	tgatactttc	ttttctatca	ttctttttat	gtttaaacag	29160
tttcattaga	aattcttttt	tactttataa	tctaggtctt	tgtttagtat	cgttttccaa	29220
tctgtgataa	taagtccatg	aggattattt	tcagtgcgtg	gaatttgtct	taatttccct	29280
gtagttacaa	gttgccctttt	tagaatagag	gtttctcgct	ctatacgttg	gatgccatag	29340
tactcaaaaag	ataggttgtt	catgtccacc	ttgatactat	ctgtcataat	tgttactgtt	29400
gcagaactcg	ctaatttggt	gttgaaatat	cctttttctt	ttaaattatt	atattgtttt	29460
aatccgctat	catcaattag	atacatggct	ttttccatgt	tgtattttat	aaattcatcg	29520
tctggtggta	atgtgaaaaa	taaagtgtgg	aatagattta	tgtggctctt	acattcgact	29580
tccaagttga	cttctgtacc	agtttggttt	actagtacag	ggacatcatt	atccaaaaca	29640
tatatttttt	ttctttcagc	ttttactaaa	gagaaacaaa	aggctagtac	catacctgaa	29700
ataactatac	tagttgcaaa	acagccaatg	gataaaaatt	cggctaattt	gatttttatt	29760
tctaagtttt	taataatcat	gattatgtga	atttaaaatt	taatgaatct	ttttacatag	29820
ctgcaactgg	tccacctgta	gccggagctg	ctacagcttt	ggttgcgatg	gctgctcctc	29880
caaccatgcc	tcctactgct	tgccctactc	cagttgtact	tacaatccat	gtagaaacaa	29940
aaggtattgt	aagcatggca	aatgtctcaa	gtaatgctgt	aagaaggaag	ctattgacac	30000
ctccagaggt	cattccgaca	tacatgacaa	atgcagcttc	atttctaagc	gcataattcta	30060
aaatttcaat	ttctctttct	atcccatatt	gcattactac	taaagaaatt	gataataacta	30120
tatatgcaat	acatgaatat	aaactaacac	tgacaaaacg	agctatccat	tgtatataag	30180
catcccgaaa	tgacggtaaa	acagagaatg	caaaagctag	tggaccaaga	ataactaata	30240
ttcctgtgaa	tatgatttgt	aggaaaaaga	caaaatagggt	acatacttgc	caaaaagtaa	30300
cgacaataaa	ttcaatgata	ttaaacattt	tcatttttaac	cttagcgact	acataatacat	30360
ataatccagc	tatcttgtct	ccaatagctg	agaagctctat	actaaaatca	taccatttct	30420
tatccttaac	ttcattttcg	gctctttcaa	cttctaataga	agtatgtaat	aactctactg	30480
ctacgctatc	aatgagtgc	tatctattac	gagaaagtaa	ttctacttct	tctatctggg	30540
tcgtaaacat	agccttgctt	cgtgctgtta	ataactctcc	gggataactg	attagattaa	30600
taaagggat	ccagaacata	agaaccaatc	ccagtgcgaa	tggacgcaat	aacgggataa	30660

P065778_P067963GB sequence listing_updated MRX002pl_ch.txt

tctctaattt	tttatctcca	ctcatcattt	tgaagctttc	tactccaaaa	tataacaaca	30720
taaagattgc	tgccaatgct	tgtgcatccg	caataaattc	tccgaataga	acagttgttt	30780
tatctcttag	tccatcaaat	aattcaaat	agaatttatc	tattaactca	ttcatggctc	30840
attattgttt	tatttatatt	attcaatctt	gttattaatg	aaagaacctc	tattagtctt	30900
ttatcaaaat	ctaaataggc	ttcccttttt	ttagagttac	tcatatgtga	atcatggatt	30960
atatctatgt	tcttttttat	tctagtaact	tcatacagtt	taacttcaac	atgttcttta	31020
ttaccgccat	tagaagaata	ttcgacaagt	tttttattta	tatcattaag	aatatcattt	31080
ctacgatttt	tagttaaagt	atattgataa	tcaatttctt	tatctccaaa	tttgaagagt	31140
tcctgtctat	atatgggtat	aacattatac	ccttcttttt	ctgtttctga	tttattgtac	31200
tctacggctg	ccatcatggg	aatttcttgt	aactggaaat	tacgtctatc	ttccttcccg	31260
tatttgcgt	gtaaccctaa	gcccggcaaa	ggaaatttaa	tacccaaaac	ctttttatata	31320
catatccagt	aatgatacca	ttctggttgt	agtcgtactc	tatccataaa	ttccatatta	31380
ttaagcacgc	tccatttccc	tttatctttt	acaggcattt	gggaataggt	attagaagta	31440
ccaataatca	acattagggg	aaaaaataaa	agcactcttt	tcatattatc	ttttagggtt	31500
tactttataa	ttctgtaata	aatcatcaac	taattttgaa	cgattatctt	tgtattttaa	31560
tacccccgga	gctaattgtt	gtaatactcc	atttcttttt	gctgttttca	tctgtcggca	31620
tacagcgtat	gctatacctc	tcattgtttt	tagttcatta	ataacatact	taagcaagtc	31680
tattctttgc	ttattatcca	taagggtttac	atctgtcccg	acaatagcga	cctgataaat	31740
gtattgtgtc	aaatccgcag	tgcgattttac	taattctagc	tctgtttttg	ctgacaccaa	31800
taataaagcc	gggtcaccta	cagcaagttc	aaccatttgt	ttttgatatt	taccaatata	31860
tgtctgcaata	tcagtgcagt	agataatata	ttttcctgtt	tttatgatgg	cttctacaga	31920
ttttaggcta	ttataaaatt	tgctttggaa	aaatttcaat	tgaaccattt	tttcaactgat	31980
ttgtttttgt	ttttaggctta	ttttgagcttc	atctctcttc	acttttagaga	aagaagtatg	32040
ttgcacctta	tgattagcta	taagtgtttc	catacagggt	atatccaaga	ctgccttttg	32100
cgaatatgca	acttgggtta	aagtagatgc	taccactaaa	ataaatagga	ttttcttcat	32160
gatattatct	ttaacgggtt	gtaatccatt	tgtattttat	taggatatac	ttatataatg	32220
gttgttcccc	tatgatgta	agtatatctt	ttaggcttcc	atcatcggag	tgatacccta	32280
gtaccttatt	gacttgtaaa	acccaatcca	tatttttttaa	tttggaagat	tttaggtcta	32340
ttataaaatt	atccaatcct	gtttggaaac	taccataaat	gatattgata	tatccaacag	32400
catctttttc	aattcgttct	gtagtaaatg	tgaaatatct	gtgtagagaa	acctctactc	32460
caaatacatt	tccataattt	cctctttttt	taaatacttc	attaaaccga	ttacggtttt	32520
ctttattggg	aagttgattt	atggtaaata	tttgcttttg	atttacttcc	gttagggata	32580
aaagatttgc	tatttcttga	tatttgtcta	taaatcttact	ttgggtcta	aggcataata	32640
tatcggagtt	gctgattata	gagtttttga	ctacaggatt	actaattatg	tcctccagtt	32700
cttgagtaac	aaccattgcc	ataccccaaa	atttacgaac	tgttttatac	aaatagagta	32760
tatagccagc	catcataggg	ctagctatgg	ctttccatgc	ttcttcaatt	attaatgcct	32820
ttctgttctt	ttttaatctc	attttttgaa	taaaaacgtc	cataataatt	aaggttacta	32880
ttggaaataa	ttcagggtca	tccttaattg	catcaatttc	aaaaactata	aagggttctt	32940
caaaaaggga	agtgtaaaaa	tcctcattaa	gagttttttc	taactgtcct	cctttataga	33000
attttttttaa	tagaaactta	tagttagtaa	tatcaaaatc	aattttgttc	tccttgcaaa	33060
tgataggat	aatgcgtagg	gaaaattcgt	agaaagagtt	aaaagataag	ctttcaactt	33120
ttatttcttt	caatatactt	tccttcttct	ggattcgtct	ttctattata	gaaagtaatc	33180
tagtttcagg	attatcaagc	tcttggcggt	taaagccttt	ttcgtatgaga	atgttttgta	33240
tcgctttttc	tgcttgggtt	ttttctccgc	ctttctcttt	ttctactagt	tgctgttaatt	33300
tctctatttt	ttcggaaggt	atcttgcgtt	cttctttttc	cctttcgttt	tcaaattctt	33360
cttcattgac	ttgaaattcg	agtagtaaat	tttcacgtat	ggcttctttt	tccgcatctg	33420
aataaccatt	aaagggatga	aagtagaaag	aatagatttt	ttctatggta	atatccataa	33480
tttcttcttc	ttgtcttttg	acctcaccat	ttgcaccttt	ccataatcagg	aaaattaatg	33540
atttaagaaa	gtttttcttt	gttaccttat	actcttcttc	agtaattcgg	aaaggattca	33600
tagataatag	cttgcttttca	gaataagtaa	tgtattttg	atgatagtat	tcgcacattc	33660
ctgaataact	atgccctgta	tctaccaata	caatatcagt	gttatctaaa	acctattgtc	33720
ttactttgga	gttgacatag	aaagacttac	cagaaccact	tggacctaaa	acaaagaagt	33780
tggagttatt	tgtatatatt	ttctcacctt	ctttcccggg	catatctatt	ccaacaggca	33840
atccttgtct	gtctgtaaaa	taagtaagaa	aagggctgtt	ttctgttact	tgtaattttt	33900
ccttgaacaa	aagacaaatt	gcagcatcgg	aagtgtttag	aaatttgtca	taactgttta	33960
gggtgattgc	gtttcctggc	agtcacattt	cgaataattc	taattgggtg	aaacattgtt	34020
tattaataat	aatgccacaa	tcaaaaagag	atgtttcaac	atagttgata	gccttactaa	34080
tatcatcaag	accagcaaga	atttatattt	aatgtgcata	tacaagcatt	tgcccttctc	34140
tggcaatatc	cgactgcact	cgttctatgt	cttctacaca	taaatcattt	gcagggtcag	34200
gcatttcttt	atgttttttc	tttttgcctt	ctaatttgtt	tgcttctgtt	cgttggctct	34260
gaatatttat	tacttgatta	tagataattg	tgtctatacc	tggtgtatca	tgcaaaaaag	34320
agagtaagtc	aacaggaaac	cttagcccaa	tattgacctc	tttatatggt	tttataacag	34380
aaggaaaatt	aacttcgtca	atatctacaa	gagaaatgca	ctgtacgttt	ttttctccaa	34440
ttataagatt	ttcttctctt	gctttgatatt	tttttaggct	tactgtttgc	tgattgaaat	34500
tgatagatag	aaatcttttt	atatataatt	ctatttctatt	ttcattttaat	agtttagctc	34560
ttattcctct	gttagcgaat	agtcctaata	cttttgtgat	gttttctaata	aaagtatcaa	34620
accttcgagg	gtcaaaagaa	aagaatttag	acctttctac	ttctcctgta	ataacaagat	34680
aagtagaaat	atcagtatat	attcgtctct	taaaatgttc	aaaataacga	tttgataaat	34740
agtcgttctt	cctattctgg	ggtggtaaaa	atgatttttt	acatagaata	tcctgttttt	34800

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

gtattgtata tccagttcct aatactttga ggatattagt aaataagtgg tgaatatcat 34860
agtaagcatc catatctgct gaatactgta ttataggatt ttcacattta atgataacag 34920
aatagtcgcc ctttcggtta tagaatatag gagtattgtc tattgtttca ataccaatat 34980
aaggagcttc aaattcactt ttctttttca taagctttat ttttttctat ctcttataaa 35040
agtgcgtgat actatatata tgcctttttc tttatctttc ctgtgaagcc cttttctttg 35100
taattgcatg gttatttccta accctccaaa cataactatt acaagagtta tacctcccca 35160
cataaaaagaa gccagagtag aaacaatagc acataaaaagt aaagcactaa taatacaagc 35220
tccaccgata tatatgaact tgccttttaa tcctttgaaa ataaggggct tttgtagccc 35280
cttatataca ttgtaacttg gatactcttt cgacatatta gattccgaag aatgctttta 35340
cgacaacacc tgatacaacc agaaagatac atgaccccat ccagcccata acagcctttt 35400
gtacatcttg gtcaccagag ttccatttta aataaactcg cactgctcca actaatccta 35460
ctagaccttc tagtatctac atcatgtttc ctaggggggtc catgtagggt gcaagttcag 35520
aactagctgc atcaattccc gcagcacctt gtgcaaaagt gttagtact accattatgc 35580
taatggctaa agcgaatgct ctttgagcaa tttttgaaaa aaactttttc atttgaataa 35640
aaatttagttg tttattttgtt aaaattttacg tgtgaaaaca tgctttttcc ttttagcaaga 35700
agttgtttcca ttggaataacc ttgtgtttca acttccattt caatagattc atttacagat 35760
acataattctt gttcagattc ttttttttca tctctttttt cgtatgagcc tgtttcaaaa 35820
tcctcatctca caactttgtg aggtattttc ttctctcttc ctattgaaat aatctcttct 35880
tcctcacctg tattggtttt gctttgcttt aggaaagcat catacaggat gtttgcagcg 35940
tagtaaaacta cataaatggc aaatacagcc atgataaatt gtgaataact catattctta 36000
aatttaaaag tttcattaat cgaccctttt tctgtacttt tgatttataa tagtactaga 36060
ggtaataaca ggggaaaaag ccctagttta aaatagtttc gcgaatagtt gaattttatga 36120
aacttggatt taaataaaat ggagataata ggctacgctc gtgtttcaac gaggggaacag 36180
aatttagatt tgcagctaga tgcctttaaa gaagccggat gcaaacttat atttgaggaa 36240
aaagtatcag gagtaagga tagaccgaa ttagataaag cccttgcata tttgcgagaa 36300
ggtgatactt ttgttatctg gaagctagat agattaggac gttctttgaa agatttagtt 36360
tatatagttg attgtttgca gaaaagaaaa gttgcattca aaagcatagt tgatggtatt 36420
gatactaata gtgctctagg aagatgtcaa tttggaaatt ttgcttcatt ggctgaatat 36480
gaacgtgaaa taatagtaga acgaactagg gctggattac aagctgcaaa agaacgaggg 36540
aaacttacgg gacgacctat agggttatcg gaagatgcaa agagaaaagc tatagcagca 36600
aagcgtttat atgaaaatcg ggattattct atagatgaaa tatgtagaat tttacacatt 36660
ggaagtaagg ctactttgta taggtattta cgttatgaaa aagtaagatt gatgaataga 36720
agaaaataat agggcgttac ctttcaggtc gggcttttcg ctgcaagtc tgcctacgct 36780
gtgggctttc cgtgcaatc cctaacgcac tttccaccc acccttctaa ggtatatcca 36840
atgctttgct tttttaccg cttctatgaa gcacctacaa aagcaaggca ttggatatcc 36900
ggttttatag acttcatggt ccctaaaggg aatattccgt ttataaaacc ttatctctca 36960
cccaaatat ataaaacttt agggaaaaga taatacgtta aaaatcagcc agttataaac 37020
tatttttaac aaaaataatt gtcttattat ttgcgacatt tatagaaaat tactactttt 37080
gagtattgaa aataaagaga taaataaact ttaagcgtgg tttggctgcc agtataaaga 37140
acagcaaaaa aaattatgaa atctactttt gataaaaaatg cagagaagtt tgtaaacctt 37200
atggttgaaa aaattgaaag tttgtctatg aattggcaaa aaccttggtt ctctaaagtc 37260
aactctaaac agaacttttt accacaaaat ttaacaggtc gtacttatag tgggtgaaac 37320
gcttttttac ttttttttt gtgtgaaaaa tataattatc taaactcctgt ttttttgaca 37380
ttcaatcaag cacgaaacga aggtattaat gttctaaaag gtgctgttgc ttttctgtt 37440
tattatacat tttttgtgc ttatcatcgt cagacaaatg aaaaaatttc atatgatgaa 37500
tatacaaat tatcggaaga agaacaaaaa gaataccgtt tagcagctta taaaaatat 37560
ttccaagttt ttaatttaga ccaacaaaac tttgcggaaa aatatcccaa tagatgggat 37620
atattaaagg cttaaattttc aggagaggaa cagccacaag aagagaaaga aatgtatgta 37680
aatccaatc ttgatgaaat gaataagaat caaaattggg tatgtcctat tcaaacggtt 37740
tctagtata gtgctgtttt ttcaatatca aatgatagca ttactttacc tttaaagagc 37800
caatttaagg acggagaaag tttttatggt acagaattac atgaaatggg acatagtaca 37860
ggtgttaaaa atagactaaa tcgaaaagga ttttatgaaa atgataaatt caattatggg 37920
cgtgaagaac ttgtagcaga attaatatcg gctttgtctg gtgtatatatt ggggtatttct 37980
gtaaccgtca gagaagaaaa tgcggcttat ttaaaatcat ggtgcaaagc aataaaaagaa 38040
gaacctaaat ttttatagga actcgcattt gaaaaccctt aaatcttcag tttaggggat 38100
gaaaaatgca gggtagcgca gctacccttg gttttcgatg ttttttttga tgggtttcctg 38160
actgacattt ccgactgatg acacaaaata tccatccgtc caaaatgtgt tttcccagta 38220
aaatacatgt ctaaggtaat tttcatgtct tttccaaatg gcagttgttg acatttgttt 38280
tagcctcctt acgatttgca gcggagagag ttttggttcg ctgcatatca tcatgtgaat 38340
atggtctttg tcggtttcca tgacctcaat gttaaagtct gacaggtctg atatgttctg 38400
catgatttgc ttcatgtcat attccactgc tccaatgagt agcttcttcc tgtatttgca 38460
tacaatatc acgtgatatt tgatgagaaa cttcgagtgg ttctttgaaa tgtaatcttt 38520
ctgtatcatg gtctcatttt aaatcgttac ttttgccata tgttacgtgc ctacaaatat 38580
agaatctatc cgacagatga gcagaagggt tttgttgcaa agaccttcgg ctgctccgt 38640
tttgtctata attgggcatt gaacctgaaa atcacagcct acaaggaaag ccaaggaaagc 38700
ctcggcaacg tatacttgac caatttgatg aagagcgagc tgaaggtgga gcatgagtgg 38760
ctttctgaag tcaactccca gtccttgcaag agttccttgc gtaatcttga tacagcctat 38820
accaatttct ttcgcaacac caaggctgtc ggtttccac gcttcaagag ccgcaaggac 38880
aagcagagct tcctttgccc acagcattgc cgtgtggatt ttgaaaaagg aacaatcaca 38940

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

atccccaag cgaaagatat tcctgccgtg ctgcaccgca gggtcaaggg tacggtgaag 39000
actgtcacta tcagcatgac cccttcggaa agatactttg cttccgttct ggtggacacg 39060
tccatgcaag gaatgaagcc ttccgaaccg atgctgtgaca cgaccgtcgg cattgacttg 39120
ggcatcaagt cgcttgccgt atgtttctgac ggacgcacgt ttgccaatcc caagaacttg 39180
cagagaagct tagaccgctt gaagttgcta caaaagcggt tgagccgcaa acagaaaaggt 39240
tctgccaaac gcaacaaggc acgcatccgt gtagcccgcc tacaggaaca catagctaac 39300
agccgtaaga acagccttca caaaatcacc catgcactca cgcacgacag ccaagtgcgc 39360
actatctgca tggaagattt gaacgtgaaa gggatgcagc gtaaccacca tttggcacia 39420
gccgtaggag atgcttcttt cggatgtgtt ctaactttgc ttgaatacaa gtgcagttgg 39480
tatggcgtga acctcattaa gatagaccgc tttgccccaa gttcgaagac ctgcggcaaa 39540
tgccgctatg tgtacaaaga attgaatctt agcgagcgca gttggacatg cccggaatgt 39600
ggtagacatc acgaccggga cttcaatgcc gcttgcaaca tcaagggaatt tggcttgaaa 39660
gccctacca cggagcgtgg gaaagtcaag cctgtggact gtcctcttgt ggatgaccga 39720
cctcgtgtcc taaaaagcaa tggcaggaag aagcaggaaa agagaggagg tattggtatc 39780
tccgaagccg ctaaattctt agtttagcgg tagttcactt actgtattgg cagatgctat 39840
taaaggtagt aaattcatag cccagcatct aaataaagg ctagatgtgg aagaagttga 39900
agaagagaaa aatacaaaag ttgcttaaa gttccttccc ccttatttgg ggggggagtt 39960
cttttttcaa acgcaaaaa agaaccaaaa aggtttaatc gcttcacttt gttacgctcc 40020
aatagttttg ctatcggtaa acccaccac ctttctaagg tatgtttctt tatcccttct 40080
gcaatcctta gtaaagttcc actacctttt aggttaactcc actttagtaa gcattgcaga 40140
agcggaaaca tgacgcaaat taaaatacat tctcactttg agaatacatt ttaatgcgtc 40200
ttgttgtcta acccaataag aactataggg aaagaatttg ataccgtact tttcggagtt 40260
ccggcatgta tgggcaaaac tggcatgatg aaatgatacc gaattatcat tctgggcaca 40320
ccctacagaa caaccttttg ataccaaata caaaaagctg ccggaagccg gacgcaaaga 40380
attgatacca taaaacatta ggggaaaaga acaggaacag aataccatat tatatatata 40440
aataatatat gaatatataa tatataaata aacaatatat aatatgtgat taatatactc 40500
cacttccaga aagagcaaca cgaagaatct tcttttccct aaagttcctt gtgtcgtttc 40560
tctctatacc tgaatacagg aaaacggctg catcataaaa gaaaagacac cgacaccatt 40620
caggaactgc cgccatcgg caaaaggatt gtacctaat gatactttt ctatcagcac 40680
tgagagagaa ccgggaaggt atttgatacc gtacttttcc gggttctgcc cggcatggac 40740
gataagagaa cattattatg ataccaaaaa actttagggg aaaataaaac ttcggcactc 40800
tataagccta aaactatttt taacaaaaat aattgtccta ttatttgca catttataga 40860
aaatcactat ctttgatgat tgaaaataaa gagataaaca aacctttaaa gctgggttgg 40920
ctgccagtat aaagaacagc aaacaaaatc atgaaacatt gcttctttaa tccatttcgt 40980
agccaactgt tagggctatt tttcagtatt aattcattaa tcattttttt atgaaaaaag 41040
agtttacatt acgcttagac gatgcagcct gtgcggagtt agaaaatcta aaaaaattat 41100
ctggtgaaaa aacagatgct aaagctatta gatttgcata tcagaattat gcaactttga 41160
atgataggta tattgaaaca caacggcaaa taagaacgtg gaaagataaa tatgcagcgt 41220
taaataaagc tgttgatgat tacttgtctt cttttgaagc attgaagaaa actacagatt 41280
gatagttaat tattagaat gtgaaaggat taacaaatat aggggtaaat tagaaaattaa 41340
cgtataactg tatataaata aacgaattat gaatgaaaga acaatccaaa tagacgtaat 41400
tggaanaata gaaggtactc aatttatgaa gtgtaagcta tatacaaatg aaaatattgt 41460
cattatcatg atgaatgaat ttgattatga acggttgaaa gaagaaggaa tcttcataag 41520
agatggcaaa agtcgagatt cagccggggt gttgaataca accaatactt tcatcgaaaa 41580
aaattaatac tcaaaacaaa aaagaatgat tatggataaa aaagaaaaga attttgccac 41640
atacaagaa tttgcaaaga tgcttcggga agtggcaaac atatactcta aactgggtga 41700
cgaaccattg ttgaaagaag gatatgagta taacgccatt agagatgctg ttcagtatgt 41760
aacgaacaaa cagcattttg attactttat acagccttgg aaggatgagt tctacgtat 41820
gccctttgat gtagcaagc gactgattat ggtgctgaat gtggctgaat gccatgctac 41880
aggaaaggaa atagattacg ataattatga ttgggataaa tgaccataat ttttcgaata 41940
gtgtgaaagg gaatagatgt catataatca aaatatagat agaatgttta ttgaatataa 42000
ggtatatcgt aggggtgcag atttgaagcc ttttatatct aggggtgaac ttccttcttg 42060
tcagatgatt gggaaaaaaa agttttagg aaaaaagca aaaatggagg ctgtttatag 42120
acttacaggg aaacgtttgc cagaagacta tacaacagag caggtaaaaa attttcttac 42180
ggtagaattt tttaatacgt ctttatggca taagtataga aagatttaca atgaagtttc 42240
caatgaaaaa gaaattgttg ttgagaacta tagttatcaa tatacattag ttgtagaatt 42300
agcaaaataa tcgaatttat cattggatga aggaaaaatt gtacattttg ttatgtgcga 42360
actgttagga aatccttgtg aaacgtataa agggatgaaa aaccctataa tttctttacg 42420
aaaagattat gatagataaa gcaaaaacat tagatgaatg ctttaaggaa ctaattctta 42480
aaagagggtg gtctaaaaat agtccatatg accgccgaac tgcataagg cataaaaaagc 42540
aatccttga aggaacgttg cccgatgaat ttaaaagagt atatttgcaa agtgctgggt 42600
atacaatagt gcagccggag ctttgccgac aggaattata aaacaaagaa aatggactgg 42660
aggaacataa taagaaatct attagaatgt atcattgcta tttttagaat gattttcata 42720
gggctatttt atatagccaa gtttatgttt gtgttcttta tctactttt ttttggagta 42780
ttaatcagtc aaaataataa acgatggtaa atagagaaat aaaagcccga aaacgtgcgg 42840
tgaaagaaga aaaagaagaa atagacggtg agattgttag aattaggaaa gggcatcctc 42900
gtacaaatct tcctgtgaaa ctcccagaaa atcccacatg gctgaaacaa cctaattgtag 42960
ttacattaat ggctggtgat ttaagacag tacagattag aatcttaatt gctgttatag 43020
agaaattaca ggtatgcata gaattaagta ttcagcatct agataaatat ggtacatcta 43080

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

ttccatgcga gcaattatct ttatttcaag aatattcaga ccgtataaga gtagatatcg 43140
catatcggga tttgggcgtt aatccagacc aatacaagga agtaaaaagc atgggttcgta 43200
aattaatcag tattcctgta gagcttgatg ttaaagaccc aataacaggt gaggatagtt 43260
ggtctattac tggtttattc actaaggcaa atatacctaa aactccttat tcaagaggtt 43320
tttctttaga aatggataga gaggttgcta aagttttcat taatgttgat agaggtttta 43380
cacgctatat aaaagagata gctttaagag cgcaaagtag atatacaata agaattgtata 43440
tgctgattag ctcatggaaa gaaaaaggtg gtttttctat ttatgtggat agatttcgga 43500
aattcttaaa attagaagat aaataccccg aattttaaga tttgtataaa cgtgtaatac 43560
gccctgttta cgatgatttg tttgaacagg ctgattgctg gtttgaaatg gcagaagttt 43620
atcgtaattc aggcgatata cagccttata aacttaattt caaagttatt aagtctgcat 43680
tatcaaagaa ggaagaagaa ctattaaaag gacaaaagaa gatgataacg aatttttgtt 43740
ctttgcactt tgcaatgaag gacgaacatt tgcagcagtt tattccacag attacattaa 43800
gcaactataa agcagtagta actaagatgc tttatctagg cgaatatgtt agagataact 43860
ggaataaaat ttcaaataaa gcagaatatt gtttatccgt attattaaaa gaagtagaaa 43920
tactccccgg aatgattgga gaagaaaaag aagatgaata aaagttgggt tttgtccct 43980
aggaggggtc taaaagtttg gtttttgtcc ctaagaagtt ggggttttgt ccctaagaag 44040
ttgggttttt gtcccctaaga agttgggttt ttgtccctga ttttttacca ttatctgttg 44100
tttttcaaat agttaccctt ccatttttaa gggactacc atcactagct gataaaaaaa 44160
acctgataat cataccaaat acaaaaaagg aacttttctt attacataaa cccataaaaa 44220
aggaactttt ctcataatct taacacgaac tttagggaaa agaacatcta ttaacaaaaa 44280
aagacgctat atgatacaac taatcaatca aaagttgggt ttttgtccct atctaaaaaa 44340
accatatttt aaaaagtttg gtttttgtcc ctatgctttt ttgatatact gtagggaaaag 44400
aaattgatac cgaattatca ttctctgtac accctgcaga acgccttttt gataccaaat 44460
acaaaaagca gtcggaagcc ggacgcaaaa aattgatacc ataaaacatt agggaaaaag 44520
aacagggaac aaataccata ttatatatat aaataatata tgaatatata atatatgaac 44580
ctataaacat ataatatatg attaatatac tccacttcca gaaagagcaa cacgaagaat 44640
cttcttttcc cttaaagttct ttgtgtcgtt tctctctata tctgaataca gaaaaacggc 44700
tgcatacataa aagaaacgat accgacacca ttcaggaaact atcgcccatc agcaaaaagga 44760
ttgcatctaa ttgatacctt ttctgcctgc actggagaga aaccgggaag gtatttgata 44820
ccgtactttt ccgggttctg cccggcatgg acgataagag aacattatta tgatcaatac 44880
ttcggtaaat ttttaccgat aaattaaaaat taacataga atcggcataa tccggttcaa 44940
aatttatattc aagagatcat tgaaatactg tcaagaataa atcgtaagg agtaagaaaa 45000
gggatgaaaa agatgtgcta aacagctgaa aatcaacaga aaaagtattt cataattcac 45060
tgatttttag taaattgaa gtacttcacc acttttaatt atgactaaag aatcactcct 45120
tatgcaatac caatccgagt gcagaaacgc tctcgaatca gctgtaaata taagcaaadc 45180
ttttcagaaa gtattcatgg atgcaatgaa attattcatg gctataacct accgcatcaa 45240
tttctacaaa atgggacggg atggatgttt ctcggaacag acataccgca acaattttga 45300
gaacgacggc ttgtactggg ttctcttcaa tgaagccatc atcagggaaac accttaagg 45360
tggtcgcaag gcgatagccg ttgatccgtc ttctattcca aaatcaggca gcaaaacgcc 45420
gtggattggc tatttctggt ccggttggtc cggtgaaatc aaacgtggac tggaaataac 45480
cggatttggg gttatagacg ttgacaacca tgaatgtatg actttgggct ctgtacagac 45540
acctgacaac gcaacgctgg aaagctgtga gaagaatctt gttgactggg acagctctta 45600
ccttatcagc atacaggaac agctgaaacg tatttctggc acagtcgtgt gtgatgcgtt 45660
cttttcaaaag gcaactttca tcaaaccatt tcacgataac ggtttccacg taataagccg 45720
tttcaggaat gatgccgtat tgttttatcc caccttagaa aataggacag gaaaacgcgg 45780
acgtccaaaa ttacatgacg agaaaattga ctttgaaaat ctggacatca caagatgtac 45840
cgagtacaaa gtgaacaagg gtaaacctta cggactgaaa gcatactcca aagcactcaa 45900
acgcttttgg agcttggtcgt tatggtacct catggatgga agaacggaca aatggcagct 45960
gtatttctct acaaacgaaa tacagaacgc acaggatgtc ctggactttt acagaaacag 46020
tttccaactc gaattctgct ttcgggatgc caagcaacat gccggaatag caaactgtca 46080
gtctacagac ttcaggaaac tggcattcca cttaaatgca tcacttgtag cgataaacct 46140
cgccaaggct gcctgtaaga agatgggaat aaaatattcc atatcatcat gcaagtcagt 46200
catacacaat gcttacatgc ttgaacgatt tatttgcgtg tctgggattg aaccaaacac 46260
gcaattaat tgaacacttt tcaaagaact cattttattt actgccagag ccgcttaggc 46320
tgggctaatt ttaacgaac tattgtttac tataattgat aattgatgac gttatgatat 46380
atagtacaaa gcataataaa aatacaaatg aagatcctaa aacatctgtt atttttgaga 46440
atctgatgtt attaccagac gatctttttt gggaaattct aagagaatca acccctaatt 46500
gtaaaatatt acctaatgat gctggatatt tacttcatag tgatgattat ttttggcctc 46560
attggaattc taaaggtaat tatgatgctg ggaatctaaa ttttgtagaa ccagatgttt 46620
tttttcgctt ttctaatttc gatataatcg tagaagccaa attatcagat tgttcaggcc 46680
agaattatga ggaatgggaa cgagaattta aatcttatct caacgaatac ggagaagaga 46740
aaaaaacagt atattttatt gctgtagggt gtaaatagat attaaatatt gaggaaccac 46800
tgattgttga tgggtataaa tgtccaattg taaaatttca ttggtttggg atattaaatc 46860
aggtttataa aagatgggaa gaatttgata atcgaatact tcaagaatct tcaataaaga 46920
gaatcttaaa aaatgttata gaaggtttta atcttatggg agtttatatt tataataata 46980
aaataaatct aaaagagttt acaagtatac aatctttaat tagagctttt gatatagtac 47040
aatagttcgt taaaaattag cccagcctaa gcggctctgg cagtaaataa aatgagttct 47100
ttgaaaagtt tgtcaattaa ttgctgtgtt ggttcaatcc cagacacgca aataaatcgt 47160
tcaagcatgt aagcatgtgt tatgactgac ttgcatgatg atatggaata ttttattccc 47220

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

atcttctttac aggcagcctt ggcgaggttt atcgtgcaa gtgatgcatt aaagtggaa 47280
gccagtttcc tgaagtctgt agactgacag tttgctattc cggcatgttg cttggcatcc 47340
cgaaagcaga attcgagttg gaaacgtgtt ctgtaaaagt ccaggacatc ctgtgcgttc 47400
tgtatttcgt ttgtagagaa atacagctgc catttgtccg tcttccatc catgggttac 47460
catacagcca ggctcacaaa gcgtttgagt gctttggagt atgctttcag tccgtaaaagt 47520
ttacccttgt tcacttttga ctccgtacat cttgtgatgt ccagattttc aaagtcaatt 47580
ttctcgtcat gtaatttttg acgtccgcgt tttcctgtcc tattttctaa ggtgggataa 47640
aacaatacgg catcattcct gaaacggctt attacgtgga aaccgttatc gtacaatggt 47700
ttgatgaaag ttgcctttga aaagaacgca tcacacacga ctgtgccaga aatacgtttc 47760
agctgttcct gtatgctgat aaggtaagag ctgtaccagt caacaagatt cttctcacag 47820
ctttccagcg ttgctgtgtc aggtgtctgt acagagccca aagtcataca ttcattggtg 47880
tcaacgtcta taactccaat accggttatt tccagtcacac gtttgtattc accggcaca 47940
ccggaccaga aatagccaat ccacggcgtt ttgctgcctg attttggaaat gaaagacgga 48000
tcaacggcta tcgccttgcg accaccttta aggtgttccc tgatgatggc ttcatgaaag 48060
gaaaaccagt caaagccgtc gttctcaaaa ttgttgcggt atgtctgttc cgagaaacat 48120
ccataccgtc ccattttagt gaaattgatg cggtcaggta tagccatgaa taatttcatt 48180
gcatactga atactttctg aaaagatttg cttatatfta cagctgattc gagagcgttt 48240
ctgcactcgg attggtattg cataaggagt gattcttttag tcataattaa aagtgggtgaa 48300
gtacttctaa ttactaaaa atcagtgaat tatgaaatac tttttctgtt gattttcagc 48360
tgttttagcat atctttttca tcccttttct tactccttga cgatttattc ttgacagtat 48420
ttcaatgatc tcttgaatat aattttgaac cggattatgc cgattctatg tttaatttta 48480
atttatcggg aaaaatttat cgaagtattg tacagtagtt aaattatcaa cagataaatt 48540
cgaatttaata ccatttggaa gaaaagatat tattatggag ttaatttca 48600
attactagct aaaggtaaag atgatataata tttatcttta gggatttggg ttaaagatgg 48660
acttattact gttgggttaa ataatagaga tggttgggca cgaaagtttt gtgaactaat 48720
agagcaaaac aaatctctta attctgtgta ttcaaaatta gaaacaacag aatatgatcc 48780
tgataaattt ttatattttg aaccaactaa taagtttaat gaagaatttg cacaaaaaga 48840
aacatttgat gggcaggtag atttattatt tctttttgtt aaagaagttt gtatgaacta 48900
tatagagtaa tatttgattt atctttttac agaattgtca ttgtcataat tttctttttg 48960
accaacttcc cactcacgtt tctctccatg gcttccacca ccaaagtcac gcaatttact 49020
tttaccaaag agaagtgcag tatgtctctt gttttgtaaa tgcttatgtt gccctgattt 49080
cttaacaggc gtgtttataa atttctttta ccgttcaagg ctgcaatttct cttcagtaag 49140
atttataatg atgtgtgtc tgaagttgat ggcataagtt gcacccatc cctgacggat 49200
ggtgaagccc tcttcatgca atcggcttct gacggaggaa acattttcgt cattgaatac 49260
ctcacgcaga cggtttacag tatcagtgtg gtatgtgtgt cttttccggg gtatgtttc 49320
attcagtgtg tctgaaatga gtcttcagat cttttagttt tgcaaatata tcactttatt 49380
tgatacatta tcggcaggta ggcattgccga taatgatttt tattcgtccg gaaacagatt 49440
cttttcaaga tcaattcttg gaacctgtct caggtaagac tcttgttcca tggcagctt 49500
tcccataagc aggatgacag actcctcgtt gggcattgca ccacgcaccc tcgtaactcg 49560
ccggaagtcc ttctgcaggc gttctatcca gttcgtagta tatacatag attggatgag 49620
gtggtcatag ttcaggtaag tgaaatatgc cttgtaggaa gcacccacac cacttttctt 49680
gatactccta taataccggc cccattgggc acagaattgc tgccattcac tccaggcctg 49740
ttctactgta tagtttctgt cccctgtccg gaaaatatgc ctcaaattct ctgccacatc 49800
tcctttgtcc ccgttacgga catcgtctca gatattgcgc tttagggtgg tagtgcatt 49860
ctgaagttaa gttcctggga acacttcaat gatgacatct tcaagtcctt taagaccgtc 49920
cgcgcatata agaccgattt taccgacacc tctctcgtac aggtcatgca gcatctcacc 49980
ccagcccaaa gcactttctg tcggtttgtt gaagataccg agtacctccc tggctttgtc 50040
ctccttcacg gacagaacga catagaaggc ttccgtatca acgctacgtc tgcgggtgac 50100
ctttatgtgt acgcagtaaa tgaacaccac aggaatatag ctttccagag aacgttccag 50160
ccagtcgtgt acatccttgc gcaggtagtc aagcatccgc gatatactgg ctttgcgtga 50220
gtgctcgcca tagatgtcgt tgaagacttc accaactgtt tcctgagtca gacctttggg 50280
gtacaagggt ccggcaagtc gtttacactc ttcttctctga tcacggagta tggccaatat 50340
accgggatga aagttaccgt acctgtcacg tggaatacgg aaagtcaatg tacgtccata 50400
cccatatgta cgaccaggac ggtagccatt gcacttgttg cctgaaacac cctcttcatt 50460
aagatattcc ctgcgctctg atatcatcag gctttcaagc attattttca tcaaattcatg 50520
taagccattt tctttttccg aatgcttgca tatcagctcg gaaagttgtt cttttgtgaa 50580
atccataaag tctactcttt ttttaggttt attggtttgc tgctacaatt ctaaaaaatc 50640
tgtagacttt tttattatcc tatttcagac acactttttg gaacagtatc acaggttttc 50700
atgattatag ctccgtactc caccaatagt caaattgagc ctgtttcctg cgatatcctc 50760
atggattgaa ggtatctcaa aacaaaacat cattctctca tagtaaatgg tcttatcttc 50820
ttccaaaaaa tcttttactg acttgtgaat agtttcggga atttccctt tgatgatatg 50880
acttactctg atttcaggca gttcaatact ttcacttggg aaaaccctgt tagctgcttc 50940
tcatacagat tcaataaagt tgggatggga gatggttatt tcattgtcct tgctgaatac 51000
aggtacaatg caatcatctt ttagatgttc tcttctgtg tcttttgggt tagcctcaat 51060
aaaagagagt tttttacttc tcttctgtac aagatggatt ctacatcaac aatttcttgt 51120
ttagacaaat caaatgtcct gttttaccct gcttgataa atcaagttag ccttgaaggc 51180
tgtagttgca ttgtctccac atcttatgaa atttggatta tagttaatac tcggtttatt 51240
cttatctctt ttagattgaa ttttcttctg cataaaatca gagatcaatt gttgataaca 51300
ttcaggatat ttatgataaa tggcggtcac tttctctata gtttttagtcg tattttattg 51360

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

ctgtttttatc atttcaacag tcactccatc aattgcacca atcaaggata atttgtcctg 51420
ttgttgggtgt aatgggtaaag tcgggctttc ccataaacag gttagtccta tccttgcttg 51480
caatggccttg atgcttcatg ttgatgtcaa agactatagt aaattcatag tttattccat 51540
ctctcattac agcttttaaac cctacttttt caggcacgat ttgcccattc ttctcattca 51600
atacatagtt ctgtgtgcac ctcatagtgc aaatgatatg cttctcactt tgcaatatat 51660
tctgcataaaa agcattaatt tttggagtaa ctttctgcca attagtgaat ctattacttc 51720
gcaaattggc atgatactcc aacagattat ccagcattg ggaaatggaa tctatgataa 51780
ttactttctat tcctgcatcc tcacatatcc caatggcttc catatagggt tcaggagtaa 51840
aattgtcctg aagagaaaaga acattataac tgcctaagtg agcatataaa tcagcacttt 51900
cattttcact atctataatt gctatttttac tccaatctcc acacaacca taggtaagaa 51960
ataaggcaga gtaagtttta ccactgcctg cacatccttg aagagcaagt tttatttttg 52020
cttgcttctt tcgtcaaact cttaacagca tcatattaaa aatgaaatat ctactgcatt 52080
caatctttca ctatagttct taatcaaatt ggagccatag gaaagaatct cagggtcctt 52140
aattttctct tttcttaact tagaagcaat tatcacttta tctgttttga tatatcctac 52200
ttttctacta tgagtgtatc taacaatact tcggtaaatt tttaccgata aattaaaatt 52260
aaacatagaa tcggcataat ccggttcaaa attatattca agagatcatt gaaatactgt 52320
caagaataaa cagtcaagga gtaagaaaag ggatgaaaaa gatatgctaa acagctgaaa 52380
atcaacagaa aaagtatttc ataattcact gatttttagt aaattagaag tacttcacca 52440
cttttaatta tgactaaaga atcactcctt atgcaatacc aatccgagtg cagaaacgct 52500
ctcgaatcag ctgtaaatat aagcaaatct tttcagaaag tattcatgga tgcaatgaaa 52560
ttattcatgg ctatacctga ccgcatcaat ttctacaaa tgggacggta tggatgttct 52620
tcggaacaga cataccgcaa caattttgag aacgacggct ttgactggtt ttccttcaat 52680
gaagccttca tcagggaaca ccttaaagggt ggtcgcaagg cgatagccgt tgatccgtct 52740
ttcattccaa aatcaggcag caaaacgccc tggattggct atttctgggt cgggtgtgcc 52800
ggtgaataca aacgtggact ggaaataacc ggtattggag ttatagacgt tgacaaccat 52860
gaatgtatga ctttgggctc tgtacagaca cctgacaacg caacgctgga aagctgtgag 52920
aagaatcttg ttgactggta cagctcttcc cttatcagca tacaggaaca gctgaaacgt 52980
atttctggca cagtctgtgt tgatgcgttc ttttcaaagg caactttcat caaacatttg 53040
tacgataacg gtttccacgt aataagccgt ttcaggaatg atgccgtatt gttttatccc 53100
accttagaaa ataggacagg aaaacgcgga cgtccaaaat tacatgacga gaaaattgac 53160
tttgaaaatc tggacatcac aagatgtacc gagtacaagg tgaacaaggg taaactttac 53220
ggactgaaa cactatccaa agcactcaaa cgctttgtga gcctggctgt atggtacccc 53280
atggatggaa taaggacag atggcagctg tatttctcta caaacgaaat acagaacgca 53340
caggatgtcc tggactttta cagaacacgt ttccaactcg aattctgctt tcgggatgcc 53400
aagcaacatg ccggaatagc aaactgtcag tctacagact tcaggaaact ggcattccac 53460
tttaatgcat cacttgacgc gataaacctc gccaggctg cctgtaagaa gatgggaata 53520
aaatatccca tatcatcatg caagtcagtc atacaacatg cttacatgct tgaacgattt 53580
atttgcgtgt ctgggattga accaaacacg caattaattg acaaactttt caaagaactc 53640
attttattta ctgccagagc cgcttaggct gggctaattt ttaacgaact attgattcta 53700
atgtaaatag gaaataattt atcattttctc tgttgtctaa cacagatttt aaaacttgcc 53760
atatataact aataatcaat attatacgaa tattatttta gtgtaaacat tctcttaatt 53820
tagtgtaaac atgaagtaaa cactactaca tgaaaatcag aaaaataaag taatataaca 53880
tagaaaaagg gacttgctgt aataaacaag ccccttaact tattaattat tagtaaatat 53940
ctgtttttct tctttagagt ttattcctca atagcagcct gcgccatacc gatatagatt 54000
taatattcaa atacttaact gcatcgtgta agcctacagt aagcgaatat ttatctaata 54060
ttgttttgat taatgattcc cagcttagag gatattcctc atagcggctt gtgccttgct 54120
aattcctttc tgattattag acgtttacca tacaagtgtg agcctatagt aagcaactt 54180
tcttgataac ttattgaccg gaattttctc acttaataca atatggtcgt aagtgcata 54240
atcttaatac gctagaactt acatggtaag tgaagcggc attcacttta cttttgctc 54300
tccatcaacc ctttgatgaa taattaaata ttaatagata tacaacattt cagttttatt 54360
ttttctcta tctttcaata gttcaataat tacgtcctta tccttcaggt ttgaatcaag 54420
acgtaaaaatc tgtgagttca gactctctat ctgttccttc agaagcttga ttgtttccct 54480
caggttttct gtttctttct tttcgtgga taactgcacg gccagttccg catcacctat 54540
caggttggtt gcatttccat ccaatgaaac ggctgcaagg tgtgccgata tatgatgctg 54600
tctcggacag aaaagggaag agaaattgaa gtccaatgct tcgctgactt taataagcct 54660
gcacgtttcc attgtctccc tttccagtat gcggtttatg tgctgctgcg gtacacctat 54720
tttgcgccca agctcagatt tgcttaatcc aagctcggtg cgtcttttgt cgatagcctg 54780
acctacatgc acgtgtttta tgtcattatc catgcgattc cttcaataaa tatatcttaa 54840
acaataaatc atcaaacaaa tatttggtta tataaaccat tttatggtac tttgtggtgt 54900
aacatattca tttggtgaat acaaagttaa acattaaata ttaaaccatc aacaattatg 54960
tctgaaaact tagaaaaaat ccgtccggca cttgttgccc ttgaagtagg tgaatcagtt 55020
tcattcccta tttcacgttt gaaaagcgtc cgtacacagg cctcagagct tgggtgccatc 55080
tacaaccgtc agttcaagac caggactgat agggaaaccc aaaccattac ggtcaaacga 55140
acagtataga aaccaaatca ggtttatatg aagatattac agtttctgga ccattctata 55200
ccatacgaaa cattcctgaa tgacctctcc tccagaattg tcaggcaatt gaaagccgac 55260
aaggatgatc ctgaattcat cagccagagg aaggcatacg agctgttttg ccgcaggaat 55320
gtagaaagggt ggaaacgtca gggaaagggt gtttcctata aaagaccgg taaggtggaa 55380
taccgcacag cagacctcag gcttctccag cgtaccaccc aggactattt tgatgaaagt 55440
cagccgaaac aggcagaaaa accggtcaag aaagataaat gataaacata ttatggctaa 55500

```

P065778_P067963GB sequence listing_updated MRX002pl_ch.txt

tacactaata	ttgataaact	ttatttggtt	agtttagccg	tgataactcta	tgaaatataa	55560
agaaagcaat	tatagtaggt	acaggaatgt	gcgtcagtaa	cctttgttcg	ccagcttata	55620
gtttaaaata	aagccggaca	ggcttttttt	atcgacacatt	cataatgatt	ttataataat	55680
gaaagaaatc	agaccagcgt	gcgatccaaa	cggtgtctat	tcagtcaagc	gcacctgtgc	55740
tgaactcggg	atcagcaaca	agacactcaa	aaaatacaga	gaaaacgggt	atatccaacc	55800
gctcaatcct	aataaatatca	gccgtccgaa	atactccggc	cagtcaataa	tcgattgttg	55860
gaacctgttc	agtacgttat	gataagcgaa	acaaccatac	ggaaagtaag	ggaaacttgcc	55920
atagaagacg	tactcagtc	ttatgtcaga	ctgtccagaa	aaggctcaac	cctgatgggg	55980
ctttgtcctt	ttcattccga	aaagaccggg	tcctttgccc	ttaccccaag	caagaatctc	56040
ttccactgtt	tcagctgtaa	ccgtggcggg	gattccatta	cgtttataat	ggaaaaggaa	56100
aaccttttct	tcagttccgc	tgtggaattt	accataatat	accataatat	tccggtagaa	56160
tacatcagtg	aagagcgcag	tgaggaacag	atggccgaag	ccaagcaccg	ggagtcactt	56220
ctgacagttc	tcgatacagt	acagtccttc	ttcctgcaaa	atttaagagc	aacagacaag	56280
gaagagagcc	ttgatgccag	agcctacgca	tacggccggg	ggcatgagga	gttctgtgcc	56340
tttgccggaa	taggctatgc	accgaaggac	ggtcaggcct	ttatggattt	ctgcagaagc	56400
aaggctctga	acgaagaact	gctgtacgaa	ctcggcatgt	tcaagcgtgg	tgaggacgga	56460
aacacatacg	ccatgtttccg	acagcgtatc	atgattcccg	tgagaaacag	atggggacgc	56520
atcattgcct	atacagccag	atacatcgga	gacaacagga	aagctcccaa	gtatatcaac	56580
tcggcaacaa	gcattgattta	ctccaaggga	gaaacagtat	tcggtattga	ccgtgcagcc	56640
agactgcgtg	atgccgacta	ttatatcatt	gtggaagggt	ctcctgatgt	cctgagaatg	56700
cagtcgattg	gatacgacaa	tacagttagc	tcacttggaa	caacttggag	tgacagccag	56760
ttcgagcagc	tgtatcctca	tgtatcctca	ctctgtttca	ttccagattc	agatatgtcg	56820
gaaggcaagc	catacggacc	tggatttgag	gcgggtgatga	ccaatggggc	tgacagccata	56880
agaaaaggat	tccatgtaac	agtcaggga	cttccitttg	cagaaatacc	atccgaggca	56940
gaaggaaaag	tacaatatgc	caagaatgat	gccgacagct	atatccgcag	cagggaagat	57000
tatacttcac	ttccggaaaa	gcattttatc	atctggttgg	cacagaaacg	ttttctggta	57060
gccggttcca	tggtagagga	aagaaaagtgt	gttgcggaaa	tagcagacct	gttgcgttat	57120
ataaaagacc	agcttgtgta	tgaccagtgt	atagaacaac	tctccagact	gcacggcaag	57180
gtaaagctat	ggcgtgatgc	cgttaccag	gcacgtgggg	aagccaggag	aaggaacgac	57240
aaacctgcgg	ccatgaacga	gatgcagcgt	gaagctgaac	tgctgcgcca	gttcgggtctg	57300
ttcgtcaggg	aaaactgtta	ctactccatc	ggtgaagatg	atgatgaacc	gtcaagaatc	57360
tccaacttca	taatggaacc	actgttccat	atcagagatg	agataaacgg	aaccagaatc	57420
ttccgtatga	gaatgatgta	caatgtatgc	agggctatag	aactgaagga	gtctgaatta	57480
tgctcgctga	gcaacttcca	acagaagggt	ggttccactgg	gcaattatgt	atggctggcc	57540
aagatagaca	aactcaaccg	tgtaaaggaa	tacctgtact	caaagaccga	tacggcagaa	57600
cgtatcagaa	aactcggctg	gaatgcagct	gaaggattct	ttgcttttgg	aaacgggaata	57660
ttttttgcag	gcacattcaa	tgctgttgac	gaattgggta	tagtccgttg	tatcaacggc	57720
aaggccttct	atataccggc	actttcaaaa	acttatctca	acaatccgga	gatattccag	57780
tttgaagac	ttatggtgca	tgagaaccgt	aacggaataa	aactgtatga	ttacgtaaaa	57840
agacttatgg	aagtattcgg	tgagaatgca	agtgtagcct	tctgttacct	tcttgccacc	57900
ctcttccgtg	acatcatatt	cagacgtacc	cgccactttc	ccatcctgaa	ccttttcggt	57960
gagaaaaggaa	ctggttaagac	aaccttggtc	acttccctcc	agtccttttt	cctgcacgga	58020
gtagatccgc	ccaaccttgg	agtaacctct	gtaccggcca	tgaacgaccg	tgtgtcacag	58080
gccgtcaata	ctcttgccgt	gcttgatgaa	tacaagaacg	acctcgacat	acgcaagata	58140
gcctatctga	aaggactctg	ggcggtggc	ggccagacca	aaaagaatac	gaatacagac	58200
gggatggcag	cacagaccat	tgtcacaaca	ggtgtagccc	tttgcggcca	ggacaagccg	58260
acacaggata	tggcactcta	tacctgtgtc	atcttctctg	cctttttcaa	gacatcattc	58320
aaccagaatg	agaaaagggc	ttatgaagac	cttgtatcag	tctgcaacat	gggacttacc	58380
catctcactc	tggagatact	gggacaccg	gaactgtttg	agaagaattt	tccggaaata	58440
tattccatca	ccaagcgtga	gctggctgcg	aaattggata	atgaaaccat	ccatgaccgt	58500
attttcggga	actgggttat	tccactggcc	accttcagaa	cactggagac	tgctcattgac	58560
gtgcctttca	gctatgcaga	attgtttgat	acggcagtc	gaggaatacg	aaatcagaat	58620
gaactggctc	aggaaagtcc	agagatagcg	gacttctgga	gtatgcttca	gggattccag	58680
acttcaggga	aatgtattga	gaaggcacat	taccgtataa	ggtatatgaa	atccttccgt	58740
ccattgtctg	taaaagaaga	tatagaattt	aaagaagcac	gtcctattct	ctatctgaac	58800
acggcagccg	ttgcatcact	gttcaacagc	cggaaacgcg	gttccacctc	caatcgctcg	58860
aattgggtcca	ccatcatgtc	ctacctgaaa	tccccatgct	catacctggg	actgaagcag	58920
gacagattca	ccatacttct	gccaagcggg	cttccctgact	ataccattga	cattgtgaat	58980
ggagagcagg	ttaagaagggt	aaaagtaaac	cgctccgaagg	cattatgctt	tgattatctc	59040
cagctgaagg	agactttcgg	actggatctt	gaaactgagg	ttgtcgctga	agtacaggac	59100
atgaagggaag	aaatgacttc	cggacacaaa	caatatcctg	agcagaaagg	cttattttta	59160
ttgagaattt	acaataataa	attatcatca	gaaaaatcca	atccttttta	atgtatttctg	59220
caagcaatta	tttacagtta	tcttttggat	tttcaaaact	taactcttat	ttttgtagaa	59280
atcttgcaaa	aaaaggagtt	aagtttatga	tttttagagtt	ttgtgtcagt	aattacttgt	59340
caataaagga	tgagttaaaa	atatcctttg	ttgcaactgc	tcttaaagat	gttcttaccg	59400
agtcaaatga	tatgataact	gtacccgata	ccggattatt	tgtattacgg	agtgcagtg	59460
tttatgggtgc	aaacgcttca	ggaaaatcaa	atgttctaaa	ggctatttgc	ttttacaggc	59520
gttttatcac	ggactcttcc	aaaaacagtc	aggccggaga	agcaattgat	gtagagaact	59580
tccggttgaa	taccacttca	atggatgagc	cgactacaat	ggaggcaacc	tttattgttg	59640

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

aagggtttcac ttaccgttat ggtttttgagg ttgacagcaa agctgtacgt gccgaatggc 59700
tgtaccagcg cacaaataaaa aagagagcca aagaagttga aatattctac aggcagagaag 59760
aagaaaccac tgttcatcag aaaagttctt tattgataga gcttgtaaac aagaaaaatg 59820
tgcgtgacaa tgctttactg ctgtctactg gggcacaatt caatgagccg atagcagtca 59880
gtatcctgca atggctgaat gatatgcatg tgatattttg caatgatgag gaaagactgt 59940
ggaacaggc tataaagtct atggatgatg agaatctccg tttgctgatt actaactttg 60000
caaaatatgc agatctgggg atagacagta tcgtaaaaaa agataaccgt atcgtttagta 60060
ctcaccggca atatgatgat gaggggaaaag aaaccaatag tgtagctttt tcattcagca 60120
gtaatgaatc ggaaggatca ataaaaatatt tttctttgtc atatcctatc attgatgctt 60180
tggataatgg aaaactttctt gttattgatg aacttaattc aaagcttcat cctctgttgg 60240
ttcgtaaaaa catcggcctt ttcaattcgg caaaaaacaaa cccaaagggg gcacaactac 60300
tttttacaac tcatagatacc ttcttggttaa gcgctgggtat gtttcgccgt gaccagatat 60360
ggttttacaca gaaaaacagt ttccggttcta ctgaagcgta ttcactgggt gaataataaag 60420
tacgcagcaa tactccattt gaaagggatt atctgctggg taaatatggg gcaactccca 60480
ttatcgggtg aatggagagg gtctttaata tggaggaatg agtatgggaa gacaaacaaa 60540
aaaggaccat cgttcaggca gtctgaccag aaagcagggg acgagaaatg taaaacagtc 60600
ttttctcata gtagtgaag gggtagctac agaaccagac tactttaagg ctttccgtat 60660
gacaactgcc acagtcaaag ctataggtca ggcaatgaat actataagtc ttgtcaataa 60720
ggcaatcagc atacgtgata ccgaacaaaa gaagaagcat tactatgatc agtggtgggt 60780
tggttttgac aaggatgatt ttcttgcaaa ggacttcaat caagcaataa ttttggctca 60840
aaagaacggt ttccgtgttg cttacagtaa ccaggcattt gagtattggg ttctatttga 60900
ttttaatctc tatcgaggtc ctctccatcg ccagaattat gcagatatgc tgtcaaaact 60960
tataggaatg ccatattcaa aaagtgaagg atttggttact gtcattgtata ataggcttta 61020
tcacctgcaa tcacaggcaa taaagaacgc aaatgtagta cttaacgagg tttcaaatgg 61080
aaatcctgcc atggaagaat cttcgactac tgtacattta ttgattgaag aattgaataa 61140
atatgtttga tatagtgggt tgcattaaga ataaaaacata gttaaatgag agtttaataa 61200
aaggtaataa ctgtatttaa gataattggg acataacata attaatgtat tgaaaaaatg 61260
gaaatagggt atataataaa aggatataca ataaaagagt atattggaga tgggtggatg 61320
ggatttgggt ttaaggttga gaaagatggg ctttaaaaaa atgtaacaca 61380
acagatgatg agtatgtctc aagatttaag agagagatac gaatgatgga aacaataaac 61440
aataatagaa tagtaaaaaa tattgataaa gatattgatg cttcaattcc ttattttata 61500
atggagttat gtgatgaatc gcttgaaaat gctgttgaaa gaggattgtc cgaagagaaa 61560
aaatttgatt atatatgca attgtgtgat ggattaaaag ggctacatga tcaaggaata 61620
attcatagag atattaaacc tggtaatgct cttattgttg atgacaaaat aaaagtgta 61680
gatttaggtc ttgggaaatt tattaaacgt gatactcctt gtttgactcc tactgatgat 61740
aaatatatgg gaacatacga ttatatggct ccagagatat atattgatgg taaggggaaga 61800
gatgcagata aacggagtgat tatcttctct ttaggaaaat tattatattt tatatttaca 61860
gatcaatagt tcgttaaaaa ttagcccagc ctaagcggct ttgttgctta atccagaca 61920
ttctttgaaa agtttgtcaa ttaattgcgt tttgttctta atccagaca 61980
tcgttcaagc atgtaagcat tgtgtatgac tgacttgcac gatgatattg aatattttat 62040
tcccatcttc ttacaggcag ccttggcgag gtttatcgct gcaagtgatg cattaaagtg 62100
gaatgccagt ttcttgaagt ctgtagactg acagtttgct attccggcat gttgcttggc 62160
atcccgaag cagaattcga gttggaacg tgttctgtaa aagtcaggga catcctgtgc 62220
gttctgtatt tcgtttgtag agaaatacag tgcctatttg tccgttcttc catccatggg 62280
gtaccataca gccaggctca caaagcgttt gagtgctttg gagtatgctt tcagtcctga 62340
aagtttacc ttgttcactt tgtactcggg acatcttggt atgtccagat tttcaaagtc 62400
aattttctcg tcatgtaatt ttggacgtcc gcgttttctt gtcctatttt ctaaggtggg 62460
ataaaacaat acggcatcat tcctgaaacg gcttattacg tggaaaccgt tatcgtacaa 62520
tggtttgatg aaagtgtcct ttgaaaagaa cgcactgtgc cagaaatacg cagaaatacg 62580
tttcagctgt tctgtatgc tgataaggta agagctgtac cagtcaacaa gattcttctc 62640
acagctttcc agcgttgctg tgtcaggtgt ctgtacagag cccaaagtca tacattcatg 62700
gttgtcaacg tctataactc caataccggt tatttccagt ccacgtttgt attcaccggc 62760
acaaccggac cagaaaatag caatccacgg cgttttgctg cctgattttg gaatgaaaga 62820
cggatcaacg gctatcgctt tgcgaccacc ttttaaggtg tccctgatga tggcttcatt 62880
gaaggaaaaa cagtcaaagc cgtcgttctc aaaattgttg cggtatgtct gttccgagaa 62940
acatccatac cgtcccatth gtaggaaatt gatgaggcca ggtatagcca tgaataattt 63000
cattgcatcc atgaatactt tctgaaaaga tttgcttata tttacagctg attcgagagc 63060
gtttctgcac tcggattggg attgcataag gagtgattct ttagtcataa ttaaaagtgg 63120
tgaagtactt ctaatttact aaaaatcagt gaattatgaa atactttttc tgttgatttt 63180
cagctgttta gcatatcttt ttcatccctt ttcttactcc ttgacgattt attcttgaca 63240
gtatttcaat gatctcttga atataatttt gaaccggatt atgccgattc tatgtttaat 63300
tttaatttat cggtaaaaaa ttaccgaagt attgatagat ataattcccag gaagtaatca 63360
ttcttttgaa aatataatct ttagctgcca attaaaagaa aaatttgaga gtacaaaagc 63420
atcttcatta ttttttagtac ttgatgtttc aggcctctat gataatttat ataaagctgg 63480
gcagtgtacat aatatcgctg agcaagtgcg atcagtttctg ttgacaatat cagaattcta 63540
agaaatttct ttatggaagt ttgggtgatag agctgatttt gttgaaaata tcggattaga 63600
gaatattcag tctgttaaaa atgtacattg tgaaggtact ggaactgaat taaatgcttt 63660
cgtaaatgct gccagtggtc caataaatga tgggtcttta gttattatat ttactgatga 63720
cgatttaggg tctataaaga aagctgcttt gaattataaa aataaaagca aagtattttg 63780

```

P065778_P067963GB sequence listing_updated MRX002p1_ch.txt

```

gcagataatc gtatatgggg agcataagaa tatttcatca gaaatatcga attgttcaaa 63840
tgtgtctttg atctgtatgg atgattatgc ttctaaaagt aagaaaagaaa ttaatcaaat 63900
gttattgaat gattatattt tatggaaaaa taaataatac aaagataaaa gtctaaatat 63960
aactaatgta agtataatac aaataatggg tatatttaga cttttgttct attttgcctt 64020
atatacagaa atgataggcc tgaacttatg cgcttgatct tttggcggtt cctgaatagt 64080
tcctgactgc atggaataaa gccaaagcctt attttccctt tgcccttcta cctctgtaga 64140
cgaccacaac cagcattcac ccggattcag attaatcgga gttccaccga cttcagttat 64200
acattcatta atctgggtgcc ggacagcgaa cagataagag agttgccgga cagaaggaat 64260
ataagccgat tgtccataac tccacaaatc aaaagacttg atagctattg gtgataggac 64320
ttcatcatta ttgaacaaag aatagggtatt ctcatctccg tcctcatcag tcaatgatgc 64380
agaagtaccc tggtaataac caagactgtc ggcaaaagcc agtggttcca tatcatgaat 64440
gtaaactgca taaccaagat tgtcagcatc aggactacgg ttacatgga aaactatgcc 64500
aacagcttct ttgtcagatt gcttgaattt gtccatggac aatatatttc cgtccgaaca 64560
aaccacattg ccaacctgaa gggaagataa cagttcggtg acatcttcat gttcacaaatg 64620
acaggaagtg agcaacagcc cactccatgc cagaatcggt aataaaaaatc tgttcagctt 64680
cataacagtg ggatttcaaa tgacctgatt acacattgcg cttccttgtc cataatgaac 64740
cagtattcag aacgggatgg ctgtccgtca gaatcagtag cttcatactc tatctttacc 64800
ttccaaccgt tgaacggctt gcgttccctg ctggcttcat cacctgtagg cttcagttct 64860
tctgtaacca tcagagagcg gagtgccgtc atggcatcca tctgatgttt catctgaccg 64920
gatatcccggt gacattctga atctggatta tcaaaatctg tatcctccat aaacctgcgg 64980
ctgattttca tcatggccac agaaagagcc atcttctcct tcatgctaac atactcacgg 65040
ccaaatacag aatccggttt gctgataccc acaatcttta cggattccgg attgtccacc 65100
gaagccatca gtgccttttt ggccatatcc tgtgccttat ttctcgctgtt gccggaacag 65160
ccggttccca ttccgagcag gactgccact gcaggcagta tcagaagttt ctttccctgt 65220
ttcatatctt tacgatttga agtttgtccg gggccagacc gagacgtttg cggtaaatgg 65280
aaccgtcttc ccggtacatc tccagttcgt atgaagtaat gttcttctca caaagttcct 65340
tcgcctcttc cagtgtcagc tgatggcctc ctatatctct ccatatggcg aatgagcacg 65400
gtgtttcctg attgctgtag ttggaacagt tgaaagccct tgttcccaca cgtacctcgc 65460
cgccgcagtg cggacacctg ccgataacag actgcatatt gaccgcaccg tcatcagcaa 65520
gttccagcac ttcgggaaat gcttttcctt ccttgggtgga aaagccgtcc agaaggatac 65580
ggcgtttctc taaaaattca gcaatctccc cgtcattcat tttccggttg ccgatgatgg 65640
cattgatgtt gagcacacaa gaaggatgct cacctgtgtt gttttcgag cgatagccct 65700
tgcatgtttt caccacgttg ccgccgcaga acgggcagcg tcctataatc ttcttttctg 65760
aatccatatt cctgataagt tacattgttt gaattaatgt aatgagacc cccggttcca 65820
gtccgcaacg atctctccta tgatgttctt gccggacatc acgcttgccc aaccttccgg 65880
gtcaagagag aaccagaggt cgttccatga gagtgtgcgt acctgccatg ccaggataaa 65940
gaggtcggta ttgacagcct ccagtctggg cagtacctcg tttgcaatgt agtaccgctc 66000
ggaagaactg agcaggttta ccttgtgctt ctcttgccct ccgtcagaac cgcctgtatc 66060
atagcttccg gaagtcacca gttgttctat gaacggataa agcgcagcca tctgggttgc 66120
ggcatcagcc agctcgtccg aaacgattgc agcgatggcc gtcccttca ggttactgcc 66180
gaccgatttg agcagcagac tgcagttctg gggtatctcc gtggtcacca gttccccggc 66240
acgtttaatc tgatagagat tctgcatggc acctgtgca ttggaaagat attccagcag 66300
cttgttctcc acactgtgta ccctgtcgag tgcaaccggt acggcagctt cggcagcaat 66360
gattttctcg tgtgccttct gacgtttgtc atagatatct ttcagtgtgg aagtctgtgc 66420
aaagacagca cccgtcagtg tagggctctg ctggtgtgca aaagtgtctg tacctttcag 66480
cagaaaaaac gccaaagcag tcactaccgt tattcttaac ttgattctgt ccatatcatt 66540
cagattttac gccctttatt cctttgttcg ctacagattct gttcacgttc ctcttttgtg 66600
ggtgaaatca ccggtccat ccgctgttc agcagacagt cgttccagtc cttgaaagcc 66660
ttcggaggaa gccattgtcc catacggtag cggatgttca gctgcctggc aacctgggcc 66720
agtaggggac gtcceaagtc aggtctgaat acctttccct tcgcttcaat ccggatgccg 66780
ccgtcagtcg tgcttatctt catctgaata ccttctgca gagccatcat gcgcagtcg 66840
tatatcctcc cggccaggtc gttgtcacia cagtgcgaagg cacgtgcatt tggaaagcgt 66900
tccatgactc cggttatctg cctgtcagaa aatgtgccgc ccagtgaaac cagagccgca 66960
ctgtcccaa ca tctgtatccg gttcatctgg tagaaggcca tagcatcaaa tgcagattca 67020
ca 67022

```